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The cost-effectiveness of domiciliary non-invasive ventilation
in patients with end-stage chronic obstructive pulmonary
disease: a systematic review and economic evaluation
Janine Dretzke,1 Deirdre Blissett,2 Chirag Dave,3 Rahul Mukherjee,3
Malcolm Price,1 Sue Bayliss,1 Xiaoying Wu,1 Rachel Jordan,1
Sue Jowett,2 Alice M Turner3,4 and David Moore1*
1Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences,
University of Birmingham, Birmingham, UK
2Health Economics, School of Health and Population Sciences, University of Birmingham,
Birmingham, UK
3Heart of England NHS Foundation Trust, Heartlands Hospital, Birmingham, UK
4Queen Elizabeth Hospital Research Laboratories, University of Birmingham, Birmingham, UK
*Corresponding author d.j.moore@bham.ac.uk
Background: Chronic obstructive pulmonary disease (COPD) is a chronic progressive lung disease
characterised by non-reversible airflow obstruction. Exacerbations are a key cause of morbidity and
mortality and place a considerable burden on health-care systems. While there is evidence that patients
benefit from non-invasive ventilation (NIV) in hospital during an acute exacerbation, evidence supporting
home use for more stable COPD patients is limited. In the UK, domiciliary NIV is considered on health
economic grounds in patients after three hospital admissions for acute hypercapnic respiratory failure.
Objective: To assess the clinical effectiveness and cost-effectiveness of domiciliary NIV by systematic
review and economic evaluation.
Data sources: Bibliographic databases, conference proceedings and ongoing trial registries up to
September 2014.
Methods: Standard systematic review methods were used for identifying relevant clinical effectiveness and
cost-effectiveness studies assessing NIV compared with usual care or comparing different types of NIV.
Risk of bias was assessed using Cochrane guidelines and relevant economic checklists. Results for primary
effectiveness outcomes (mortality, hospitalisations, exacerbations and quality of life) were presented,
where possible, in forest plots. A speculative Markov decision model was developed to compare the
cost-effectiveness of domiciliary NIV with usual care from a UK perspective for post-hospital and more
stable populations separately.
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Results: Thirty-one controlled effectiveness studies were identified, which report a variety of outcomes.
For stable patients, a modest volume of evidence found no benefit from domiciliary NIV for survival and
some non-significant beneficial trends for hospitalisations and quality of life. For post-hospital patients, no
benefit from NIV could be shown in terms of survival (from randomised controlled trials) and findings for
hospital admissions were inconsistent and based on limited evidence. No conclusions could be drawn
regarding potential benefit from different types of NIV. No cost-effectiveness studies of domiciliary NIV
were identified. Economic modelling suggested that NIV may be cost-effective in a stable population at a
threshold of £30,000 per quality-adjusted life-year (QALY) gained (incremental cost-effectiveness ratio
£28,162), but this is associated with uncertainty. In the case of the post-hospital population, results for
three separate base cases ranged from usual care dominating to NIV being cost-effective, with an
incremental cost-effectiveness ratio of less than £10,000 per QALY gained. All estimates were sensitive
to effectiveness estimates, length of benefit from NIV (currently unknown) and some costs. Modelling
suggested that reductions in the rate of hospital admissions per patient per year of 24% and 15% in the
stable and post-hospital populations, respectively, are required for NIV to be cost-effective.
Limitations: Evidence on key clinical outcomes remains limited, particularly quality-of-life and long-term
(> 2 years) effects. Economic modelling should be viewed as speculative because of uncertainty around
effect estimates, baseline risks, length of benefit of NIV and limited quality-of-life/utility data.
Conclusions: The cost-effectiveness of domiciliary NIV remains uncertain and the findings in this report are
sensitive to emergent data. Further evidence is required to identify patients most likely to benefit from
domiciliary NIV and to establish optimum time points for starting NIV and equipment settings.
Future work recommendations: The results from this report will need to be re-examined in the light of
any new trial results, particularly in terms of reducing the uncertainty in the economic model. Any new
randomised controlled trials should consider including a sham non-invasive ventilation arm and/or a
higher- and lower-pressure arm. Individual participant data analyses may help to determine whether or not
there are any patient characteristics or equipment settings that are predictive of a benefit of NIV and to
establish optimum time points for starting (and potentially discounting) NIV.
Study registration: This study is registered as PROSPERO CRD42012003286.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Airflow obstruction A ratio of forced expiratory volume in 1 second to forced vital capacity that is
less than 0.7.
Chronic hypercapnic respiratory failure Evidence of chronic respiratory disease, high partial pressure of
carbon dioxide in the arterial blood, normal pH, high bicarbonate (British Thoracic Society Standards of
Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 2002;57:192–211).
Chronic obstructive pulmonary disease A chronic progressive lung disease characterised by airflow
obstruction that is not fully reversible. The airflow obstruction does not change markedly over several
months and is usually progressive in the long term.
Cost-effectiveness acceptability curve A graph that illustrates the probability of an intervention being
cost-effective at varying willingness-to-pay per quality-adjusted life-year gained thresholds.
Domiciliary setting Any non-acute/non-hospital setting. Most likely to be the patient’s home, although it
could also be, for example, a care home.
End-stage chronic obstructive pulmonary disease A state of chronic respiratory failure that occurs
in patients who remain symptomatic despite maximal therapy and in whom there no hope of cure,
irrespective of predicted length of remaining lifespan.
Exacerbation A sustained worsening of a patient’s symptoms compared with the usual stable state which
is beyond normal day-to-day variations and which is acute in onset [National Institute for Health and Care
Excellence. CG101 Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary
Disease in Adults in Primary and Secondary Care (Partial Update). London: NICE; 2010].
Incremental cost-effectiveness ratio The ratio between the difference in costs and the difference in
outcomes between one or more intervention.
Non-invasive ventilation Ventilatory support to a patient through the upper airways. It enhances the
breathing process by giving the patient a mixture of air and oxygen from a flow generator through a
tightly fitted facial or nasal mask. Also known as non-invasive positive-pressure ventilation, non-invasive
ventilation assists the patient in taking a full breath and helps to maintain an adequate oxygen supply to
the body.
Post-hospital population For the purposes of this report, the population of chronic obstructive
pulmonary disease patients who commence domiciliary non-invasive ventilation immediately after an
admission to hospital/exacerbation.
Probabilistic sensitivity analysis A type of analysis that demonstrates the uncertainty in model
parameters and is used to provide an estimate of the level of confidence decision-makers should have in
the conclusions of an economic evaluation. Conducting a probabilistic sensitivity analysis involves applying
distributions to all uncertain parameters and then running the model multiple times, randomly using values
from the distributions in the model to produce multiple pairs of costs and effects.
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Severity of chronic obstructive pulmonary disease This can be defined by the Global Initiative for
Chronic Obstructive Lung Disease criteria.
Stable population For the purposes of this report, chronic obstructive pulmonary disease patients
described as being in a stable state, with no recent exacerbations/hospital admissions or other major
change in clinical parameters over a defined period (e.g. 4 weeks).
Usual care Standard approaches to disease management. This is multidisciplinary in nature, and will depend
on severity of disease and effectiveness of individual treatments. The full treatment pathway is outlined in the
National Institute for Health and Care Excellence clinical guidelines. In brief, smoking-cessation support is
offered to all chronic obstructive pulmonary disease patients, pulmonary rehabilitation is offered where
appropriate, short-acting bronchodilators and short-acting muscarinic antagonists as necessary are the initial
treatment for the relief of breathlessness and exercise limitation and, where necessary, long-acting muscarinic
antagonists and/or long-acting β2-agonists with or without inhaled corticosteroids are offered. Other
treatments may include oral corticosteroids, oral theophylline, oral mucolytic therapy, combined oral and
inhaled therapy, long-term oxygen therapy and lung surgery.
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List of abbreviations
6MWD 6-minute walking distance
A&E accident and emergency
BIPAP bilevel positive airway pressure
CEAC cost-effectiveness acceptability
curve
CI confidence interval
COPD chronic obstructive pulmonary
disease
CPAP continuous positive airway pressure
CRQ Chronic Respiratory Questionnaire
EPAP expiratory positive airway pressure
EVPI expected value of perfect
information
FEV1 forced expiratory volume in
1 second
FVC forced vital capacity
GOLD Global Initiative for Chronic
Obstructive Lung Disease
GP general practitioner
GRADE Grading of Recommendations
Assessment, Development and
Evaluation
HR hazard ratio
HRF hypercapnic respiratory failure
HRG Healthcare Resource Group
HRQoL health-related quality of life
ICER incremental cost-effectiveness ratio
ICU intensive care unit
IPAP inspiratory positive airway pressure
IPD individual patient data
ISRCTN International Standard Randomised
Controlled Trial Number
ITT intention to treat
LTOT long-term oxygen therapy
MRF-28 Maugeri Foundation Respiratory
Failure questionnaire
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
NIPPV non-invasive positive-pressure
ventilation
NIV non-invasive ventilation
NPV negative pressure ventilation
PaCO2 partial pressure of carbon dioxide
in the arterial blood
PaO2 partial pressure of oxygen in the
arterial blood
pO2 partial pressure of oxygen
PSSRU Personal Social Services Research
Unit
QALY quality-adjusted life-year
QoL quality of life
RCT randomised controlled trial
RR relative risk
SABA short-acting β2-agonist
SD standard deviation
SE standard error
SF-36 Short Form questionnaire-36 items
SGRQ St George’s Respiratory
Questionnaire
SRI Severe Respiratory Insufficiency
Questionnaire
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Plain English summary
Chronic obstructive pulmonary disease (COPD) is a lung condition which is thought to affect about 5%of adults. Patients develop a cough and breathlessness which gets worse over time, and many
experience ‘flare-ups’ (exacerbations), which can lead to a hospital stay.
Non-invasive ventilation (NIV) is a treatment delivered by a small machine with a tight-fitting mask that
blows air into the lungs. NIV is often used in hospital, but there may be benefits to using NIV overnight or
during the day at home.
We collected all available evidence on the use of home NIV by COPD patients. In the case of patients
starting NIV after they leave hospital following an exacerbation, we found a limited number of studies that
showed either benefit or no benefit from NIV. At present it is not possible to say conclusively whether
or not NIV reduces the chance of future hospital admissions or whether or not it extends life in these
patients. Additional studies are currently ongoing.
When home NIV is started in patients who are more stable and have not had a recent exacerbation, the
results show a trend towards fewer hospital admissions; however, but this finding is also not conclusive.
Some patients may experience benefit but it is not possible at the moment to predict who these
patients are.
We have created a mechanism to consider whether or not home NIV represents good value for money for
the NHS. All this information will help determine how, when and in which patients to use home NIV, and
what future research is needed.
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Scientific summary
Background
Chronic obstructive pulmonary disease (COPD) is a chronic progressive lung disease characterised by
non-reversible airflow obstruction that mostly affects middle-aged or elderly people who have smoked.
Treatment for COPD is based on pharmacotherapy, pulmonary rehabilitation and, in some cases, long-term
oxygen therapy (LTOT), and is mainly symptomatic. Many COPD patients experience worsening of symptoms
(exacerbations) on a regular basis. Exacerbations are a cause of increased morbidity, mortality and the poor
quality of life (QoL) seen in COPD and place a considerable burden on the health-care system, particularly if
they result in hospitalisation. Non-invasive ventilation (NIV) is a method of providing ventilatory support via a
mask without an endotracheal tube. There is good evidence that patients with hypercapnic respiratory failure
during an acute exacerbation will benefit from NIV in hospital; however, the evidence for its use in stable
COPD patients is more limited. Suggested benefits are prevention or delay of exacerbations leading to a
reduction in hospital admissions and/or increased survival and improved QoL. Previous systematic reviews have
not fully considered these outcomes. In the UK, domiciliary NIV is considered on health economic grounds if a
patient has had three hospital admissions with acute hypercapnic respiratory failure, although there is only
sparse economic evidence to support its use. Therefore, an economic evaluation in a UK context is required.
Given that the baseline risk of an exacerbation varies between patients and may affect any potential
benefits from NIV, two populations were considered in this report: patients in a stable state of disease
(stable population) and those immediately after a period of exacerbation-related hospitalisation
(post-hospital population).
Objectives
The aims of this report were to undertake:
i. a systematic review of randomised controlled trials (RCTs) and non-RCTs comparing domiciliary NIV with
usual care, or different types of NIV, in stable/post-hospital COPD patients
ii. an overview of existing systematic reviews of RCTs comparing domiciliary NIV with usual care, or
different types of NIV, in stable/post-hospital COPD patients
iii. a systematic review of uncontrolled studies (patients on domiciliary NIV only) with the aim of
supplementing the findings from controlled studies where evidence was lacking
iv. a systematic review of the evidence on the cost-effectiveness of domiciliary NIV compared with usual
care only in COPD patients
v. a model-based cost–utility analysis to determine the cost-effectiveness of domiciliary NIV compared with
usual care in stable/post-hospital COPD patients.
Methods for the clinical effectiveness review
Studies were eligible for inclusion if they met the following criteria: they were systematic reviews, RCTs,
non-randomised controlled studies or uncontrolled studies; the study population comprised adult COPD
patients (with or without LTOT or hypercapnia); the intervention was any form of domiciliary NIV added to
(any form of) usual care; and the comparator was usual care only or another form of NIV. There were no
restrictions on outcomes but, based on the need to inform the economic model, the primary outcomes for
the review were considered to be mortality, hospitalisations, exacerbations, QoL, adverse events and
adherence to NIV/discontinuations. Other outcomes, such as lung function and blood gases, were
considered secondary outcomes.
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Bibliographic databases (including MEDLINE, EMBASE, The Cochrane Library and the clinical trials registers)
were searched up to September 2014, and citation searching was undertaken. There were no
language restrictions.
Study selection was performed in duplicate using predefined criteria, based on full texts where necessary.
Disagreements were resolved through discussion and/or referral to a third reviewer. Reference
management software was used to document the study selection process.
Risk of bias was assessed using the Cochrane risk of bias tool (for RCTs), with additional criteria considered
for crossover trials. For non-randomised controlled studies, risk-of-bias assessment criteria were based on
Cochrane Handbook guidelines, and adapted in consultation with the wider review team. Uncontrolled
studies were not formally quality-assessed.
Data extraction was performed by one reviewer using a standardised, piloted data extraction form, with a
proportion checked by a second reviewer. Data were extracted on study and population characteristics,
intervention and comparator characteristics, study quality and results. Formal data extraction was not
performed on uncontrolled studies.
For analysis, studies were grouped according to whether the population was stable or post hospital (post
exacerbation). Random-effects meta-analysis was undertaken for mortality and some hospitalisation results,
with separate analyses for each outcome, population type (stable or post hospital) and study type (RCT or
non-randomised controlled). Further subgroup analyses (e.g. based on LTOT or level of hypercapnia) were
not feasible. Results for exacerbations and QoL were reported narratively and for secondary outcomes
were presented in forest plots without a pooled estimate. Given the small number of trials in each
meta-analysis, construction of funnel plots was deemed inappropriate.
For the review of cost-effectiveness studies, economic models, trial-based economic evaluations and
costing studies were eligible for inclusion. Relevant outcomes were cost-effectiveness, cost estimates,
resource-utilisation estimates and quality-of-life/utility estimates. Included studies were appraised using
relevant economic checklists.
A Markov decision model was developed to compare the cost-effectiveness of domiciliary NIV with usual
care from a UK perspective for two scenarios (stable and post-hospital populations). This is the first
economic model evaluating domiciliary NIV in COPD and potentially the first to differentiate between
COPD populations by proximity to a recent exacerbation requiring hospitalisation. The model was
structured to consider the short-term increased risk of readmission and subsequent mortality after a
hospital admission and the long-term natural history of the disease. The model had a time cycle of
1 month and a lifetime time horizon. All costs and outcomes were considered from a UK NHS perspective
for a price year of 2012. Where possible, data to inform the model were taken from the systematic review
of clinical effectiveness. Other sources included previously published audit and cohort study data.
Clinical effectiveness results
A total of 31 controlled studies (21 randomised and 10 non-randomised) were identified, on which the
main findings were based. Sixty-five uncontrolled studies met the inclusion criteria and were used to
supplement data from controlled studies where appropriate. Seven relevant systematic reviews
were identified.
For the stable population, there was a moderate amount of evidence to suggest no difference between
domiciliary NIV and usual care in terms of survival (up to 24 months’ follow-up). There appeared to be
a trend towards fewer hospital admissions/days in hospital with NIV in studies reporting this outcome, but
this difference was not statistically significant. There was little evidence on exacerbations (not leading to
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hospitalisations) and no significant differences were found. For QoL, there appeared to be a trend
favouring NIV, but a consistent benefit could not be demonstrated and there was heterogeneity in
reporting tools and time points. There was some evidence to suggest a benefit from NIV for improving
blood gases (based on mainly unadjusted results) but clinical significance of this potential improvement
remains uncertain.
There was less evidence overall for the post-hospital population, and no benefit was evident in terms of
survival from RCTs, although non-randomised controlled studies found a statistically significant difference
in favour of NIV. Findings for hospital admissions were inconsistent, with one trial finding a statistically
significant difference in favour of NIV, one marginally favouring NIV and the largest trial marginally
favouring usual care; these findings may be suggestive of population differences but it is not possible
to confirm this based on the current data. Quality-of-life data were reported in only one RCT for a
post-hospital population, and there were no differences between NIV and usual care. Limited data
(from two trials) suggested a potential benefit from NIV in terms of reduction in partial pressure of
carbon dioxide in the arterial blood (PaCO2).
No further subgroup analysis (beyond study design and population) was possible given the small number
of trials, the lack of reporting of relevant characteristics and other potential sources of heterogeneity
within and between studies. Exploratory analyses suggested a trend towards a correlation between
changes in CO2 and hospital admissions. Such a potential correlation was not observed for mortality.
However, the analysis uses aggregate data for change in CO2 and also for mean difference in hospital
admissions, and a causal association therefore cannot be inferred even if there is potential biological
plausibility. Further, this was a post-hoc analysis, which is subject to a number of limitations. It does
suggest that there needs to be further investigation of the association between CO2 and clinical outcomes,
such as hospital admissions.
There was a lack of reporting of some details relevant to study quality, particularly regarding handling of
missing data. Only three RCTs included a ‘sham NIV’ arm, a lack of which may have led to performance
bias and/or bias in patient-reported QoL. The non-randomised studies were more prone to bias overall.
Three small, short-term RCTs comparing different NIV settings were included. No conclusions could be
drawn regarding potential differences in QoL. One study found a statistically significant result in favour of
higher pressure for reduction of PaCO2.
Adverse events were inconsistently reported but were in line with those known to affect NIV patients
(e.g. mask discomfort, pressure experienced as too high, inability to sleep, etc.) and generally not serious.
There was only one potentially more serious adverse event (reported across all studies), which was a
suspected barotrauma.
Systematic review of cost-effectiveness
Two cost analyses suggesting that domiciliary NIV may be cost-neutral or cost-saving were identified.
However, neither study conducted a full cost-effectiveness analysis. There was, therefore, a need for a
de novo model to estimate lifetime cost-effectiveness of domiciliary NIV in a UK COPD population.
Results of economic evaluation
Base-case results for the stable population suggest that domiciliary NIV may be cost-effective at a threshold
of £30,000 per quality-adjusted life-year (QALY) gained, with an incremental cost-effectiveness ratio (ICER)
of £28,162 per QALY gained. Probabilistic sensitivity analysis suggested that domiciliary NIV had a 55%
probability of being cost-effective at the above threshold, demonstrating the uncertainty around the
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxix
impact of domiciliary NIV on hospital admission in this population. The effectiveness estimate for a
reduction in hospital admissions applied was not statistically significant. Key drivers of the model were
clinical effectiveness (hospital admissions and utility), duration of effect and elements of the cost of
domiciliary NIV provision. NIV was found to be more cost-effective (approaching an ICER of £20,000 per
QALY gained) when the benefits were assumed to last a lifetime, but there is currently no clinical evidence
to support this. Speculative modelling found that, for NIV to be cost-effective in the stable population,
there would need to be a 24% (or greater) reduction in the rate of hospital admissions per patient per
year with NIV or an increased utility score of 2.5%. The population expected value of perfect information
(EVPI) was £596M, which reflects the value of removing all uncertainty regarding the decision to adopt
domiciliary NIV at a willingness-to-pay threshold of £30,000 per QALY gained. This value is high because
of the large population potentially affected by this decision and should be considered indicative owing to
uncertainties regarding the prevalence of COPD and the proportion considered end-stage and stable.
For the post-hospital population, cost-effectiveness findings reflected the disparity of effectiveness findings
from the three available RCTs. As pooling of effectiveness results was not appropriate, base cases were
generated incorporating the individual effectiveness estimates from the three RCTs. Results ranged from
usual care being dominant to ICERs below £10,000 per QALY gained, depending on the base case. The
probabilities of NIV being cost-effective at a threshold of £20,000 per QALY gained were 0%, 72% and
100% for the three base cases. Speculative modelling found that, for NIV to be cost-effective in the
post-hospital population, there would need to be a 15% (or greater) reduction in the rate of hospital
admissions per patient per year with NIV. The results from the EVPI conducted for each case also gave very
mixed values for perfect information to inform the decision to offer domiciliary NIV to this population.
In both stable and post-hospital populations, the model was sensitive to risk of admission and death.
This highlights the importance of collecting more robust data on patient characteristics that determine
these risks.
The model results must be viewed as speculative because of the uncertainty around effect estimates and
some parameter inputs, a lack of long-term data and a lack of quality-of-life/utility data.
Conclusions
Overall, the evidence from RCTs could not consistently demonstrate a benefit from NIV compared with
usual care in either stable or post-hospital populations, although there was a trend towards fewer hospital
admissions and, to a lesser extent, towards improved QoL for the stable population. A benefit in terms of
survival for the post-hospital population was shown in non-randomised controlled studies only, and the
findings for hospital admissions (from RCTs) were inconsistent.
There was also too little evidence to draw any conclusions on the potential benefits of higher-pressure
NIV settings. In line with the clinical findings, a speculative economic model found that NIV may be
cost-effective in a stable population at a threshold of £30,000 per QALY gained, but this is associated with
a large amount of uncertainty. It is not possible to draw any overall conclusions regarding cost-effectiveness
in a post-hospital population, as the results based on three different base cases are too disparate and are
also based on limited evidence. It is likely that the broad categorisation into stable and post-hospital
patients has not been able to capture more subtle differences between patients, who may derive more or
less benefit from NIV. The findings of the report based on aggregate study-level (RCT) data are sensitive to
the emergence of future study data. Further evidence, potentially from currently ongoing trials but more
probably from individual patient data (IPD) analyses, is required to determine whether or not there are any
other patient characteristics or equipment settings that are predictive of a benefit of NIV and to establish
optimum time points for starting (and potentially discontinuing) NIV.
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Recommendations for future research
A number of currently ongoing studies may add to the evidence base. The results from this report will
need to be re-examined in the light of any new trial results, particularly in terms of reducing the
uncertainty in the economic model. Given this, recommendations for additional RCTs would be premature,
but any new RCTs should consider including a sham NIV arm and/or a higher- and lower-pressure arm in
order to evaluate effects of different settings. An appropriately conducted IPD analysis of all study data
may be more useful in informing some of the outstanding questions about the type of patient who might
benefit most from NIV. The feasibility of IPD to examine potential effect modifiers should be explored but
will be dependent on sufficiently high event rates and availability of information on effect modifiers for
all patients.
Study registration
This study is registered as PROSPERO CRD42012003286.
Funding
The National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 Background
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a chronic progressive lung disease characterised by
non-reversible airflow obstruction, mostly affecting middle-aged or elderly people who have smoked. The
most important cause of COPD is cigarette smoking, although other risk factors are thought to be indoor
and outdoor air pollution, occupational exposures and diet.1 Over time, patients experience increasing
breathlessness, leading to increasing disability and loss of health-related quality of life (HRQoL). Many
COPD patients will experience worsening of their symptoms, often precipitated by infection, on a regular
basis.2 These are known as exacerbations. COPD accounts for one in eight medical hospital admissions in
the UK, most of which will be for exacerbations, and costs the NHS in excess of £800M per annum.3
Currently, treatment is mainly symptomatic, although it also aims to slow down disease progression. The
main evidence-based treatments are inhaled agents, such as bronchodilators4 and pulmonary rehabilitation.5
Diagnosis
Airflow obstruction is diagnosed by spirometry, performed after use of a bronchodilator. Spirometry
generates a forced expiratory volume in 1 second (FEV1) and a forced vital capacity (FVC); it is the ratio
between these two figures that defines airflow obstruction. Although definitions of airflow obstruction are
inconsistent and controversial,6 National Institute for Health and Care Excellence (NICE) guidance currently
defines airflow obstruction as FEV1/FVC< 0.7.4 This is one of two common definitions; the other is to
define it as any value of FEV1/FVC that is less than the lower limit of normal for the patient’s age.6
Severity
Severity of airflow obstruction is graded using categories of FEV1 as a percentage of predicted normal
values of a healthy reference population.1,4 Table 1 outlines some severity categories. The definitions of
different grading categories vary somewhat and have changed over time. For example, the Global Initiative
for Chronic Obstructive Lung Disease (GOLD)1 has proposed a revised COPD grading system that
incorporates symptoms and HRQoL into the severity categories.
Most research studies evaluating treatments use FEV1 % predicted to select and describe patients. FEV1 is
also often used as an outcome measure to describe prognosis of patients, as are clinical measures such as
dyspnoea and exacerbations, HRQoL and health-service utilisation (e.g. hospital admissions1).
Severity of airflow obstruction does not necessarily reflect either the level of disability experienced or the
frequency of exacerbation, and composite measures to capture the global impact of the disease have been
proposed.1,7 However, they are not yet widely used as the basis for treatment decisions.
TABLE 1 Severity of COPD
GOLD category NICE category FEV1 % predicted
1 Mild > 80
2 Moderate 50–79
3 Severe 30–59
4 Very severe < 30
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In more severe disease, respiratory failure can occur [hypoxia with resting pO2 (partial pressure of oxygen)
< 8 kPa]. Respiratory failure may be either type 1, in which arterial carbon dioxide is normal or low, or type 2,
in which the patient is hypercapnic (elevated arterial CO2). It is not yet clear which factors predispose to the
different types of respiratory failure or how quickly it will develop or progress. Type 2 respiratory failure can
also result in acidosis of the circulating blood; this is known as acute hypercapnic respiratory failure (HRF).
Acidosis is not present in the stable state, as it is compensated for by renal mechanisms of acid–base balance.
End-stage COPD could be defined in several ways; classically, it would concern those patients in the terminal
stage of their disease who were likely to die within months, a situation which is not always clear. Attempts
are being made to define the disease trajectory at the end of life, but it remains hard to predict.8
Alternatively, patients with end-stage COPD might be defined as those who have developed chronic
respiratory failure and remain symptomatic on maximal therapy, with no hope of cure. This is a significant
population, who could potentially be stabilised for years. For the purposes of this report, the latter, broader
definition prevails, as this encompasses the wide population for whom domiciliary non-invasive ventilation
(NIV) has been considered in some studies and in practice.
Exacerbations
Exacerbations or ‘flare-ups’ of COPD occur in approximately 50–60% of moderate/severe COPD patients
per year.2,9 An exacerbation can be defined as an acute event characterised by a worsening of the patient’s
respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.1
The most common causes are respiratory tract infections, either viral or bacterial, although other factors,
including pollution,10 can precipitate them. Exacerbations play a very important role in COPD, as they are a
key cause of increased morbidity, mortality and poor health status and place a considerable burden on the
health-care system.11
It is estimated that approximately 75% of exacerbations can be managed in the community with
antibiotics, corticosteroids and bronchodilators.12 Half of exacerbations treated in the community result in
patients recovering to their baseline level in about 7 days; however, in 14% of such events patients do not
reach their baseline level after 35 days, and a few never return to baseline.13
In general, a severe exacerbation is defined as one that results in hospitalisation (Table 2). Approximately
15% of COPD patients per year have exacerbations severe enough to lead to hospital admission, with a
median length of stay in the UK of 8 days. This contributes to over half of the total direct costs of COPD to the
NHS.3,15 Between 10% and 25% of patients admitted with HRF caused by COPD die in hospital.16 Readmission
for an exacerbation within 3 months is high, at over 30%, as is 30-day mortality. In those requiring artificial
ventilation in hospital (intubation or NIV), mortality may be as high as 40% at 1 year after discharge, and the
all-cause mortality 3 years after hospitalisation is higher still.16 It is therefore evident that hypercapnic COPD
patients, and those who have previously used ventilation in hospital, may have a poor prognosis.
Exacerbations have an adverse effect on a patient’s quality of life (QoL).11 It may take many weeks for the
symptoms to abate and lung function to recover; they have also been shown to lead to a rapid overall
decline in lung function.17 Some patients appear to suffer from frequent exacerbations while others do not.
Those reporting two or more exacerbations of COPD per year are classified as ‘frequent exacerbators’.2
TABLE 2 Severity of exacerbations14
Severity of exacerbation Defining features
Mild Uses normal medication more than usual
Moderate Requires antibiotics and/or steroids
Severe Admitted to hospital
Source: Jones and Higenbottam (2007).14
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Exacerbations are important outcome measures in COPD and a reduction in exacerbation frequency is an
important target to achieve for any intervention.
Quality of life
Health-related QoL is known to be impaired by COPD, even at relatively early stages,18 and gets worse
with more severe disease and with exacerbations.19 Many tools are available to monitor HRQoL
in COPD, and have been reviewed elsewhere;20 they may be generic (i.e. used in any health problem),
respiratory-specific or COPD-specific (e.g. COPD assessment test).21 Tools commonly used in clinical trials
include the St George’s Respiratory Questionnaire (SGRQ)22 and the Chronic Respiratory Questionnaire
(CRQ). As with all questionnaires, it is possible that scores vary between the tools used; indeed, this has
been the case in COPD when comparing a generic tool [Short Form questionnaire-36 items (SF-36)], the
SGRQ and the CRQ.23 Other tools include the Severe Respiratory Insufficiency Questionnaire (SRI) and
Maugeri Foundation Respiratory Failure questionnaire (MRF-28).24
Management of chronic obstructive pulmonary disease
Pharmacotherapy in stable COPD is mainly directed at airflow obstruction and inflammation. It is recommended
that short- and long-acting bronchodilators be used in a stepwise manner, with the addition of inhaled
corticosteroids later in the disease. In addition to pharmacotherapy, pulmonary rehabilitation is recommended
for breathless patients.4 This is a programme of exercise and education which has been shown to be very
beneficial in COPD patients.25 Patients may also be taught various self-management techniques, the efficacy of
which has recently been reviewed by some of the authors of this report.26
In general, treatment is aimed at improving lung function, defined by FEV1, and/or HRQoL and
exacerbation frequency. Many drug treatments have also tried to improve longer-term outcomes, such
as lung function decline12 and mortality,27 with limited success. In addition to the general treatments
described above, long-term oxygen therapy (LTOT) should be considered28 in patients with pO2 < 7.3 kPa,
or < 8 kPa in the presence of cor pulmonale,29 because it improves mortality. Other forms of oxygen use in
COPD are more controversial; oxygen use just on walking (ambulatory oxygen) is used in selected patients
not on LTOT if their oxygen levels drop on objective testing.30 Short-burst oxygen therapy, defined as
oxygen used outside the context of LTOT or ambulatory oxygen, is not recommended because of lack of
benefit.31 Another treatment that has been proposed for selected COPD patients is domiciliary use of NIV,
which is the subject of this review.
Non-invasive ventilation
Non-invasive ventilation is a method of providing ventilatory support via a mask, without the placement
of an endotracheal tube. In contrast to traditional intensive care unit (ICU) mechanical ventilators, NIV
machines are generally compact and lightweight and can be applied by a patient with minimal or no
assistance; it is therefore possible to use them outside the hospital. Machines will deliver pressure support
during the breathing cycle and will sense the respiratory cycle such that, if no breaths are taken, back-up
breaths can be delivered. NIV aims to improve tidal volumes while breathing and reduce ventilatory effort by
resting tired respiratory muscles, as well as to improve fatigue, lung function and gas exchange, particularly
during disease exacerbations.
Types of non-invasive ventilation
Non-invasive ventilation delivers two different pressures; that is, a different pressure on inspiration
[inspiratory positive airway pressure (IPAP)] from expiration [expiratory positive airway pressure (EPAP)].
It differs from continuous positive airway pressure (CPAP), another non-invasive form of respiratory
support, which aims to maintain a continuous level of positive airway pressure. The type of NIV is generally
described by the way in which the machine is set up, such that it will be either pressure controlled or
volume controlled. In pressure-controlled settings, the main descriptors for treatment will be the IPAP and
EPAP, although a back-up rate will usually also be set. The mask type may also be described, with most
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patients using a full-face mask, although nasal-only devices are also available. Once patients start NIV, the
parameters can be varied according to their ability to tolerate treatment and their response; for instance,
an in-patient NIV protocol might start at relatively low IPAP and titrate upwards until the patient’s blood
gases improve, stopping any further elevation in pressure if the patient finds it uncomfortable. While there
is no widely accepted definition of low-pressure and high-pressure NIV, there has been work to suggest
that degree of IPAP may relate to outcome, and there has been an increasing trend towards the use
of higher pressures in more recent studies32,33 compared with older studies.34,35 The type of NIV most useful
to COPD is not clear; neither are the optimal pressure setting and optimisation protocol. It is likely that
there will be significant patient variability and individualised protocols will be required.
Domiciliary NIV is usually used overnight during sleep, although hours of use may gradually climb with
time until daytime use is also needed.
Use of non-invasive ventilation for chronic obstructive pulmonary disease in
hospital settings
There is good evidence that HRF during an acute exacerbation should be treated with NIV;4 a Cochrane
review (Ram et al. 200436) of NIV found statistically significant benefits in favour of NIV for a wide range
of outcomes, including treatment failure (based on eight trials), risk of intubation (based on 14 trials),
length of hospital stay (based on eight trials), complications (based on three studies) and mortality
(based on 10 trials).
Use of non-invasive ventilation in stable chronic obstructive pulmonary
disease patients
The evidence from NIV use in a hospital setting led to trials of domiciliary NIV, aimed at reducing mortality
and readmission rates; this is the subject of this report.
Increasingly employed for longer-term treatment of patients suffering from chronic HRF due to thoracic
cage disorders, neuromuscular disorders and various other causes of nocturnal hypoventilation syndrome,37
long-term NIV offers theoretical benefits in certain groups of chronic end-stage COPD patients. Clinically,
despite the success of NIV in acute HRF with COPD, survivors continue to suffer from further episodes/
exacerbations after discharge.38 Thus, a utility of domiciliary NIV is thought to lie in preventing recurrent
admission to hospital and slowing declining health.
The National COPD strategy consultation in 2010 highlighted NIV as an area of COPD therapy that
warranted review and/or further research.39
Domiciliary non-invasive ventilation: existing clinical effectiveness evidence
Despite the existence of a number of randomised controlled trials (RCTs) and systematic reviews of RCTs,
there remains uncertainty around the clinical effectiveness of domiciliary NIV in COPD, particularly with
regard to patient and health service-related outcomes likely to be important in an economic model
(e.g. survival, hospital admissions, exacerbations and QoL). See Chapter 5, Review of systematic reviews,
for a more detailed assessment of existing systematic reviews.
Domiciliary non-invasive ventilation: existing cost-effectiveness evidence
Currently, there are no cost-effectiveness studies of domiciliary NIV in patients with stable end-stage
COPD, only cost studies (see Chapter 6, Results).
In the UK, domiciliary NIV is considered on health economic grounds if a patient has had three hospital
admissions with acute HRF,40 although, given the absence of a full economic evaluation, such use could
be considered not fully evidence based. Given this, an economic evaluation of domiciliary NIV in stable
end-stage COPD is warranted.
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Decision problem
This project was commissioned to determine the cost-effectiveness of community-based NIV in patients
with stable end-stage COPD plus chronic HRF. However, a scoping review of the existing clinical
effectiveness evidence, in particular existing systematic reviews, found that there was a lack of reporting
on outcomes likely to be important for informing economic modelling; therefore, it was decided to
additionally undertake a systematic review of the clinical effectiveness with the aim of using the findings to
populate the economic model where possible.
Population
The National Institute for Health Research (NIHR) call relating to this project (11/27/01) specified ‘adult
patients with stable end-stage COPD plus chronic HRF, who have required assisted ventilation (whether
invasive or non-invasive) during an exacerbation or who are hypercapnic or acidotic on LTOT.’
The following points are worth considering:
l This specification includes a number of types of patient, that is:
¢ stable patients who have required assisted ventilation during an exacerbation
¢ stable patients who are hypercapnic on LTOT (regardless of whether or not they have required
assisted ventilation during an exacerbation)
¢ patients who are acidotic on LTOT.
l ‘Acidotic on LTOT’ implies the absence of stable disease, as it usually requires acute treatment
in hospital.
l The determination of whether or not a patient has stable disease and/or end-stage disease is, to some
extent, subjective.
In order to capture all relevant groups, studies with both stable patients and post-hospital (exacerbation)
patients were eligible for inclusion into separate analyses.
This report therefore necessarily considers a broad definition of patients, that is any adult patient with
COPD with or without HRF (however defined), and includes any patients recently discharged from hospital
(following an exacerbation) or more stable patients, without restriction to a specific disease severity.
Setting
The NIHR brief specified a community setting and this was taken to mean any setting where NIV was not
used in an acute setting or a research setting. Therefore, evidence was not considered when NIV was given
in hospital or immediately before hospital during an exacerbation or, for example, when NIV was given
during exercise assessment as part of a pulmonary rehabilitation programme. In practice, only studies
where patients used NIV in their own home were identified, although other domiciliary settings, such as a
care home, would have been eligible.
Intervention
Any form of NIV, whether continuous or intermediate, added to (any form of) usual care was considered.
There were no restrictions according to length of daily use.
While the term ‘NIV’ in its broadest sense refers to any type of NIV, as opposed to invasive techniques, in
this context it is used to mean a system that delivers two different pressures. The following terms can all
mean NIV (i.e. systems with two positive pressures), provided they are non-invasive: bilevel positive airway
pressure (BIPAP), non-invasive positive-pressure ventilation or nasal intermittent positive pressure ventilation
(both referred to as NIPPV), non-invasive mechanical ventilation, positive pressure ventilation and (nasal)
proportional assist ventilation.
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Negative pressure ventilation (NPV) is rarely used routinely but also delivers two pressures (although one
relates to ambient pressure); studies using NPV would have been eligible for inclusion and would have
been considered separately (none was identified). CPAP was excluded, as it delivers constant pressure and
is thus a distinct therapy; it is primarily used to treat sleep apnoea.
Comparator
While the NIHR brief did not specify looking at different types of NIV, it is becoming apparent that higher
pressures are increasingly being used (see Chapter 1, Types of non-invasive ventilation). Therefore, studies
with head-to-head comparisons of different NIV settings (particularly pressure, or pressure vs. volume
controlled) were of interest and considered. Other differences include mask type and number of hours of
use per day. Length of daily use and a need for longer periods of use, for example during the day as well
as during the night may also be related to severity of disease.
Discontinuing domiciliary NIV was not covered by the remit for this report. Therefore it is not considered.
However, the availability of evidence on the effect of discontinuing was noted (see Chapter 4,
Discontinuation studies).
Outcomes
As the NIHR brief was for an economic evaluation, the primary effectiveness outcomes were considered
to be those relating to survival, health-care service utilisation (as a results of exacerbations), patient QoL
and adherence to NIV/discontinuations. Secondary outcomes {relating to lung function, blood gases,
exercise capacity [e.g. 6-minute walking distance (6MWD)], quality of sleep, activities of daily living and
acceptability} were not relevant for the economic model, as cost and utility changes associated with
changes in these outcomes cannot be measured. However, in order to present a full clinical picture of the
effect of NIV, and to be consistent with previous systematic reviews, data on key secondary outcomes
were extracted and presented. A decision was made to focus on lung function (FEV1, FVC), blood gases
[partial pressure of carbon dioxide in the arterial blood (PaCO2), partial pressure of oxygen in the arterial
blood (PaO2)] and 6MWD. Hydrogen carbonate (HCO3–) and pH are to some extent reflected in other
blood gas measures, and measures of activity are reflected to some extent in QoL measures and 6MWD.
Further, there is a lack of validated questionnaires for activities of daily living and also for sleep quality;
hence, data were not extracted for these outcomes.
Study design
Based on an overview of existing clinical effectiveness reviews of RCTs, it was apparent that a lack of large,
long-term studies, variations between study methods and physiological or clinical outcomes measured,
and a lack of adjustment for clinical variables (such as oxygen use or prior acute NIV use) have limited the
conclusions that can be drawn. In particular, RCTs appear to have insufficiently long follow-up periods to
capture outcomes relating to survival, long-term HRQoL, exacerbations over the long term, adverse events
or adherence rates. Further, the clinical perception is that inclusion criteria for the RCTs may be narrow
and restricted to patients with very specific characteristics, calling into question their applicability to a wider
population. There may also be clear subgroups within current trials which warrant formal meta-analysis not
conducted in prior reviews.
As a further review based on RCTs alone might be insufficient to derive all the necessary (long-term)
parameters needed to adequately populate an economic model, non-randomised controlled studies and
uncontrolled studies are also considered in this report.
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Chapter 2 Aims of the review
G iven the remit and the above context, the aims of this report were to undertake:
1. a systematic review of RCTs and non-RCTs comparing domiciliary NIV with usual care, or different types
of NIV, in COPD patients either who are in a stable state of disease (stable population) or who
commence NIV immediately after a period of hospitalisation/exacerbation (post-hospital population)
2. an overview of existing systematic reviews of RCTs comparing domiciliary NIV with usual care, or
different types of NIV, in COPD patients
3. a systematic review of uncontrolled studies (patients on domiciliary NIV only) with the aim of
supplementing the findings from the controlled studies where evidence was lacking
4. a systematic review of the evidence on the cost-effectiveness of domiciliary NIV compared with usual
care only in COPD patients
5. a model-based cost–utility analysis to determine the cost-effectiveness of domiciliary NIV compared with
usual care only in COPD patients (stable and post-hospital populations).
Aims 1 to 3 relate to the systematic review of clinical effectiveness and are addressed in Chapters 4 and 5
of this report; aims 4 and 5 relate to the systematic review of cost-effectiveness and the economic model
and are addressed in Chapters 6 and 7.
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Chapter 3 Clinical effectiveness review methods
This chapter outlines the methods for the review of clinical effectiveness as detailed in the aims(see Chapter 2).
The protocol for this project was registered with PROSPERO (2012:CRD42012003286) and has been
published on the NIHR Health Technology Assessment programme website (www.nets.nihr.ac.uk/projects/hta/
112701). A version of the protocol was also published in the journal BioMed Central Systematic Reviews.41
Searches
Searches for studies to populate the systematic review were devised to incorporate a combination of text
words and index terms relating to NIV (intervention) and COPD (population). Given that NIV has been in
routine use since the early 1990s, and one of the main co-interventions/comparators (LTOT) since the
1980s, searches were run from 1980 to September 2014, inclusive, to ensure that no relevant studies were
missed. No study design or language restrictions were imposed.
The following sources were searched:
l bibliographic databases – MEDLINE, MEDLINE In Process & Other Non-Indexed Citations and EMBASE
via Ovid, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health
Literature (EBSCOhost) and Science Citation Index Expanded (ISI)
l MEDLINE and EMBASE via Ovid and NHS Economic Evaluation Database (Cochrane Wiley) for studies
relating to QoL, cost and cost-effectiveness
l Applied Social Sciences Index and Abstracts (ProQuest), Social Sciences Citation Index (ISI), International
Bibliography of the Social Sciences (ProQuest), PsycINFO (Ovid) and Sociological Abstracts (ProQuest)
for qualitative studies
l metaRegister of Current Controlled Trials, International Standard Randomised Controlled Trial Number
(ISRCTN) database, UK Clinical Research Network, the World Health Organization’s International
Clinical Trials Registry Platform Portal and ClinicalTrials.gov for ongoing studies
l the Cochrane Airways specialised register
l The British Library’s Electronic Table of Contents and ISI Conference Proceedings Citation Index for
abstracts and proceedings.
In addition to the above, experts in the field were consulted, citation lists of included studies and relevant
reviews were checked and selected websites were searched for grey literature. For full search strategies,
see Appendix 1.
Study selection
Screening and study selection strategy
Titles (and abstracts, where available) of articles identified by the searches were screened by two reviewers
for relevance to the review question using prespecified screening criteria. Hard copies of potentially relevant
articles were acquired and assessed against the full inclusion criteria (Table 3) by two reviewers independently.
Discrepancy between reviewers was resolved by discussion or by referring to a third reviewer. Where
necessary, translation (full/part) of non-English-language articles was undertaken to facilitate this process and
subsequent reviewing. The study selection process was illustrated using a PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) flow diagram. Reference management software (Reference
Manager version 11, Thomson ResearchSoft, San Francisco, CA, USA) was used to record reviewer decisions,
including reasons for exclusion.
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TABLE 3 Study selection and analysis criteria
Study selection
criteria Included Excluded
Study design RCTs, observational studies with n> 1, systematic
reviews (at least one database searched)
Narrative reviews, commentaries, non-human/
laboratory studies, single-case reports
Publication type Full articles, letters, conference abstracts
2010–present, ongoing study reports
Conference abstracts from 2009 or older
Population COPD patients. Studies where only a proportion
had COPD were included. There were no
restrictions by disease severity, history of
exacerbations or comorbidities (except where
patients also had sleep apnoea)
Studies where the primary condition was not
COPD; patients with overlap syndrome
(COPD and obstructive sleep apnoea)
Intervention Any type of NIV added to (any) usual care. NIV
here means any non-invasive system delivering
two different positive pressures. Studies using
NPV were eligible for inclusion
Any invasive system, or non-invasive system
delivering continuous pressure, such as CPAP
Setting Any domiciliary setting (e.g. own home, nursing
home)
Studies where:
l research staff were present during the study
l NIV was given during exercise as part of a
pulmonary rehabilitation programme
l NIV was given in hospital
Outcomes for
analysisa Included Excluded
Primary l Survival
l exacerbations
l hospital admissions or other health-care
resource use
l QoL (generic or disease specific)
l adverse events
l adherence
Quality-of-life questionnaires that were not
disease specific (e.g. SGRQ) and not generic (e.g.
SF-36), for example relating to anxiety/depression
(HADS)
Secondary l FEV1
l FVC
l PaO2
l PaCO2
l pH
l HCO3–
l exercise capacity (6MWD)
l dyspnoea
l quality of sleep
l levels of activity/daily living
Other secondary outcomes such as:
l MIP/PImax
l RV/TLC
l VC
l MEP
l airway resistance
l CT imaging for assessing lung function
l endotracheal intubation frequency
CT, computed tomography; HADS, Hospital Anxiety and Depression Scale; MEP, maximum expiratory pressure;
MIP/PImax, maximum inspiratory pressure; RV, residual volume; TLC, total lung capacity; VC, vital capacity.
a Study selection was not restricted by outcome. The outcomes presented here represent the primary and secondary
outcomes for the analysis of the included studies.
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Selection criteria
Study design
Systematic reviews, RCTs and controlled or uncontrolled observational studies with n> 1 were included.
There were no restrictions on the type of RCT (e.g. parallel, crossover).
Patient group
Adult patients with COPD, with or without hypercapnia and with or without LTOT. When only a
proportion of patients in a study met the inclusion criteria, the study was eligible for inclusion. Data were
extracted only where results for relevant patients could be separated. Patients with any comorbidities were
included, except where they had overlap syndrome (COPD and obstructive sleep apnoea).
Technology
Any form of NIV, whether continuous or intermediate, added to (any form of) usual care.
Setting
Any domiciliary setting (e.g. own home, care home).
Comparators/control (for controlled studies)
(a) Any form of usual care with no NIV (or with sham NIV); it is noted that both the setting and the nature
of usual care in the absence of treatment with NIV may be different from those of treatment with NIV;
such differences did not affect inclusion/exclusion decisions, but were noted and commented upon.
(b) Studies comparing alternative methods of NIV.
Outcomes
Study selection was not restricted by outcomes. Based primarily on the need to inform the economic
evaluation model, outcomes to be analysed from included studies were:
l mortality
l hospitalisations, including accident and emergency (A&E) admissions or other health-care resource use
l exacerbations (and requirements for associated medication)
l QoL
l adverse events
l adherence to NIV/discontinuations.
These were considered to be the primary outcomes for this report.
Other outcomes likely to be reported in included studies were:
l lung function (FEV1, FVC)
l blood gases (PaO2, PaCO2)
l pH
l HCO3–
l dyspnoea
l exercise capacity (e.g. 6MWD)
l other patient-related outcomes such as quality of sleep, activities of daily living and acceptability.
These were considered to be secondary outcomes, as they could not be used to inform the economic
evaluation model. However, data were extracted for FEV1, FVC, PaO2, PaCO2 and 6MWD (see Chapter 1,
Decision problem).
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Publication type
Identified ongoing and/or unpublished studies were included if they met the above criteria. The triallists
were contacted for additional information and data. Conference abstracts from 2010 were considered,
as these may relate to studies that have not yet been fully published.
A summary of study selection criteria is shown in Table 3 (see also Chapter 1, Decision problem).
Assessment of risk of bias
Data were extracted to allow quality assessment of the included studies. For systematic reviews, the AMSTAR
(A Measurement Tool to Assess Systematic Reviews) checklist was used.42 The risk of bias tool from the
Cochrane Handbook43 was used for RCTs. The domains relate to selection bias, performance bias, detection
bias, attrition bias and reporting bias. For crossover trials, the following additional areas of risk of bias were
assessed:44 (1) if there was a carryover effect; (2) if only first-period data were available; (3) if analysis was
appropriate to crossover trials; and (4) the comparability of results with those from parallel-group trials.
For controlled observational studies, risk-of-bias assessment criteria were based on the guidelines outlined
in chapter 13 of the Cochrane Handbook;45 these were adapted in consultation with the wider review
team. The most relevant criteria relate to how the groups were selected and differences in patient
characteristics, as well as potential differences in usual care and differential loss to follow-up or outcome
assessment. Uncontrolled observational studies were not formally quality-assessed. See Appendix 2 for all
quality-assessment criteria.
The GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework46 was
used (for primary outcomes of controlled studies only) to consider inconsistency (or heterogeneity)
between studies, precision (uncertainty) of results, likelihood of publication bias and applicability of results
to population(s) of interest.
Data extraction
Data relating to all aspects of the study were extracted by one reviewer using a standardised, piloted data
extraction form in Microsoft Excel® version 2010 (Microsoft Corporation, Redmond, WA, USA); a second
reviewer checked all numerical data. For foreign-language papers, independent checking was not always
possible. Data were extracted on study and population characteristics, intervention and comparator
characteristics, study quality and results.
In particular, details were sought on factors that could potentially inform subgroup analysis and economic
model parameterisation, including severity of disease (GOLD stage), level of hypercapnia, number of
patients on LTOT, history of exacerbations (frequent vs. non-frequent exacerbators), obesity, ruling out
of sleep apnoea (overlap syndrome), whether or not patients were in a stable state or commenced the
study immediately after a hospital admission, details on type of ventilation (e.g. different pressure settings)
and number of hours of use per day of NIV.
Not all studies reported exacerbations as a predefined outcome; instead, some reported it as an adverse
event or reason for discontinuation. In this case, the data were still extracted and the potential for selective
reporting was assessed.
Authors were contacted for additional information on primary outcomes where results could potentially be
included in a meta-analysis and/or inform the economic model (hospitalisation and survival data).
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Uncontrolled studies were explored when relevant data were not (sufficiently) available from controlled
studies; in particular, larger uncontrolled studies with longer follow-up times were considered. See
Chapter 4, Survival, Hospitalisations, Exacerbations and Quality of Life, for more details on selection of
uncontrolled studies. Formal data extraction was not performed.
Analysis
Primary outcomes
Narrative synthesis of evidence was undertaken for all included (controlled) studies. For primary outcomes,
meta-analysis was undertaken in Stata (Version 10, StataCorp LP, College Station, TX, USA) where there
was clinical and methodological homogeneity between studies reporting the same outcome and using the
same outcome statistic (reported or calculable, see Appendix 3 for more detailed methods). As outlined
in the decision problem (see Chapter 1, Decision problem), a distinction was made between stable and
post-hospital populations, and studies were subgrouped accordingly for meta-analyses. Studies were also
subgrouped according to study design (RCTs or non-randomised controlled studies).
Given probable residual clinical heterogeneity, a random-effects model was deemed most appropriate.
The I2 statistic (which gives the percentage of the total variability in the data caused by between-study
heterogeneity) was reported and commented on where appropriate. Further subgroup analysis (beyond
stable and post-hospital populations or study design) was considered, subject to sufficient numbers of
studies being available.
Construction of funnel plots to aid assessment of potential publication bias was planned where there were
at least 10 studies in a meta-analysis. Sensitivity analyses, that is assessments of the robustness of any
meta-analysis conclusions to the inclusion/exclusion of low-quality studies (those at most risk of bias), were
planned, subject to sufficient numbers of studies and adequately reported quality criteria. Heterogeneity
between studies (in terms of population and intervention characteristics) was explored in order to assess
the feasibility of an indirect comparison. Small numbers of studies and/or clinical and methodological
heterogeneity precluded the undertaking all of these analyses.
Secondary outcomes
Secondary outcome results (for FEV1, FVC, 6MWD, PaCO2, PaO2) were presented in forest plots to show
the overall direction of effect, but were not pooled (see Chapter 1, Decision problem, for choice of which
secondary outcomes to analyse). The following factors potentially leading to between-study heterogeneity
were explored when considering whether or not to undertake meta-analyses: baseline imbalances,
adjusted or unadjusted results, time points presented, type of RCT (parallel or crossover) and adequately
presented (or calculable) data.
Presentation of results
In the following chapters, results have been presented separately for (1) studies comparing NIV and usual
care (with or without sham NIV) and (2) studies comparing different types of NIV. When possible, results
are reported by population and study design.
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Chapter 4 Clinical effectiveness review results
This chapter presents the results of the clinical effectiveness review.
Volume of evidence
A total of 7402 titles (and abstracts where available) were screened independently by two reviewers using a
screening form. Overall, 432 full texts were obtained, and full inclusion and exclusion criteria (see Table 3) were
applied by two reviewers independently. Full texts of three further studies, identified through citation checking,
were also obtained and assessed for inclusion. All discrepancies were resolved through discussion. Twenty-one
articles could not be obtained (see Appendix 4, see Table 54) and further details to aid decision-making on
four articles were requested from study authors without reply (see Appendix 4, see Table 55).
A total of 158 articles relating to 140 individual studies met the full inclusion criteria. The article selection
process is outlined in a flow diagram in Figure 1 and a listed of excluded studies can be found in Appendix 4
(see Table 49). Twenty-nine studies were not further analysed, despite meeting the inclusion criteria, because
results were not separable for COPD patients where studies included mixed populations (25 studies),47–70
two studies addressed a different question71,72 (discontinuation of NIV; see Discontinuation studies) and one
was a study protocol of an RCT.73 In the case of one further study67 in a COPD population, results were not
presented for the usual-care group and the information was not obtainable from the authors.
Further information required
(no response from authors)
(n = 4)
 
Articles identified through
other source
(n = 3)  
 
Manually removed
duplicates
(n = 1249)
Records excluded
(n = 5700) 
Full-text articles excluded
with reasons
(n = 273)
Unavailable full-text
articles
(n = 21)
Full-text articles assessed
for eligibility
(n = 3) 
 
 Included articles
(n = 3)
Total included articles
(n = 158)
 
Id
en
ti
fi
ca
ti
o
n
 
In
cl
u
d
ed
 
Sc
re
en
in
g 
El
ig
ib
ili
ty 
Records identified through
database searching after
automatic removal of
duplicates
(n = 7402)  
 
Records screened
(n = 6153)
Full-text articles assessed
for eligibility
(n = 432)
Included articles
(n = 155)
FIGURE 1 Flow diagram depicting article selection for clinical effectiveness review.
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Of the remaining 111 studies, there were 21 RCTs (18 comparing NIV with usual care and three comparing
different types of NIV), 10 non-randomised controlled studies (five prospective and five non-prospective),
eight systematic reviews and 72 uncontrolled studies. Of the 31 controlled studies, six (19%) were available
only in a language other than English (Chinese, German, French and Polish) and required partial or
full translation.
The division of the included articles is outlined in Figure 2.
Appendix 5 gives brief details on all 72 uncontrolled studies; systematic reviews are discussed in Review of
systematic reviews, and controlled studies are reviewed in the sections below.
Uncontrolled
(95 articles)
(n = 93 studies) 
Controlled, non-randomised
(14 articles)
(n = 12 studies)
RCTs
(37 articles)
(n = 27 studies)
Systematic reviews
(12 articles)
(n = 8 studies)
vs. Control
(n = 18)
vs. NIV
(n = 3)
NIV discontinuation
(n = 2)
Results not 
separable for COPD
(n = 3)
Protocol only
(n = 1)
Prospective
(n = 27)
Retrospectivea
(n = 45)
Results not
separable for COPD
(n = 21) 
Prospective
(n = 5)
Retrospectivea
(n = 5)
Results not
separable for COPD
(n = 1) 
No control group data
(n = 1)
Included articles
(158 articles)
(n = 140 studies)
Studies considered in
this report 
Studies not considered
in this report
FIGURE 2 Outline of included studies. a, Including data analyses and cross-sectional studies.
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Clinical effectiveness results: non-invasive ventilation versus
usual care
This section details the studies (18 RCTs and 10 non-randomised) that compared NIV with usual care.
Study and population characteristics
Patient numbers across the 18 RCTs varied between 13 and 201 (total number of patients 1095). Only
three RCTs had > 100 patients (by McEvoy et al. in 2009,74 n= 144; Struik et al. in 2014,75 n= 201; and
Köhnlein et al. in 2014,76 n= 195). Length of follow-up varied between 3 and 24 months. There were two
crossover trials34,77 (3 months’ follow-up). One RCT was reported as an abstract only;78 this was an interim
(3 month) report of the ongoing HOT-HMV (Home Oxygen Therapy versus Home Mechanical Ventillation)
trial (see Ongoing studies). One RCT was reported in two publications (by Duiverman et al. in 200879 and
201180), the first79 reporting outcomes after 3 months, during which time usual care in all patients took the
form of a rehabilitation programme, and the second80 reporting over a longer follow-up period, with usual
care now switched to less-intensive home-based rehabilitation.
Patient numbers across the 10 non-randomised controlled studies varied between 34 and 140 (total
number of patients 664). Five were prospective studies, in which a group of patients on NIV and a group
of patients receiving only usual care (usually those who refused NIV) were followed up over a period of
between 12 and 35 months. Five were retrospective analyses of previously gathered data, with follow-up/
analysis periods of 6 months, 12 months and 4, 8 and 10 years (see Study quality on quality assessment
for potential selection bias in non-randomised studies).
The average age of patients across RCTs and non-randomised controlled studies varied between 60 and
73 years, and there were typically more men than women (between 41% and 98% men).
Most RCT populations were described as having GOLD stage 3 or 4, had mean FEV1 % predicted values
that were indicative of severe/very severe COPD and/or were described as severe (with no indication of
the classification system used). One RCT81 reported no details. There are unlikely to be major differences
between RCTs in terms of severity, although the relative proportions of patients with stage 3 and 4 disease
are unknown. Most RCTs described populations as being hypercapnic, although the PaCO2 cut-off points
for inclusion varied (e.g. > 6 kPa, > 6.6 kPa). Three RCTs34,81,82 presented mean PaCO2 levels only, which
were suggestive of at least a proportion of patients being hypercapnic. Two RCTs83,84 included normocapnic
patients, while one85 stated that the number of hypercapnic patients included was small.
Seven of the non-randomised controlled studies also appeared to include mainly GOLD stage 3 and
4 patients; three studies86–88 provided no details. Eight studies included hypercapnic patients (based on
PaCO2 cut-off points for seven), one86 presented mean PaCO2 levels only, which were suggestive of at least
a proportion of patients being hypercapnic, and a further study87 provided no details.
A distinction has been made between ‘stable’ patient populations and those who commenced NIV after
hospitalisation. In the stable populations, authors of the studies have specified that patients should not
have been hospitalised within a certain time period. This time period varies between studies (from 4 weeks
to 3 months). Not all studies with stable populations have defined a time period but may merely have
described patients as stable. For populations described as ‘post hospital’, there was clear evidence in the
study report that treatment with NIV commenced after an episode of hospitalisation (because of an
exacerbation). There is no information, however, on timings, for example how soon after an exacerbation
were patients admitted or how long the period in hospital was before NIV was initiated. This classification
has informed the presentation of results (see Clinical effectiveness results: non-invasive ventilation versus
usual care and Clinical effectiveness results: non-invasive ventilation versus non-invasive ventilation) and the
economic evaluation scenarios (see Clinical effectiveness review discussion). Note that there is limited
information on time since last exacerbation (for either population), with the exception of the controlled
study by Paone et al. (2014)89 where all patients were enrolled 3 months after discharge from hospital
after an exacerbation; they were free from exacerbations for at least 4 weeks and, therefore classified as stable.
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Most RCTs included stable populations (13 out of 18), with five75,78,90–92 including a post-hospital
population. Four non-randomised controlled studies89,93–95 included stable populations, four86,96–98 included
post-hospital populations and there was no description for two.87,88
Data were sought on patients’ exacerbation history in order to make an assessment of whether any
could be described as frequent exacerbators. Most studies provided no information. One RCT92 stated
that all patients had had previous exacerbations and three non-randomised controlled studies in stable
populations89,93,94 specified at least one previous admission because of severe exacerbation.
Most RCTs (13 out of 18) provided details on assessing patients for obstructive sleep apnoea, for the
purpose of ruling out patients with co-existing disorders (overlap syndrome); there were no details for
five.76,78,81,84,92 Only four out of nine89,93–95 non-randomised controlled studies provided clear details.
Details of the study and population characteristics of the RCTs can be found in Table 4 and for the
non-randomised studies in Table 5.
Intervention and comparator characteristics
A number of devices were used to administer NIV, reflecting preferences of different countries and
changes in devices over time (see Appendix 6). Masks were nasal, oronasal or full-face, sometimes
depending on patient choice.
Inspiratory (IPAP) and expiratory pressures (EPAP) were set according to target pressures, target volumes or
target blood gases. IPAP settings were compared across studies to ascertain whether or not there were any
differences in pressure (see Appendix 6). Pressure was inconsistently reported, for example as mean or
median, at the start of the study or at discharge, or described as ‘highest tolerated pressure’, adjusted to
patient, or at a level to achieve specific blood gas pressures. Not all studies gave numerical values. Given
this lack of consistency and the absence of an agreed cut-off point, it was not possible to dichotomise
studies according to high/low pressure (see Clinical effectiveness results: non-invasive ventilation versus
non-invasive ventilation for RCTs comparing different NIV settings directly). RCTs with the highest IPAP
(mean ≥ 20, where described) in the current set of studies were Duiverman et al. (in 200879 and 201180),
Murphy et al. (2011)78 (interim results from the ongoing HOT-HMV study) and Köhnlein et al. (2014).76
The non-randomised controlled studies with the highest pressures (mean ≥ 20 cm H2O, where described)
were Budweiser et al. (2007)96 and Heinemann et al. (2011).97
Patients in both treatment arms continued to receive usual care, which was normally standard medical
therapy, including LTOT where required, to optimise symptom control (Table 6 shows proportion of
patients on LTOT in the RCTs/controlled studies). In 10 studies most (> 90%) or all patients were on LTOT,
a smaller or unknown proportion of patients were on LTOT in 11 studies, six studies gave no details and in
one study only 4% were on LTOT.84 It is likely that there were regional variations in what constitutes
usual care.
Three studies had what could be considered to be more intensive usual care: the RCT by Duiverman et al.
(200879 and 201180) started with patients who were in a 12-week (in-hospital or outpatient) multidisciplinary
rehabilitation programme, followed by a long-term home-based rehabilitation programme (one or two sessions
per week of physiotherapy at community practice); the patients in the study by Garrod et al. (2000)84 were also
in a pulmonary rehabilitation programme for part of the RCT; and the non-randomised controlled study by
Clini et al. (1996)94 included as usual care a ‘home supervision programme’ [including physical, occupational
and dietary information, a link service between hospital and community health service via telephone contact
with general practitioners (GPs) and with patients, monthly physician visits to assess treatment and give further
advice and the checking of equipment and decisions on hospitalisation]. It is unclear how additional usual care
might influence the effect of NIV.
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TABLE 6 Proportion of patients on LTOT
Study NIV arm, n/N (%) Usual-care arm, n/N (%)
RCTs
Bhatt et al. 201383 No details
Casanova et al. 200085 19/20 (95) 22/24 (91.7)
Cheung et al. 201090 Before admission 10/23 (43.5) Before admission 11/24 (45.8)
Clini et al. 200299 All (100) All (100)
De Backer et al. 201191 No details
Duiverman et al. 200879 14/31 (45) 16/35 (46)
Duiverman et al. 201180 14/24 (58) 18/32 (56)
Garrod et al. 200084 2/45 (4, unclear which treatment arm)
Gay et al. 1996100 4/7 (57); 24-hour oxygen use (four patients),
nocturnal oxygen (two patients)
6/6 (100); all on 24-hour oxygen
Kaminski et al. 1999101 All (100) All (100)
Köhnlein et al. 201476 67/102 (66) 60/93 (65)
McEvoy et al. 200974 All (100) All (100)
Meecham-Jones et al. 199577 All (100) All (100)
Murphy et al. 201178 No details
Sin et al. 200782 Unclear. For patients with arterial oxyhemoglobin saturation of < 90% despite nocturnal
non-invasive (positive) mechanical ventilation, supplemental oxygen was entrained to
maintain arterial oxyhaemoglobin saturation of ≥ 90%
Struik et al. 201475 76/101 (75) 78/100 (78)
Strumpf et al. 199134 Only stated for 7/19 completers. 6/7 (86) completers on oxygen
Xiang et al. 200792 All (100) All (100)
Zhou et al. 200881 No details (likely to be at least some given
random treatment allocation)
All (100)
Non-randomised controlled studies
Budweiser et al. 200796 Prior to study 54/99 (54); upon discharge
94/99 (95)
Prior to study 23/41 (56); upon discharge
33/41 (81)
Clini et al. 199893 All (100) All (100)
Clini et al. 199694 All (100) All (100)
Heinemann et al. 201197 Oxygen therapy prescribed according to guidelines – proportion on oxygen unclear
Laier-Groeneveld and
Criee 199588
No details
Lu et al. 201298 All (100) All (100)
Milane and Jonquet 198586 No details
Pahnke et al. 199787 No details
Paone et al. 201489 All (100) All (100)
Tsolaki et al. 200895 Part of usual care ‘as indicated’
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Study quality
Full quality assessment details can be found in Appendix 2. For the 18 RCTS, risk of bias regarding random
sequence generation was low (10 studies) or unclear (eight studies); risk of bias regarding allocation
concealment was also low (seven studies) or unclear (11 studies). Blinding of patients was not possible
unless a ‘placebo NIV’ was used; this was the case in three studies. Cheung et al. (2010)90 carried out an
open-label study which used CPAP in the non-NIV arm and stated that ‘care had been taken to avoid
biasing the patients into believing either mode was superior’. Sin et al. (2007)82 also used CPAP as sham
therapy, while Gay et al. (1996)100 used the same NIV equipment in the usual-care arm but ‘ventilated’
with lowest EPAP level and had no added IPAP or timed breaths.
There was little information overall on blinding of outcome assessors, with only three RCTs giving some
detail (Clini et al. 2002,99 Sin et al. 200782 and Köhnlein et al. 201476). For more objective outcomes,
such as survival and hospitalisations, a lack of blinding may be less important than for more subjective
assessments such as QoL questionnaires. However, a lack of blinding may also inadvertently lead to
performance bias, with a potential for NIV patients to receive more medical attention, which could in turn
have an effect on any outcome.
A risk-of-bias rating for incomplete data/handling of missing data was derived as described in the methods
(see Chapter 3, Assessment of risk of bias). As noted in the methods section, the cut-off points are
arbitrary and a lack of reporting may in some cases be contributing to a high risk-of-bias rating. A high
loss to follow-up for outcome assessments which require clinic attendance may to some extent be a result
of the nature of severe COPD, with patients finding it difficult to travel. There were nine RCTs34,75–77,79–83,100
with a high risk of bias for incomplete data in the NIV and/or the usual-care arm (for at least one
outcome). None of these contributed to the primary outcome meta-analyses. However, it was noted in the
relevant results sections where RCTs had a high risk of bias for incomplete data.
Two34,77 of the 15 RCTs had a crossover design. Both appeared to use appropriate statistical methods,
although the possibility of a carry-over effect was not explored for one.77 Both were at high risk of bias for
incomplete data, and it in some cases it was unclear during which treatment period patients dropped out.
No sensitivity analysis was performed on the basis of the quality assessment, as (1) a lack of reporting
hampered classifying studies according to quality and (2) a lack of reporting is not necessarily an indication
of poor study quality. Ideally, a risk-of-bias rating would have been generated for each outcome within
each study. Where reported, a distinction has been made for blinding and incomplete outcome data for
the different outcomes (see Appendix 2); however, this information was frequently not available. Overall,
incomplete data are less likely to be an issue for mortality and hospitalisations/severe exacerbations, while
outcome measurements that required patients to attend a clinic are more prone to missing data.
The non-randomised controlled studies were not given a risk-of-bias rating. Of the 10 controlled studies,
five89,93–96 had a prospective design and five appeared to be retrospective analyses of data, although this
was not always clearly described. One prospective study89 used a matched design, which may result in
more similar groups at baseline and thus less biased results. Retrospective studies are more prone to bias,
as outcome measurements and usual care cannot be retrospectively standardised for both groups. Most
usual-care groups were made up of patients who were eligible for NIV, but could not adhere (e.g. because
of mask intolerance) or did not want to continue; however, in three retrospective studies,86,88,97 levels of
blood gases determined eligibility for NIV, and one retrospective study98 gave no details. All prospective
studies89,93–96 and one of the retrospective studies98 gave details on similarity between NIV and usual-care
groups in terms of baseline characteristics, and there appeared to be no major differences. There were no
details in one retrospective study,87 and the other three may have differences in blood gas levels as these
determined eligibility for NIV. Three studies86,96,97 report that NIV patients had more follow-up visits
(at hospital or home) than usual-care patients, which may have impacted on the effectiveness of their
usual care.
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There were very few details on blinding and frequently incomplete details on losses to follow-up, whether
or not intention-to-treat (ITT) analysis was performed and/or how many patients were contributing to
results at different time points. Four of the five retrospective studies reported only survival, in which case
loss to follow-up may be less of a problem in terms of accessing outcome data.
The potential impact of quality findings are discussed in the individual results sections; however, a formal
sensitivity analysis based on quality was not undertaken for non-randomised studies (because of the small
number of studies in meta-analyses and difficulties in ascertaining quality cut-off points).
Results from RCTs and non-randomised studies were not pooled because the inherent differences in
susceptibility to bias.
Overview of outcomes
Table 7 shows the primary and secondary outcomes (as defined in this report, not by individual study
authors) where data have been extracted and analysed. Where studies have reported hospitalisation as a
result of an exacerbation, this has been included in the results only once (under hospitalisation) in order to
avoid double-counting (e.g. Tsolaki et al. 200895). Where a study has reported severe exacerbations
(Cheung et al. 201090), it has been assumed that patients will be hospitalised and this has also been
counted as hospitalisation. Where exacerbations have been reported without any indication of severity,
they have been presented separately.
TABLE 7 Main outcomes
Study Primary outcomes Secondary outcomes
Included in
meta-analyses
RCTs
Bhatt et al. 201383 QoL, adherence FEV1 % predicted, FVC %
predicted, PaCO2, PaO2
–
Casanova et al. 200085 Survival, exacerbations,
hospitalisations, adherence
FEV1 % predicted, FVC %
predicted, PaCO2, PaO2
Survival
Cheung et al. 201090 Survival, exacerbations,
hospitalisations, adherence
PaCO2 Hospitalisations
Clini et al. 200299 Survival, hospitalisations, QoL,
adherence
FEV1 % predicted, PaCO2, PaO2,
6MWD
Survival,
hospitalisations
De Backer et al. 201191 Adherence FEV1, PaCO2, 6MWD –
Duiverman et al. 200879 QoL FEV1 % predicted, PaCO2, PaO2,
6MWD
–
Duiverman et al. 201180 Exacerbations, hospitalisations,
adherence
Garrod et al. 200084 Exacerbations, QoL, adherence FEV1 % predicted, FVC, PaCO2,
PaO2
–
Gay et al. 1996100 Adherence FEV1 % predicted, PaCO2, PaO2,
6MWD
–
Kaminski et al. 1999101 Survival, hospitalisations,
adherence
FEV1, FVC, PaCO2, PaO2, 6MWD Survival,
hospitalisations
Köhnlein et al. 201476 Survival, hospitalisations, QoL,
adherence
FEV1, FVC, PaCO2, PaO2, 6MWD Survival,
hospitalisations
McEvoy et al. 200974 Survival, hospitalisations, QoL,
adherence
FEV1 % predicted, FVC, PaCO2,
PaO2
Survival
Meecham-Jones et al. 199577 QoL, adherence FEV1, FVC, PaCO2, PaO2, 6MWD –
continued
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There were only very limited data contained within RCTs or non-randomised controlled studies that linked
exacerbation, hospitalisation, QoL and survival data (i.e. number of exacerbations leading to hospitalisation,
number of exacerbations resulting in death, number of hospitalisations resulting in death or effect of
exacerbation and/or hospitalisation on QoL). These outcomes have thus been considered separately.
Uncontrolled studies were not searched for linked data.
Primary outcomes were less frequently measured than secondary outcomes (with the exception of
adherence to NIV) in the prospective controlled studies, and only a proportion of results could be
incorporated into meta-analyses (see Chapter 4, Survival and Hospitalisations individual results sections
for more details). Most prospective studies (except two78,96) reported secondary outcomes (one or more of
FEV1, FVC, PaO2, PaCO2 or 6MWD). Secondary outcome results from RCTs only are presented in forest
plots (see Secondary outcomes). These outcomes were not measured/reported by the retrospective
controlled studies.
TABLE 7 Main outcomes (continued )
Study Primary outcomes Secondary outcomes
Included in
meta-analyses
Murphy et al. 201178 Adherence – –
Sin et al. 200782 Adherence FEV1, PaCO2, 6MWD –
Struik et al. 201475 Survival, hospitalisations,
exacerbations, QoL, adherence
FEV1, FVC, PaCO2, PaO2 Survival,
hospitalisations
Strumpf et al. 199134 Hospitalisations, exacerbations,
adherence
FEV1, FVC, PaCO2, PaO2 –
Xiang et al. 200792 Survival, hospitalisations FEV1, FVC, PaCO2, PaO2,
dyspnoea, 6MWD
Survival,
hospitalisations
Zhou et al. 200881 Survival, exacerbations,
hospitalisations, adherence
PaCO2, PaO2, pH Survival,
hospitalisations
Non-randomised controlled studies
Budweiser et al. 200796 Survival, adherence – Survival
Clini et al. 199893 Survival, hospitalisations
adherence
FEV1, FVC, PaCO2, PaO2, 6MWD Survival,
hospitalisations
Clini et al. 199694 Survival, hospitalisations PaCO2, PaO2 Survival,
hospitalisations
Heinemann et al. 201197 Survival, adherence – Survival
Laier-Groeneveld and
Criee 199588
Survival – Survival
Lu et al. 201298 Survival, hospitalisations
adherence
FEV1, FVC, PaCO2, PaO2, 6MWD Survival
Milane and Jonquet 198586 Survival – Survival
Pahnke et al. 199787 Survival, adherence – Survival
Paone et al. 201489 Survival, hospital admissions Blood and sputum inflammatory
biomarkers
Survival
Tsolaki et al. 200895 Survival, exacerbations,
hospitalisations, QoL, adherence
PaCO2, PaO2 Survival,
hospitalisations
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Survival
Ten RCTs reported survival, seven in stable populations and three in post-hospital populations. All were
meta-analysed or presented in a forest plot. All 10 non-randomised controlled studies reported survival,
and all were presented in one or more forest plots. Follow-up times for all but one of the RCTs was
between 6 and 24 months only; where follow-up was beyond 24 months (in one RCT and four controlled
studies), the results have been presented in a separate plot. Relative risks (RRs) and hazard ratios (HRs)
were taken directly from the published article where possible. Otherwise they were calculated as described
in Chapter 3, Analysis (RR for all populations, HR for stable populations only). A footnote indicates where
RR or HR was calculated from event rates reported in the published article.
Figure 3 shows the RR for mortality for all studies, subgrouped by RCTs/non-randomised studies and
stable/post-hospital populations. Pooling was undertaken only within subgroups. There was no difference
in mortality between stable populations treated or not treated with NIV, based on seven RCTs and four
controlled studies. One study88 which reported no details on the population has been categorised
separately; this also found no difference. There was also no difference in mortality for the post-hospital
population based on three RCTs, but a statistically significant difference favouring NIV based on four
non-randomised studies in post-hospital populations.
Between 57% and 100% of patients within the stable populations were on LTOT (unclear for NIV arm in
Zhou et al. 200881); this was also the case for the three post-hospital studies.75,92,98 One post-hospital study
(Budweiser et al. 200796) included around 50% patients on LTOT at the start of the study; however, at
discharge most were on LTOT. A subgroup analysis for patients with or without LTOT found no difference.
Two studies86,97 gave no details on LTOT.
Figure 4 shows the HRs, again pooled by subgroup (RCT/controlled study, stable/post hospital). Unadjusted
HRs showed no difference between treatment arms for the stable populations, while the adjusted HR from
the McEvoy et al. 2009 RCT74 was significantly in favour of NIV (adjusted for those variables found to be
confounders based on changing the HR by 10% or more when added to the model: PaCO2, PaO2 and SGRQ
total score). It should be noted that the upper confidence limit for the Köhnlein et al. RCT76 differs slightly
from that in the published article, as the standard error (SE) had to be approximated from the data given.
The adjusted and unadjusted HRs reported in two controlled studies in post-hospital populations were
significantly in favour of NIV (adjusted for LTOT, haemoglobin, age and body mass index96 and for age,
PaO2, haemoglobin and haematocrit at discharge97). However, these are observational studies and there is
no way of knowing whether or not the estimated HRs are biased because of unmeasured or inappropriate
adjustment for confounders.
Of the above studies, those with the highest IPAP were by Budweiser et al. (2007)96 and Heinemann
(2011),97 both non-randomised studies. The fact that these studies showed a significant difference in
favour of NIV may be a result of the higher pressure and/or of a greater benefit from NIV in a post-hospital
population. Patients in both studies had more frequent evaluations in the NIV arm, and there may be
additional confounders which have not been adjusted for.
Figure 5 shows mortality at longer follow-up times (> 2 years). Data are not pooled as multiple time points
are presented. One RCT in a post-hospital population found no significant difference.75 Three controlled
studies, two with no details on the population and one in a stable population,93 also found no difference.
The one post-hospital study86 showed a statistically significant benefit from NIV at 2 and 5 years, with less
of a benefit at 10 years (although this was still statistically significant). It is conceivable that any potential
benefit from NIV would not be sustained for the duration of a patient’s life given the progressive
worsening of COPD. There were no details on IPAP settings for this study. The schedule of NIV was also
unusual in this study and is not consistent with all other studies, as it was used intermittently for
15 minutes every hour, up to a minimum of 4 hours. For all studies an assumption has been made that the
survival rates are based on no loss to follow-up; patient numbers have been calculated from percentages
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Stable RCT
aCasanova 200085
aKöhnlein 201476
aZhou 200881
aKaminski 1999101
aMcEvoy 200974
aClini 200299
Duiverman 201180
Subtotal (I2 = 60.4%, p = 0.019)
Stable controlled
aClini 199893
aTsolaki 200895
aClini 199694
a,bPaone 201489
Subtotal (I2 = 0.0%, p = 0.978)
Unclear controlled
aLaier-Groeneveld 199588
Post-hospital RCT
Cheung 201090
aStruik 201475
aXiang 200792
Subtotal (I2 = 25.1%, p = 0.263)
Post-hospital controlled
aLu 201298
Heinemann 201197
aBudweiser 200796
Milane 198586
Subtotal (I2 = 0.0%, p = 0.698)
Trial ID
12 months
12 months
12 months
Mean 16 and 23 months 
Median 20.5 and 28.5 months
24 months
24 months
12 months
12 months
18 months
24 months
12 months
12 months
12 months
24 months
6 months
12 months
24 months
24 months
Follow-up
1.20 (0.34 to 4.20)
0.35 (0.19 to 0.65)
0.47 (0.05 to 4.06)
2.24 (0.98 to 5.13)
1.09 (0.45 to 2.66)
0.95 (0.30 to 2.99)
0.88 (0.55 to 1.43)
1.00 (0.25 to 4.00)
0.92 (0.14 to 5.96)
1.33 (0.35 to 5.08)
1.29 (0.55 to 3.00)
1.19 (0.65 to 2.18)
1.06 (0.30 to 3.73)
1.06 (0.30 to 3.73)
1.15 (0.41 to 3.22)
1.02 (0.67 to 1.57)
0.38 (0.12 to 1.21)
0.89 (0.53 to 1.49)
0.37 (0.02 to 8.48)
0.33 (0.15 to 0.74)
0.55 (0.34 to 0.90)
0.39 (0.19 to 0.80)
0.45 (0.32 to 0.65)
RR (95% CI)
0.87 (0.66 to 1.14)
10.1 .0 0.5
RR  < 1 favours domiciliary NIV
Mortality (RR)
FIGURE 3 Mortality (RR). CI, confidence interval. a, Calculated by authors of this report; b, controlled study
with matching.
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Stable RCT unadjusted HR
aCasanova 200085
aKöhnlein 201476
aZhou 200881
aKaminski 1999101
aClini 200299
aDuiverman 201180
McEvoy 200974
Subtotal (I2 = 61.0%, p = 0.017)
Stable RCT adjusted HR
McEvoy 200974
Stable controlled unadjusted HR
aTsolaki 200895
a,bPaone 201489
aClini 199893
aClini 199694
Subtotal (I2 = 0.0%, p = 0.975)
Unclear controlled unadjusted HR
aLaier-Groeneveld 199588
Post-hospital controlled unadjusted HR
Heinemann 201197
Budweiser 200796
Subtotal (I2 = 0.0%, p = 0.583)
Post-hospital controlled adjusted HR
Heinemann 201197
Budweiser 200796
Subtotal (I2 = 0.0%, p = 0.400)
Trial ID
12 months
12 months
12 months
Mean 16 and 23 months
24 months
24 months
Median 20.5 and 28.5 months
Median 20.5 and 28.5 months
12 months
18 months
24 months
Mean 35 months 
12 months
12 months
24 months
12 months
24 months
Follow-up
1.22 (0.31 to 4.91)
0.24 (0.11 to 0.51)
0.45 (0.05 to 4.31)
3.64 (0.90 to 14.81)
1.10 (0.41 to 2.94)
0.94 (0.27 to 3.26)
0.82 (0.53 to 1.26)
0.82 (0.45 to 1.52)
0.63 (0.40 to 0.99)
0.63 (0.40 to 0.99)
0.91 (0.13 to 6.49)
1.38 (0.31 to 6.19)
1.34 (0.50 to 3.62)
1.00 (0.22 to 4.47)
1.21 (0.62 to 2.39)
1.07 (0.29 to 3.98)
1.07 (0.29 to 3.98)
0.27 (0.11 to 0.70)
0.38 (0.18 to 0.80)
0.33 (0.19 to 0.60)
0.28 (0.09 to 0.81)
0.48 (0.24 to 0.93)
0.41 (0.23 to 0.72)
HR (95% CI)
1.00.1 5.0
HR < 1 favours domiciliary NIV
Mortality (HR)
FIGURE 4 Mortality (HR). CI, confidence interval. a, Calculated by authors of this report. b, Controlled study
with matching.
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and rounding errors may have occurred. Given that the population details were unclear in two studies, it
was difficult to draw any conclusions. It could be speculated that if the study had specifically included a
post-hospital population this may have been highlighted.
Overall, the results on mortality (RR, unadjusted HR) suggest that, on average, there is no benefit from
starting NIV in a stable COPD population, and this is consistent for RCTs and non-randomised controlled
studies (n= 770 in total). This is based on a fairly limited follow-up period for mortality (up to 24 months
for RCTs), and it is possible that small differences might not manifest themselves within this time frame.
One exception is the adjusted HR (McEvoy et al. 200974), which shows a statistically significant benefit
for NIV.
The results from three RCTs in a post-hospital population also show that, on average, there is no benefit
to home NIV. One further RCT (Xiang et al. 2007,92 n= 40; not represented in the forest plots) also found
no statistically significant difference. This is in contrast to the non-randomised controlled studies in this
population, which show a statistically significant pooled result favouring NIV. Follow-up in the RCTs was
1290 and 2492 months, arguably not long enough to measure mortality as an outcome. The sample size
was small in two RCTs (40 patients in each) and larger in one RCT (Struik et al. 2014,75 n= 201).
Further subgroup analyses (e.g. by level of hypercapnia or history of exacerbations) were not possible given the
small number of studies and the inconsistent reporting of the relevant variables. Based on the inclusion criteria
(CO2 threshold) and description of populations, most studies appeared to be on hypercapnic patients, with the
exception of that by Casanova et al. 2000,85 who stated that ‘The number of hypercapnic patients in our series
was small’. Performing subgroup analysis based on reported mean baseline CO2 values would have meant
dichotomising trials based on an arbitrary threshold, and this was not considered appropriate. However, in a
Stable controlled
aClini 199893
aClini 199893
Unclear controlled
aLaier-Groeneveld 199588
aLaier-Groeneveld 199588
aLaier-Groeneveld 199588
aPahnke 199787
Post-hospital RCT
Struik 201475
Post-hospital controlled
aMilane 198586
aMilane 198586
aMilane 198586
Trial ID
2 years
3 years
2 years
3 years
4 years
During 8-year period
5–6 years
2 years
5 years
10 years
Follow-up
1.05 (0.44 to 2.51)
0.89 (0.50 to 1.57)
1.01 (0.50 to 2.03)
0.95 (0.57 to 1.56)
0.82 (0.54 to 1.24)
0.84 (0.51 to 1.38)
1.08 (0.86 to 1.35) 
0.48 (0.33 to 0.70)
0.85 (0.73 to 0.98)
0.39 (0.19 to 0.80)
RR (95% CI)
1.00.1 0.5
RR  < 1 favours domiciliary NIV
Mortality (RR) longer follow-up
FIGURE 5 Mortality (RR) longer follow-up. CI, confidence interval. a, Calculated by authors of this report.
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separate analysis, CO2 levels at baseline and change in CO2 levels were plotted against mortality, in order to
determine if baseline CO2 can predict response to NIV and whether or not the effect of NIV on CO2 correlates
with the effect on mortality (see Figure 42 and Figure 44, Appendix 7). There was no discernible relationship
either between CO2 levels at baseline and mortality or between change in CO2 levels and mortality. This was an
exploratory post-hoc analysis and subject to a number of limitations; as such the findings should be considered
to be speculative only and should be interpreted with caution (see Appendix 7 for caveats).
Sensitivity analyses by study quality were also not performed, again because of the small number of
studies, and the lack of reporting of details on quality. Only one of the RCTs80 was flagged as having a
high risk of bias regarding incomplete data. Only one RCT90 used a form of sham NIV, so patients were not
blinded in most studies. There may also be a risk of performance bias if the use of NIV is associated with
additional check-ups or follow-up visits. Assessment of potential publication or other bias through funnel
plots was not undertaken given that there was a maximum of seven studies in any given meta-analysis.
Non-randomised studies are more prone to overestimating effect size; this does not seem to be the case
here for stable populations, as the results of RCTs and non-randomised controlled studies are consistent.
The non-randomised studies in the post-hospital population do show a benefit of NIV, in contrast to
the pooled result from RCTs in this population (which shows no difference).
The potential for selection bias was explored for the non-randomised studies. NIV and usual-care arms
appeared to be similar for the stable populations (see Appendix 2 for full details), whereas Laier-Groeneveld
and Criee (1995)88 (population unclear) reported that patients in the usual-care group were normocapnic and
those in the NIV group were hypercapnic. For the post-hospital populations, baseline characteristics also
appeared to be similar in two studies,96,98 although one98 gave no detail on how groups were selected. In the
other two studies,86,97 blood gas levels determined the eligibility for NIV; that is, only patients with poorer blood
gas levels/lower level of hypercapnia received NIV.
Differences in usual care were also explored. In the studies by Budweiser et al. (2007),96 Heinemann et al.
(2011)97 and Milane and Jonquet (1985)86 (all post-hospital populations), patients in the NIV groups
received more frequent hospital evaluations or home visits, which may have led to better usual care.
These studies found a statistically significant benefit for NIV.
Uncontrolled observational studies were explored in order to determine whether there were additional
useful data from larger and/or longer-term studies (see Appendix 8 for further details). There were two
larger prospective studies102,103 following stable patients on NIV. Survival rates in one103 of these were
similar to those reported in the NIV arm of Laier-Groeneveld and Criee (1995),88 while the other102 reported
slightly lower survival rates. An analysis of patient survival depending on haemoglobin level (Kollert et al.
2013104) reported survival rates for normocythaemic patients (n= 207) of 72%, 50%, 47% and 18%
respectively at 2, 4, 5 and 10 years (approximate, estimated from graph); these were similar at 2 years and
slightly lower at 4 years compared with Laier-Groeneveld and Criee (1995),88 although a comparison is
difficult as nothing is known about the haemoglobin status in the controlled studies included in this report.
One small study105 followed both stable (n= 16) and post-hospital (n= 31) patients on NIV. This found
significantly poorer median survival in post-hospital patients compared with stable patients, which is
consistent with the population differences observed in the controlled studies.
Hospitalisations
Hospitalisation data were reported in a number of ways, for example the number of hospitalisations
(general or ICU) per patient per year, mean number of days in hospital, proportion of patients
affected by hospitalisation, time to first readmission, etc. Only the first two outcomes are represented in
Figures 6 and 7, based on eight RCTs (five76,80,81,99,101 in stable and two90,92 in post-hospital populations) and
three controlled studies93–95 (all stable populations). Severe exacerbations have been assumed to lead to
hospitalisation and have been included in the hospitalisation analysis. The hospital admissions and days in
hospital were all presented per patient per year, except for the Clini et al. (1996)94 study, which reported
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hospitalisation rates over a period of 18 months; the results have been adjusted to 1 year (which assumes
a constant rate). Additional hospitalisation data not represented in the forest plots are shown in Table 8.
For stable populations, there appeared to be a non-significant trend towards fewer hospital admissions
with NIV (based on five RCTs) and ICU admissions (based on one RCT and two controlled studies);
no difference in hospital admissions was found based on two controlled studies (Figure 6).
Note that the forest plot does not include results from all RCTs; McEvoy et al. (2009),74 who carried
out a fairly large RCT (n= 144), and Casanova et al. (2000),85 who studied 52 patients, reported very
similar hospitalisation rates74 and proportion of patients affected by hospitalisations85 in the NIV and
usual-care groups. Had it been possible to incorporate these results, the overall pooled estimate may have
shifted more towards an equivocal effect (see Table 8 for additional results). It should be noted that the
Köhnlein et al.76 study in 2014 is given a relatively small weighting in the meta-analysis, despite it being a
larger study (n= 195); this is because the standard deviation (SD) (and thus the SE) was much higher. It
could be argued that hospital admissions data are by their nature skewed (with some patients having
repeated admissions and one admission making a further one more likely) and that the median may be a
better metric to compare groups. However, all but two of the studies in the meta-analysis reported the
mean in their publications; the authors of two studies75,80 reported the median but provided the mean (SD)
on request.
For the post-hospital population, the results from the three RCTs give disparate results (significant
difference in favour of NIV92, non-significant difference in favour of NIV90 and non-significant difference
on favour of usual care75). The results have therefore not been pooled. Note that the (larger) study by
Struik et al.75 in 2014 has a similar weight in the meta-analysis compared with the smaller studies; this is
because the SD (and thus the SE) was much higher. The study by Cheung et al. (2010)90 randomised
patients to NIV or CPAP and, while this was an open-label study, the authors stressed that ‘care had been
taken to avoid biasing the patients into believing either mode was superior’. There was no sham NIV in the
studies by Xiang et al. (2007)92 and Struik et al. (2014),75 and arguably the results from the Cheung et al.90
study in 2010 could be considered more robust. However, it is likely that there are additional clinical or
methodological differences between the studies.
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Days in hospital (per patient per year) were reported, only for stable populations, in one RCT and three
controlled studies (Figure 7). There was no significant difference, although a very slight trend towards
benefit with NIV. Again, this is not based on the totality of the evidence and firm conclusions cannot
be drawn.
Additional data on hospitalisation are reported in Table 8 (note that some studies have used more than one
outcome measure and are represented in both Figure 6 and Table 8). There were no significant differences
between NIV and usual care based on three RCTs (and one small crossover RCT) and one controlled study
(stable population), with the exception of proportion of patients affected by hospitalisations at 3 months in
one study (Casanova et al. 200085). One matched controlled study89 found a significant difference in favour
of NIV at 24 months.
Three RCTs in post-hospital populations also found no significant differences, although there appeared to be
a trend for a longer time to first readmission due to any COPD exacerbation with NIV (Cheung et al. 201090).
Stable hospital admissions RCTs
Clini 200299
Duiverman 201180
Kaminski 1999101
Köhnlein 201476
Zhou 200881
Subtotal (I2 = 59.2%, p = 0.044)
Stable hospital admissions controlled studies
aClini 199694
Tsolaki 200895
Subtotal (I2 = 61.9%, p = 0.105)
Stable ICU admissions RCTs
Clini 200299
Stable ICU admissions controlled studies
Clini 199893
aClini 199694
Subtotal (I2 = 93.5%, p = 0.000)
Post-hospital hospital admissions RCTsb
aCheung 201090
Struik 201475
Xiang 200792
Trial ID
24 months
12 months
Mean 16 months and 23 months
12 months
12 months
18 months
12 months
24 months
Mean 35 months
18 months
12 months
12 months
24 months
Follow-up
–0.50 (–1.25 to 0.25)
0.30 (–0.66 to 1.26)
0.20 (–0.25 to 0.65)
–0.70 (–1.69 to 0.29)
–0.20 (–0.46 to 0.06)
–0.20 (–0.46 to 0.06)
0.00 (–0.30 to 0.30)
0.39 (–0.05 to 0.83)
–2.50 (–2.72 to –2.28)
WMD (95% CI)
–0.16 (–0.67 to 0.35)
–0.90 (–3.16 to 1.36)
–1.20 (–1.80 to –0.60)
–0.46 (–1.02 to 0.09)
–0.14 (–0.99 to 0.72)
–0.70 (–0.87 to –0.53)
–0.36 (–1.05 to 0.32)
–0.28 (–0.55 to –0.01)
% Weight
0–1 1
WMD <  0 favours home NIV
Hospital admissions per patient per year
22.35
28.47
17.75
5.25
26.18
100.00
62.57
37.43
100.00
100.00
100.00
51.70
48.30
100.00
33.44
33.04
33.52
FIGURE 6 Hospital admissions per patient per year. CI, confidence interval; WMD, weighted mean difference.
a, Calculated by authors if this report; b, individual mean differences (95% confidence interval) presented for
this outcome.
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Based on the meta-analyses, there appeared to be an overall trend towards fewer hospitalisations with NIV
(for a stable population); however, this is not based on the totality of the evidence. For a post-hospital
population, the results are quite disparate and likely to be because of clinical and/or methodological
heterogeneity or, particularly in the case of the two smaller studies (n= 40 and n= 47), chance. Arguably,
the Struik et al. (2014)75 study, which suggests no benefit from NIV in this population, could be given more
consideration, as it is based on a much larger sample (n= 201). Looking at all the evidence, no firm
conclusions could be drawn as to whether or not stable or post-hospital patients are likely to benefit from
NIV in terms of fewer hospital admissions or days in hospital, although there may be patients with specific
characteristics who would benefit.
None of the five included RCTs (stable population) had a sham NIV arm, so lack of blinding may be a source
of bias. Sensitivity analyses around study quality were not undertaken because of the small number of trials
and the lack of reporting of some quality criteria. Similarly, funnel plots were not constructed to assess
potential for publication or other bias, as there were a maximum of five studies in any given meta-analysis.
Further subgroup analyses (e.g. by level of hypercapnia, history of exacerbations, proportion on LTOT or
IPAP) were not possible given the small number of studies and the inconsistent reporting of the relevant
variables. As with mortality data, baseline CO2 levels and change in CO2 levels were plotted against mean
difference in hospital admissions in order to determine whether baseline CO2 can predict response to NIV
and whether or not the effect of NIV on CO2 correlates with the effect on admissions (see Figure 43 and
Figure 45, Appendix 7). It was unclear whether there was a trend towards an association between higher
mean CO2 levels at baseline and a greater mean difference in hospital admissions, but an apparent trend
was observed for change in CO2 levels and admissions. Such a trend would indicate that a greater effect in
terms of reducing CO2 levels correlates with a greater reduction in hospital admissions. However, as the
analysis is using aggregate data for change in CO2 and also for mean difference in hospital admissions,
a causal association cannot be inferred, even if there is potential biological plausibility. Further, this was
an exploratory post-hoc analysis and subject to a number of limitations; as such, the findings should be
considered speculative only and should be interpreted with caution (see Appendix 7 for caveats).
RCT stable
Clini 200299
Controlled stable
Clini 199893
Clini 199694
Tsolaki  200895
Subtotal (I2 = 63.8%, p = 0.063)
Trial ID
9.00 (–5.18 to 23.18)
–
WMD (95% CI)
–5.70 (–16.58 to 5.18)
–5.70 (–16.58 to 5.18)
–2.00 (–8.47 to 4.47)
–9.40 (–16.97 to –1.83)
–2.44 (–10.86 to 5.99)
0–5 5
WMD <  0 favours domiciliary NIV
Days in hospital per patient per year
FIGURE 7 Days in hospital per patient per year. CI, confidence interval; WMD, weighted mean difference
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There were three small prospective uncontrolled observational studies, two106,107 in stable populations
(n= 11 and n= 35) and one108 in a post-hospital population (n= 27) (see Appendix 8 for further details).
The study in a post-hospital population did not report before and after (NIV) data and so did not add
useful information. The studies in stable populations found a reduction in admissions/days in hospital over
time with NIV (one pre–post NIV106 and one after 1 year compared with after 2 years with NIV107). This
needs to be interpreted in the context of the small number of patients and the lack of a usual-care group,
but might be consistent with the trend observed in some of the controlled studies.
Exacerbations
Severe exacerbations (assumed to be exacerbations leading to hospitalisation) are described previously
(see Chapter 4, Hospitalisations). This section has attempted to identify additional exacerbations (mild or
moderate) which do not lead to hospitalisation but could potentially incur a cost and/or have an impact
on QoL (Table 9). However, this was hampered by a lack of reporting of severity. In some cases,
exacerbations were not a predefined outcome but instead were listed as an adverse event (Garrod et al.
2000,84 Meecham-Jones et al. 199577). As it was unclear whether or not all exacerbations were reported
(rather than only those in the context of not completing final assessment84 or in the context of cause of
death77), the data from these two studies has not been further considered.
Pooling of exacerbations data was not possible, as a number of different outcome statistics were used;
these could not be converted to make them more consistent.
There was little information on the frequency of exacerbations of differing severity (mild, moderate or
severe). Cheung et al. (2010)90 noted exacerbations without acute HRF, which may be less severe, while
Tsolaki et al. (2008)95 made a distinction between all exacerbations and those leading to hospitalisation.
Struik et al. (2014)75 reported exacerbations occurring at home.
Overall there were no significant differences in exacerbations between NIV and usual-care arms, based on
three RCTs and one controlled study in stable populations and two RCTs in a post-hospital population.
One exception was the study by Zhou et al. (2008)81 (n= 36, stable population), which reported
significantly fewer exacerbations with NIV (at 12 months). Subgroup analyses were not possible. IPAP was
highest in the study by Duiverman et al. (2011)79 (mean 23 at start of study), and between 12 and 20 in
the other studies (where reported). The study by Duiverman et al. (2011)79 also had a more intensive
usual-care arm. The study by Bhatt et al. (2013)83 differed from the others in that it included normocapnic
patients. Around half of80,90 or most85 patients were on LTOT, with no details in two studies.83,95
Given the sparsity of information, the uncontrolled studies were also considered. Only three studies
(no restriction on sample size or length of follow-up) reported exacerbations. Neither the prospective
uncontrolled study by Tsolaki107 in 2011 nor the retrospective study by Windisch109 in 2009, both in stable
populations, made a distinction between different severities of exacerbation. The report of a further small
(n= 20) Japanese study64 was not translated. It is possible that reporting of exacerbations was included
within hospitalisation and/or adverse outcome data; however, this would have necessitated reading the full
texts of all the uncontrolled studies, which was not undertaken.
Quality of life
Seven RCTs and one prospective controlled study (Tsolaki et al. 200895), all with stable populations,
reported QoL using a variety of instruments (SF-36, SGRQ, SRI, the Chronic Respiratory Disease
Questionnaire, the MRF-28 and the Profile of Mood States). Note that for the SGRQ, the MRF-28 and the
Profile of Mood States, a lower score is indicative of better QoL (or more stable mood profile for Profile of
Mood States). For the other instruments, a higher score is indicative of better QoL.
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
TA
B
LE
9
Ex
ac
er
b
at
io
n
s
re
p
o
rt
ed
in
R
C
Ts
an
d
co
n
tr
o
lle
d
st
u
d
ie
s
St
u
d
y
D
es
ig
n
Le
n
g
th
o
f
fo
llo
w
-u
p
O
u
tc
o
m
e
R
es
u
lt
s
D
ir
ec
ti
o
n
o
f
ef
fe
ct
In
d
ic
at
io
n
o
f
se
ve
ri
ty
/c
o
m
m
en
t
St
ab
le
p
o
p
u
la
ti
o
n
Bh
at
t
et
al
.
20
13
83
RC
T
6
m
on
th
s
N
um
be
r
of
ex
ac
er
ba
tio
ns
N
IV
gr
ou
p,
1/
15
;
us
ua
l-c
ar
e
gr
ou
p
1/
12
or
1/
15
(u
nc
le
ar
)
N
o
di
ff
er
en
ce
.
N
ot
pr
e-
de
fin
ed
ou
tc
om
e
bu
t
al
lr
ep
or
te
d
N
o
de
ta
ils
on
se
ve
rit
y
C
as
an
ov
a
et
al
.
20
00
85
RC
T
3
an
d
12
m
on
th
s
Pe
rc
en
ta
ge
of
pa
tie
nt
s
af
fe
ct
ed
by
ex
ac
er
ba
tio
n
3
m
on
th
s:
N
IV
gr
ou
p,
52
%
;
us
ua
l-c
ar
e
gr
ou
p,
56
%
.
12
m
on
th
s:
N
IV
gr
ou
p,
66
%
;
us
ua
l-c
ar
e
gr
ou
p,
69
%
Sl
ig
ht
tr
en
d
fa
vo
ur
in
g
N
IV
,
bu
t
no
si
gn
ifi
ca
nt
di
ff
er
en
ce
s.
U
nc
le
ar
if
%
re
la
te
s
to
IT
T
po
pu
la
tio
n
or
co
m
pl
et
er
s
N
o
de
ta
ils
on
se
ve
rit
y
D
ui
ve
rm
an
et
al
.
20
11
80
RC
T
24
m
on
th
s
N
um
be
r
of
ex
ac
er
ba
tio
ns
M
ed
ia
n
of
th
re
e
ex
ac
er
ba
tio
ns
pe
r
ye
ar
fo
r
bo
th
N
IV
an
d
us
ua
lc
ar
e
N
o
si
gn
ifi
ca
nt
di
ff
er
en
ce
.
N
o
ot
he
r
ou
tc
om
e
st
at
is
tic
s
re
po
rt
ed
N
o
de
ta
ils
on
se
ve
rit
y
Zh
ou
et
al
.
20
08
81
RC
T
12
m
on
th
s
Ex
ac
er
ba
tio
ns
pe
r
pa
tie
nt
pe
r
ye
ar
N
IV
gr
ou
p,
m
ea
n
3.
73
(S
D
1.
03
);
us
ua
l-c
ar
e
gr
ou
p,
m
ea
n
4.
86
(S
D
1.
71
)
Si
gn
ifi
ca
nt
di
ff
er
en
ce
in
fa
vo
ur
of
N
IV
N
o
de
ta
ils
on
se
ve
rit
y.
Th
is
st
ud
y
al
so
re
po
rt
s
ho
sp
ita
lis
at
io
ns
an
d
it
is
lik
el
y
th
at
so
m
e
of
th
e
ex
ac
er
ba
tio
ns
w
ill
ha
ve
le
d
to
ho
sp
ita
lis
at
io
n
Ts
ol
ak
ie
t
al
.
20
08
95
C
on
tr
ol
le
d
12
m
on
th
s
Ex
ac
er
ba
tio
ns
pe
r
pa
tie
nt
pe
r
ye
ar
N
IV
gr
ou
p,
m
ea
n
1.
4
(S
D
2.
1)
;
us
ua
l-c
ar
e
gr
ou
p,
m
ea
n
1.
8
(S
D
1.
4)
N
o
si
gn
ifi
ca
nt
di
ff
er
en
ce
Th
is
in
cl
ud
es
al
le
xa
ce
rb
at
io
ns
,
in
cl
ud
in
g
th
os
e
le
ad
in
g
to
ho
sp
ita
lis
at
io
ns
Ex
ac
er
ba
tio
ns
pe
r
pa
tie
nt
pe
r
ye
ar
le
ad
in
g
to
ho
sp
ita
lis
at
io
n
N
IV
gr
ou
p,
m
ea
n
1.
0
(S
D
2.
2)
;
us
ua
l-c
ar
e
gr
ou
p,
m
ea
n
1.
7
(S
D
1.
3)
N
o
si
gn
ifi
ca
nt
di
ff
er
en
ce
Ex
ac
er
ba
tio
ns
as
su
m
ed
to
be
se
ve
re
,
as
re
su
lte
d
in
ho
sp
ita
lis
at
io
ns
(in
cl
ud
ed
in
C
ha
pt
er
4,
H
os
pi
ta
lis
at
io
ns
)
Po
st
-e
xa
ce
rb
at
io
n
p
o
p
u
la
ti
o
n
C
he
un
g
et
al
.
20
10
90
RC
T
12
m
on
th
s
Ex
ac
er
ba
tio
n
w
ith
ou
t
ac
ut
e
H
RF
,
n/
N
N
IV
gr
ou
p,
5/
23
;
us
ua
l-c
ar
e
gr
ou
p,
4/
24
N
o
de
ta
ils
on
st
at
is
tic
al
si
gn
ifi
ca
nc
e
O
ut
co
m
e
lis
te
d
as
ad
ve
rs
e
ev
en
t,
no
t
pr
ed
ef
in
ed
ou
tc
om
e
(b
ut
al
lr
ep
or
te
d)
Re
cu
rr
en
t
se
ve
re
C
O
PD
ex
ac
er
ba
tio
n
w
ith
ac
ut
e
H
RF
(p
rim
ar
y
ou
tc
om
e)
N
IV
gr
ou
p,
7/
23
;
us
ua
l-c
ar
e
gr
ou
p:
14
/2
4.
H
R
0.
39
(9
5%
C
I0
.1
6
to
0.
98
)
St
at
is
tic
al
ly
si
gn
ifi
ca
nt
di
ff
er
en
ce
fa
vo
ur
in
g
N
IV
Se
ve
re
,
th
er
ef
or
e
as
su
m
ed
to
re
su
lt
in
ho
sp
ita
lis
at
io
n
(in
cl
ud
ed
in
C
ha
pt
er
4,
H
os
pi
ta
lis
at
io
ns
)
St
ru
ik
et
al
.
20
14
75
RC
T
12
m
on
th
s
A
nn
ua
ln
um
be
r
of
ex
ac
er
ba
tio
ns
at
ho
m
e
[m
ed
ia
n
(r
an
ge
)]
N
IV
gr
ou
p,
m
ed
ia
n
1
(r
an
ge
0–
9)
;
us
ua
l-c
ar
e
gr
ou
p,
m
ed
ia
n
2
(r
an
ge
0–
14
)
N
o
st
at
is
tic
al
ly
si
gn
ifi
ca
nt
di
ff
er
en
ce
(p
=
0.
26
)
Ex
ac
er
ba
tio
n
de
fin
ed
as
an
ev
en
t
in
th
e
na
tu
ra
lc
ou
rs
e
of
th
e
di
se
as
e
ch
ar
ac
te
ris
ed
by
a
ch
an
ge
in
th
e
pa
tie
nt
’s
ba
se
lin
e
dy
sp
no
ea
,
co
ug
h,
an
d/
or
sp
ut
um
th
at
is
be
yo
nd
da
y
to
da
y
CLINICAL EFFECTIVENESS REVIEW RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
There was heterogeneity regarding the number of QoL instruments used (between one and three), time
points of reporting QoL (between 3 and 24 months), and in the way results were reported, for example
for subscales only rather than the total score or as a mean difference between final scores rather than a
change score or adjusted score. Some studies did not report numerical data but only commented on
statistical significance or only presented results on a graph. Further, in order to pool, an assumption would
have had to have been made that all instruments were measuring QoL in the same way and were equally
valid. For these reasons it was not considered feasible to pool any QoL data.
Table 10 presents the findings. Some studies used several QoL instruments, thus contributing to a greater
proportion of the findings (e.g. Duiverman in 2008 and 2011,79,80 which also had a more intensive
usual-care arm compared with the usual care employed in most studies). Note that, for the study by
Köhnlein et al. (2014),76 results were available only for a small subgroup of patients.
The overall results were suggestive of trend towards better QoL with NIV compared with usual care, with
some results statistically significant (in favour of NIV). This is not consistent across all studies, however,
with one of the larger RCTs (McEvoy et al. 200974) finding statistically significant results in favour of usual
care, albeit for only some subscales. The one non-randomised study may have been prone to greater bias
than the RCTs; however, the authors stated that there were no statistically significant differences between
groups for baseline characteristics (thus making selection bias less probable).
The 2013 Cochrane review110 pooled 12-month SGRQ results for McEvoy et al. 200974 and Clini et al.
200299 based on individual patient data (IPD) (which were not available for this report). They found a very
small, and not statistically significant, effect in favour of the usual-care group [mean difference of 0.9,
95% confidence interval (CI) –19.21 to 21.01]. This result is based on one QoL instrument only. See also
Chapter 5, Review of systematic reviews.
Only one RCT (Struik et al. 201475) in a post-hospital population reported QoL; there were no statistically
significant differences between groups at 12 months, based on four different measurement scales.
None of the studies reporting QoL had a sham NIV arm, so there may be a risk of patients receiving NIV
being more optimistic in their assessment of QoL. However, NIV is also known to have an adverse impact
on QoL in the short term (while patients are adapting).
Given the paucity of QoL data in a post-hospital population, the uncontrolled studies were explored
(only studies with at least 10 patients considered, using one of the QoL instruments used by the
RCTs/controlled studies). There was only one small prospective uncontrolled study (Skobel et al. 2011108)
which reported QoL using a German version of the SGRQ at 3 months in 27 patients. This study found a
significant improvement in the symptom and impact domains, as well as in overall score compared with
the baseline; after further follow-up the symptom score showed a deterioration (while the scores for the
other domains remained stable). There are too few data to make an assessment of how QoL changes
might differ in stable and post-hospital populations.
There were no retrospective uncontrolled studies conducted in post-hospital populations using one of
more of the relevant QoL instruments.
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Adherence and adverse events
Table 11 shows details of the recommended schedule of NIV, any support provided for adapting to NIV,
the extent to which patients adhered to NIV and any adverse events associated with NIV, including where
these led to treatment discontinuation. Length of hours that NIV is used for per night and the percentage
of nights NIV is used for may affect the potential benefit. Overall, there was a lack of consistency and/or
detail in terms of how these parameters were reported across studies. Generally there was less detail in the
retrospective studies.
Most studies reported some detail on how patients were accustomed to NIV; patients usually had a run-in
period in hospital [between 2 and 6 days where stated, with the exception of Clini et al. (1998)93 with 15 days],
and some studies gave details of follow-up support in the home. NIV was generally recommended for
nocturnal use, with the exception of Milane and Jonquet (1985),86 who specified a schedule of 15 minutes per
hour when awake, up to a minimum of 4 hours per day, and Zhou et al. (2008),81 who also specified a more
intermittent schedule (three sessions over a 24-hour period). Some studies recommended a minimum number
of hours of use (between 5 and 9); one study74 defined consistent use as an average of > 4 hour per night.
Most of the prospective studies reported the average number of hours during which NIV was used each
day (assessed by ventilator recordings), but only three76,83,84 gave details on the percentage of patients
using NIV for a minimum number of hours on average. Average use may not be informative regarding the
proportion of patients likely to benefit from adequate use of NIV. The mean use varied between 3.1 and
9.2 hours per night, although it was not always stated if this referred to completers only. Variations may
be a reflection of recommendations given by clinical staff, disease severity or patient comfort (e.g. different
NIV pressures, ability to sleep with equipment). No retrospective controlled studies had details on average
NIV use, as this information would likely not have been captured.
There was variation in how studies reported adverse events (e.g. all associated with NIV or only those
associated with discontinuation), hampering comparisons across studies. Reasons for discontinuation due
to NIV included high pressure, inability to sleep, disturbance of partner, mask intolerance/claustrophobia,
perceived lack of effect or general discomfort or intolerance. There was one case of suspected barotrauma.92
Rates of discontinuation from NIV varied between 5% and 43%; these withdrawal rates were not all because
of adverse events but may have included other reasons (e.g. other illness). Differing discontinuation rates may
be a reflection of length of follow-up, although most discontinuation would be expected soon after starting
NIV. Other adverse events, not necessarily leading to discontinuation, included skin lesion/inflammation, dry
mouth/throat/eyes (humidification was provided in some cases), rhinorrhoea, gastric distension and anxiety.
Secondary outcomes
Results for key secondary outcomes are presented below. All results are based on RCTs only;
non-randomised controlled studies were not considered. Results are presented in forest plots in order to
show the overall direction of effect; however, pooling was not undertaken owing to baseline imbalances
between arms in many of the RCTs and a lack of reporting of adjusted results. Additional reasons for not
pooling were differences between studies in terms of time points presented, the type of RCT (e.g. parallel
or crossover) and, in some cases, uncertainty around patient numbers or exact results (where estimated
from graphs or units were converted; see also Appendix 3 for details on calculation/assumptions made).
Some studies are represented more than once (results at different time points or reported using different
metrics). All extracted (or calculated) data relating to secondary outcomes are presented in Appendix 9.
Only one study32,79 presented adjusted results using appropriate methods (linear regression analysis). Some
studies presented change scores; for most studies mean difference between post-treatment scores was
calculated for this report. Studies were separated in forest plots depending on the method used for
calculating a mean difference (adjusted, change score or mean difference based on final scores). The
Köhnlein et al.76 RCT presented all results for secondary outcomes as percentage change only, therefore
results could not be incorporated into forest plots. Findings have been described narratively for
relevant outcomes.
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Forced expiratory volume in 1 second
Five RCTs,34,74,83,85,99 all in a stable population, reported FEV1 (% predicted), at time points between 3 and
24 months (Figure 8). Two studies34,99 reported a change score; for the other three a mean difference was
calculated from aggregate final scores. There were no significant differences in any studies and no overall
trend was observed.
Six RCTs32,34,77,79,84,100,101 in stable populations and two75,92 in a post-hospital population reported FEV1 (l),
at time points between 3 and 24 months. All but one,84 which did not report sufficient data, have been
represented in a forest plot (Figure 9). There may be a very slight trend across studies favouring NIV, with
three statistically significant results, all of which show a clinically important change (of at least 120ml).
However, two of these were from the same study79,80 in a stable population; this study had more intensive
usual care in both arms than in the other studies. The other significant result was in a post-hospital
population92 (based on post-treatment scores). Overall, there is a lack of consistency in terms of direction
of effect, for both populations.
Forced expiratory volume in 1 second was measured in two further studies; however, in one82 no
post-treatment data were presented (it was stated that there were no significant changes in either arm),
and in the other91 the data presented for SDs appeared to be incorrect. The RCT by Köhnlein et al.76
measured FEV1 and found a statistically significant difference in favour of NIV.
Forced vital capacity
Two studies in stable populations reported FVC (% predicted; Figure 10). Both results were calculated from
post-treatment scores. Neither was statistically significant and the direction of effect is not consistent. Note
that the population on the study by Bhatt et al. 201383 was normocapnic and thus not representative of
the majority of NIV patients across studies.
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FIGURE 8 The FEV1 % predicted. a, Calculated by authors of this report.
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FIGURE 9 The FEV1 (l). a, Calculated by the authors of this report.
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Five studies reported FVC (l), which in four cases is presented in a forest plot (Figure 11; one study84 did
not report sufficient data to be included). Two studies reported a change score75,77 and two a mean
difference calculated from post-treatment scores. Only one study (post-hospital population)92 found a
significant difference in favour of NIV. Overall there were few data, and no consistency in terms of
direction of effect. The study by Köhnlein et al.76 reported data for FVC (unclear if % predicted or litres)
and found no significant difference.
Partial pressure of carbon dioxide in the arterial blood
Partial pressure of carbon dioxide in the arterial blood was measured in 16 studies, of which 13 are
represented in Figure 12. There was an overall trend favouring NIV for reduction in PaCO2, with seven
statistically significant results, one of which was an adjusted result. Mean difference in favour of NIV was
between 0.4 and 1.60 (the latter in the post-hospital population). A reduction of 1 kPa might make a
clinical difference, but this also depends on the individual patient and their starting value. The proportion
of patients within the individual studies achieving a (for them) meaningful change in PaCO2 is unknown, as
is the proportion reaching a threshold values of what might be considered to be ‘normal’ (around 6.5 kPa).
The three studies not represented found a statistically significant difference in favour of NIV,76 found no
significant difference82 or appeared to have errors in the data.111
Stable: change score
Meecham-Jones 199577
Stable: final score
aStrumpf 199134
Post hospital: change score
Struik 201475
Post hospital: final scores
aXiang 200792
Study
NR
NR
–0.2
0.04
Baseline difference
(NIV–control) 
3 months
3 months
12 months
24 months
Follow-up period
0.10 (–0.06 to 0.26)
–0.31 (–1.03 to 0.41)
–0.04 (–0.31 to 0.23)
0.12 (0.03 to 0.21)
Mean difference
(NIV–control) (95% CI) 
–1.0 –0.5 0.0 0.5 1.0
Mean difference in FVC (l) (effect size > 0 favours intervention)
Lung function: FVC (l)
FIGURE 11 The FVC (l). a, Calculated by authors of this report.
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
Partial pressure of oxygen in the arterial blood
Nine RCTs34,77,79–81,83–85,99,100 in a stable population and two75,92 in a post-hospital population reported PaO2
and could be included in a forest plot (Figure 13). There was a clear trend in favour of NIV for the stable
population, with some results statistically significant. There were fewer data for a post-hospital population
and no consistent trend. The difference in change for the statistically significant results was between 0.5 and
1.0. Again, a 1 kPa difference might be important but the same caveats as for PaCO2 apply. Results from
only one study79,80 with a stable population were adjusted for baseline (this study had more intensive usual
care in both arms). Three further studies (in a stable population) measured PaO2 but were not included:
two74,76 found no significant difference and the other91 appeared to have errors in the reported SD.
Six-minute walking distance
Eight RCTs32,77,79,82,83,91,99–101 in a stable population and one92 in a post-hospital population reported 6MWD
at baseline and at follow-up times between 3 and 24 months. There was one statistically significant
result for the stable population (in favour of NIV, adjusted result), but, overall, the results for the stable
population are inconsistent in terms of direction of effect, which may be a reflection of differences in
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FIGURE 12 The PaCO2. a, Calculated by authors of this report; b, measurement performed regardless of oxygen use;
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baseline values. The one post-hospital study shows a statistically significant result in favour of NIV
(improvement of 86m), but this is not based on an adjusted result. One study (stable population)77
reported medians (and ranges) only and is not represented in the forest plot (Figure 14). A further study
(stable population),76 also not represented, found a statistically significant difference in favour of NIV.
Summary secondary outcomes
Overall, there is no evidence to suggest a difference between NIV and usual care for FEV1 % predicted and
FVC % predicted (measured in stable populations only). For FEV1 (change in litres), there may be a slight
trend towards benefit from NIV for a stable population, Measuring the predicted values may be more
meaningful, as this takes into account patient age.
A clear trend towards a benefit from NIV was apparent for PaCO2, for both stable and post-hospital
populations, and for PaO2, for the stable population. Some results were statistically significant. However,
most results are based on post-treatment scores only, which do not adjust for baseline. It is possible that
baseline imbalances are likely to be evened out across several RCTs; nonetheless, using appropriately
adjusted data would give a more robust result. The results from the one adjusted study79,80 are consistent
with the overall findings. Even if the results are taken at face value, it remains uncertain whether or not an
improvement of between 0.5 and 1.6 kPa (increase for O2, reduction for CO2) translates into clinically
important benefits for patients. Any improvement also needs to be considered in the context of the
starting values, as there are likely to be ceiling effects. Most of the results were reported for completers
only; it is uncertain how many of the non-completers were still on NIV or had discontinued. Sensitivity
analyses for missing data may have been appropriate in some cases. Two of the studies in stable
Stable: adjusted for baseline
Duiverman 200879
Duiverman 201180
Stable: change score
Garrod 200684
Meecham-Jones 199577
Strumpf 199134
Stable: final score
aGay 1996100
aBhatt 201383
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aDuiverman 201180
aZhou 200881
aClini 200299
aDuiverman 201180
aZhou 200881
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Post hospital: change score
bStruik 201475
cStruik 201475
Post hospital: final scores
aXiang 200792
Study
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FIGURE 13 The PaO2. a, Calculated by authors of this report; b, measurement performed regardless of oxygen use;
c, measurements both on room air or both on oxygen at the same flow rate.
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
populations included a sham NIV arm (Gay et al. 1996100 and Sin et al. 200782). Neither found any
statistically significant differences.
Two of the RCTs34,77 used a crossover design (both stable populations), and there are less likely to be
baseline imbalances as each patient acts as their own control; findings from these two studies are
inconsistent for PaCO2, and only one of the results is statistically significant for PaO2. (Note that while a
crossover design cancels out baseline imbalances, there may be other issues relating to interaction effects,
and differences arising from the order of giving treatments.)
The results for 6MWD were more inconsistent, possibly because of baseline imbalances, and it is difficult
to draw firm conclusions. In interpreting 6MWD, the possibility of a ceiling effect needs to be considered
where patients had high baseline values. The fact that the one study79,80 that adjusted for baseline shows
a benefit at the later follow-up time80 (difference of 77m at 24 months) is potentially promising, and
consistent with benefits for other outcomes in this study, but this finding would need to be confirmed.
This study also had more intensive usual care underpinning both arms.
An assessment of overall (pooled) direction of effect for secondary outcomes was hampered by the fact
that studies reported outcomes using different methods (e.g. adjusted, change score or mean difference
calculated from final scores) and different study designs (crossover or parallel). It is possible that the
pattern of results observed may change with the use of different metrics and/or sensitivity analyses around
missing assessment data.
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FIGURE 14 The 6MWD. a, Calculated by the authors of this report.
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Discontinuation studies
Two RCTs met the inclusion criteria of this report but addressed a question that was beyond the remit of
this report, namely to look at the effect of discontinuing NIV. Both RCTs (Funk et al. 201171 and Oscroft
et al. 201072) included patients on NIV who, after a period of withdrawal, were randomised to continue
withdrawal or restart NIV. The results have not been further explored here.
Summary clinical effectiveness (non-invasive ventilation versus usual care)
Stable population
l Evidence based on seven RCTs and four non-randomised controlled studies suggests that there is no
survival benefit from NIV (follow-up times between 6 and 24 months).
l There is some evidence to suggest a trend (not statistically significant) for fewer hospital admissions/
days in hospital based on five RCTs and two non-randomised controlled studies; not all available data
could be meta-analysed and three of four other studies reported no significant differences overall for
hospitalisation outcomes.
l There was little information on exacerbations not leading to hospitalisation and no significant
differences were reported.
l There was a trend towards better QoL with NIV, with some statistically significant results; not all studies used
appropriate methods of adjusting for baseline and use of different instruments hampered comparisons.
l None of the studies contributing to primary outcomes used a sham NIV arm and so they were
potentially more susceptible to bias.
l No subgroup analyses for other important parameters (e.g. LTOT, level of hypercapnia, etc.) were possible.
l Sensitivity analyses around study quality and construction of funnel plots were not feasible.
l Results for secondary outcomes suggested a benefit from NIV for improving blood gases (some
statistically significant results); this was based mainly on post-treatment scores (unadjusted for baseline).
Post-hospital population
l Evidence from three RCTs suggested no benefit from NIV in terms of survival (follow-up times between
12 and 24 months), while four non-randomised controlled studies suggested a benefit from NIV
(statistically significant pooled result follow-up times between 6 and 24 months).
l One longer-term (retrospective) non-randomised study suggested benefit from NIV up to 10 years; this
study used an intermittent daytime NIV schedule.
l Three RCTs found inconsistent results in terms of hospital admissions: one was statistically significant in
favour of NIV, one (with a sham NIV arm) was marginally in favour of NIV and one (the largest study)
was marginally in favour of usual care. Data on hospital admissions may be skewed. Only one RCT
reported exacerbations (without acute HRF) and found no significant difference.
l Quality of life was reported in only one post-hospital study, which found no statistically significant difference.
l Sensitivity analyses around study quality and construction of funnel plots were not feasible.
There was too few data to draw firm conclusions regarding secondary outcomes, but there was a trend
towards improvement in PaCO2 based on three RCTs.
Grading of Recommendations Assessment, Development and Evaluation
The study quality and findings were also presented in GRADE tables (Tables 12 and 13). Only primary
outcomes were considered (mortality, hospitalisations, exacerbations and QoL) and only studies comparing
NIV to usual care. In line with the whole report, stable and post-hospital populations were considered
separately. Note that results presented in the GRADE tables are to some extent subjective and should not
be considered in isolation but alongside the more detailed discussions in the report. This is particular
relevant for the risk-of-bias rating. In interpreting the GRADE tables the following considerations
were undertaken:
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Risk of bias
Risk-of-bias assessment was complicated by the fact that not all quality criteria were reported in studies,
and also by the fact that NIV is a difficult intervention to blind. Some studies did include a sham NIV arm,
which may reduce performance bias, but could arguably also lead to an overestimation of benefit for NIV,
as the sham intervention may be associated with some disbenefit. As the effect of a lack of blinding is not
completely certain, an unclear risk-of-bias rating has been given for all outcomes unless there were other
serious risks of bias. Further, in assessing (differential) loss to follow-up, the cut-off points for low/unclear/
high risk-of-bias rating were to some extent arbitrary. Non-randomised studies have an inherently greater
risk of bias and have therefore been given a rating of ‘potentially serious risk of bias’, unless there was
clear evidence of more serious risk.
Inconsistency
The meta-analyses for mortality in both stable and post-hospital populations were associated with low to
moderate levels of heterogeneity (I2 of between 0% and 61%), and results may therefore not be
consistent. Meta-analyses for outcomes relating to hospital admissions were associated with moderate to
substantial/considerable heterogeneity, potentially a reflection of population differences or thresholds for
hospital admission.
Indirectness
It was assumed that there were no serious risks of indirectness, as (1) RCTs undertake direct comparisons
of relevant comparators (NIV vs. usual care), (2) the populations in included studies were eligible in terms
of the review question (with an additional distinction made for stable and post-hospital populations),
(3) intervention and comparators were considered to be usual treatments (albeit potentially with
differences between countries) and (4) at least some outcomes were patient related (i.e. not surrogate).
Imprecision
Confidence intervals around pooled estimates for mortality were fairly narrow and thus not considered to
be imprecise. There were broader CIs on some of the pooled estimates for hospitalisation-related
outcomes and for individual studies (with a small sample size). It needs to be considered that CIs will be
narrower where a greater number of studies (patients) are contributing to the results, so it is important
that heterogeneity (inconsistency) is considered alongside imprecision.
Publication bias
Publication bias was not assessed as there were too few studies in meta-analyses (five at most).
Quality
An overall quality rating was not given as this was considered to be too subjective and may be taken out
of context.
Importance
As only primary outcomes are considered, all outcomes were deemed to be of critical importance, as they
are directly related to COPD progression and/or mortality.
Absolute risks
Absolute risk reductions were not calculated, as none of the results (pooled or individual) was statistically
significant (except for survival in a post-hospital population). However, this result was based on non-randomised
studies and calculating an absolute effect without being able to compare this with potentially more robust
studies may be misleading.
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69

Chapter 5 Clinical effectiveness results:
non-invasive ventilation versus non-invasive
ventilation
This section details three studies that directly compare one form of NIV with another. All were RCTs.
Main study and population characteristics
Patient numbers in the three RCTs were very small (between 12 and 25), and follow-up was short
(6 or 8 weeks in a crossover design, Table 14). Average patient age was 65 and 71 years in two trials and
not reported in the third. There were more men than women (between 52% and 69% men). Patients had
GOLD stage 3 or 4, or at least stage 2112 (although based on mean FEV1 % predicted likely to be more
severe stages). Proportions of the different stages are unknown. Patients in all trials were hypercapnic,
although the cut-off points for inclusion varied (higher at PaCO2 > 7.5 kPa in one trial112). All populations
were described as stable, although one study113 did not give details on length of time without
exacerbations. There were no details on past history of exacerbations, and one study112 did not state
whether or not sleep apnoea had been ruled out.
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Intervention and comparator characteristics
The three crossover RCTs compared different ventilator settings (Table 15). Dreher et al. 201032 compared
high-pressure (assist/control mode) and low-pressure NIV (pressure support mode). This is similar to the
comparison in the study by Oscroft et al. 2010,112 which also compares a high-pressure mode with a
low-pressure mode.
The study by Murphy et al. (2012)113 compares two high-pressure modes, with high and low back-up rates,
the hypothesis being that high inspiratory pressures with low back-up rate would result in levels of
ventilator usage equivalent to those of high inspiratory pressures with high back-up rate.
Use of LTOT in the three studies was 100%,32 67%112 or unknown113 (no details provided).
Quality assessment
Full quality assessment details can be found in Appendix 2. Risk of bias for the generation of the
randomisation sequence was unclear for all three RCTs; two112,113 provided details of allocation
concealment. One study112 stated that trial subjects and technicians were blinded to the ventilation mode,
one113 was described as single blind and one33 was open label. Given that all patients received an active
treatment, lack of blinding may have been less important than in the studies comparing NIV with usual
care only.
Risk of bias from incomplete outcome data was rated as high for two studies. In the study by Murphy
et al. (2012),113 42% (5 out of 12) of patients withdrew, four of those during the high-pressure ventilation
period; however, it was reported that there were no differences between completers and withdrawers,
with the exception of FVC. The other study32 had a loss to follow-up of 23% (4 out of 17) and no details
on differences in characteristics between completers and dropouts. Dropouts did not appear to be
included in the analysis.
All were crossover trials and appeared to use appropriate forms of analysis; however, only one study32
performed a period-effect test for carryover effects.
TABLE 15 Ventilator settings in RCTs comparing different types of NIV
Author Mask Target Modes being compared IPAP EPAP
Dreher et al.
201032
Nasal or
oronasal
Blood
gases
High intensity: high pressure with
respiratory rates beyond the
spontaneous breathing frequency
High intensity,
28.6mbar (1.9mbar);
low intensity, 14.6mbar
(0.8mbar)
High intensity,
4.5mbar
(0.7mbar);
low intensity,
4.0mbar
(0mbar)
Low intensity: low pressure with
back-up respiratory rates of 8 bpm
Oscroft et al.
2010112
Unclear if
nasal or
full-face
mask
Pressure Volume assured: set to enable
adjustment of inspiratory pressure
up to 25, the maximum possible
with this ventilator. Back-up rate
as previously used
Volume assured-NIV:
up to 25 cmH2O
Settings that
patients had
previously used
Pressure preset: set at similar
pressure settings that subject had
previously used. Back-up rate as
previously used
Pressure preset-NIV:
as previously used
Murphy et al.
2012113
Nasal or
oronasal
Pressure High intensity: high pressure and
high back-up rate (–2 bpm)
Mean 29 cmH2O
(SD 2 cmH2O)
Mean 5 cmH2O
(SD 3 cmH2O)
High pressure: high-pressure and
low back-up rate (6 bpm)
bpm, breaths per minute.
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Primary outcomes
Given the short duration of the head-to-head trials, the only primary outcome reported was QoL. The
studies by Dreher et al. (2010)32 and Oscroft et al. (2010)112 comparing different pressures found no
differences in total SRI score32 or SF-36 and SGRQ scores,112 although there was a trend for better QoL on
the SGRQ with volume-assured NIV. The first32 of these two studies was rated as having a high risk of bias
regarding incomplete outcome data. Neither of these studies was designed to look at the main outcomes
of interest for this report as a primary outcome (their main outcomes as defined by the authors of the
study were blood gases).
Murphy et al. (2012),113 which compared different breathing frequencies, also found no significant
differences in total SRI scores, although there was a statistically significant difference for the respiratory
symptom domain in favour of high-pressure ventilation (pressure support ventilation). The risk of bias for
incompleteness of data was rated as high. It should be noted that the main aim of this study was to
compare ventilator adherence rates. No conclusions can be drawn from these small, short-term trials
regarding the effect on QoL of different ventilator settings.
Given the short follow-up times, small numbers of patients, differences in instruments and the inconclusive
results from the larger (parallel) trials, it was not feasible to assess the consistency of results across
trial design.
Adherence and adverse events
Table 16 gives details of the recommended schedule of NIV, any support provided for familiarisation, the
extent to which patients adhered to NIV, and any adverse events associated with NIV, including where
these led to treatment discontinuation.
In the study by Oscroft et al. (2010)112 patients were already established on NIV, and in Dreher et al. (2010)32
there was an indication of the number of days patients had needed for initiation of NIV. There were no
details in Murphy et al. (2010).113 All three trials stated that NIV use was nocturnal but there were no details
on minimum number of hours recommended. Data were recorded by the ventilators. Treatment compliance
was similar between study arms in two studies,112,113 and was higher in the high-intensity arm in one.32
Adverse events from NIV leading to dropouts included intolerance and claustrophobia; no conclusion could
be drawn from this small data set on whether or not (specific) adverse events and/or discontinuations are
more common with certain ventilator settings.
Secondary outcomes
The same secondary outcomes were considered for the head-to-head trials (FEV1, FVC, PaCO2, PaO2 and
6MWD). Table 17 shows the outcomes reported by the three trials and the main findings. Overall,
there appear to be few significant differences in outcomes, although this may be in part a reflection of the
small sample sizes and short follow-up times. There may be a slight trend for a benefit from high-pressure
versus low-pressure NIV, with one statistically significant result (reduction in PaCO2) shown in Dreher
et al. (2010).32 Note that not all outcomes measured in the trials have been reported here.
CLINICAL EFFECTIVENESS RESULTS: NON-INVASIVE VENTILATION VERSUS NON-INVASIVE VENTILATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
TA
B
LE
16
A
d
h
er
en
ce
to
N
IV
an
d
ad
ve
rs
e
ev
en
ts
as
so
ci
at
ed
w
it
h
N
IV
(N
IV
vs
.N
IV
)
St
u
d
y
M
o
d
es
b
ei
n
g
co
m
p
ar
ed
Pe
ri
o
d
o
f
ad
ap
ta
ti
o
n
/h
el
p
in
ad
ap
ti
n
g
to
N
IV
R
ec
o
m
m
en
d
ed
p
er
io
d
o
f
u
se
A
d
h
er
en
ce
A
d
ve
rs
e
ev
en
ts
as
so
ci
at
ed
w
it
h
N
IV
H
o
w
m
ea
su
re
d
M
ea
n
h
o
u
rs
u
se
(S
D
)
%
o
f
p
at
ie
n
ts
o
r
o
th
er
D
re
he
r
et
al
.
20
10
32
H
ig
h
in
te
ns
ity
N
um
be
r
of
da
ys
ne
ed
ed
fo
r
in
iti
at
io
n
of
N
IV
:
4.
6
(1
.0
)
hi
gh
,
pe
rio
d
1,
3.
7
(1
.0
)
hi
gh
,
pe
rio
d
2
N
oc
tu
rn
al
us
e
(n
o
fu
rt
he
r
de
ta
ils
)
V
en
til
at
or
co
un
te
r
re
ad
in
g
Pe
rio
d
1,
10
.8
ho
ur
s/
da
y
(4
.7
ho
ur
s/
da
y)
;
pe
rio
d
2,
8.
9
ho
ur
s/
da
y
(6
.4
ho
ur
s/
da
y)
Tw
o
dr
op
ou
ts
fr
om
lo
w
-in
te
ns
ity
tr
ea
tm
en
t
ar
m
du
rin
g
fir
st
pe
rio
d.
Tw
o
pa
tie
nt
s
re
fu
se
d
to
sw
ap
ov
er
to
lo
w
in
te
ns
ity
af
te
r
fir
st
tr
ea
tm
en
t
pe
rio
d
w
ith
hi
gh
in
te
ns
ity
O
ne
pa
tie
nt
re
fu
se
d
lo
w
-in
te
ns
ity
N
IV
in
ho
sp
ita
lb
ec
au
se
of
in
to
le
ra
nc
e.
N
o
fu
rt
he
r
de
ta
ils
Lo
w
in
te
ns
ity
N
um
be
r
of
da
ys
ne
ed
ed
fo
r
in
iti
at
io
n
of
N
IV
:
1.
7
da
ys
(1
.6
da
ys
)
lo
w
,
pe
rio
d
1,
1.
6
da
ys
(0
.8
da
ys
)
lo
w
,
pe
rio
d
2
Pe
rio
d
1,
7.
7
ho
ur
s/
da
y
(3
.0
ho
ur
s/
da
y)
;
pe
rio
d
2,
4.
6
ho
ur
s/
da
y
(1
.8
ho
ur
s/
da
y)
O
sc
ro
ft
et
al
.
20
10
11
2
V
ol
um
e
as
su
re
d
Pa
tie
nt
s
al
re
ad
y
es
ta
bl
is
he
d
on
pr
es
su
re
pr
es
et
-N
IV
,
m
ea
n
us
e
at
st
ud
y
en
tr
y
7.
8
ho
ur
s/
da
y
(2
.2
ho
ur
s/
da
y)
N
oc
tu
rn
al
us
e
(n
o
fu
rt
he
r
de
ta
ils
)
V
en
til
at
or
do
w
nl
oa
d
da
ta
8.
2
ho
ur
s/
da
y
(3
.6
ho
ur
s/
da
y)
1/
25
w
ith
dr
ew
fr
om
st
ud
y
be
ca
us
e
of
ex
ac
er
ba
tio
n
A
pp
ea
r
to
be
no
ne
Pr
es
su
re
pr
es
et
7.
7
ho
ur
s/
da
y
(2
.4
ho
ur
s/
da
y)
M
ur
ph
y
et
al
.
20
12
11
3
H
ig
h
in
te
ns
ity
N
o
de
ta
ils
N
oc
tu
rn
al
us
e
(n
o
fu
rt
he
r
de
ta
ils
)
V
en
til
at
or
do
w
nl
oa
d
da
ta
M
ea
n
ni
gh
tly
us
e
6
ho
ur
s
33
m
in
ut
es
(2
ho
ur
s
14
m
in
ut
es
)
1/
12
w
ith
dr
aw
al
(r
ea
so
n:
ac
ut
e
ex
ac
er
ba
tio
n)
A
pp
ea
r
to
be
no
ne
H
ig
h
pr
es
su
re
M
ea
n
ni
gh
tly
us
e
6
ho
ur
s
37
m
in
ut
es
(S
D
1
ho
ur
45
m
in
ut
es
);
m
ea
n
di
ff
er
en
ce
4
m
in
ut
es
(9
5%
C
I
–
45
m
in
ut
es
to
53
m
in
ut
es
)
4/
12
w
ith
dr
aw
al
s
(r
ea
so
ns
:
1/
12
cl
au
st
ro
ph
ob
ia
,
2/
12
in
to
le
ra
nt
of
th
er
ap
y,
1/
12
pr
ol
on
ge
d
ce
nt
ra
l
sl
ee
p
ap
no
ea
s)
1/
12
cl
au
st
ro
ph
ob
ia
,
2/
12
in
to
le
ra
nt
of
th
er
ap
y
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
Summary clinical effectiveness (non-invasive ventilation versus
non-invasive ventilation)
l Three small crossover trials with stable populations were identified, two32,112 comparing higher versus
lower pressure, and one113 comparing similarly high pressures, with settings differing in back-up rates.
l All trials were short term (6–8 weeks) and did not have the outcomes of primary interest for this report
as their primary aim. Dropout rates were high in two32,113 of the studies.
l Treatment compliance was similar between study arms in two studies112,113 and was higher in the
high-intensity arm in one.32
l Quality of life was the only primary outcome measure (based variously on SRI, SF-36 and SGRQ). No
firm conclusions could be drawn from the limited data on whether certain settings are more beneficial.
l There was one statistically significant result (Dreher et al. 201032) in terms of PaCO2 reduction with
higher-pressure NIV.
Review of systematic reviews
Eight systematic reviews/guidelines met the selection criteria for the review of clinical effectiveness of
domiciliary NIV.110,114–120 There were multiple publications relating to the authors of the Cochrane
Review,110,121–124 with only the most recent update (2013/14) being considered here110,124 (reported in
two publications).
This section concentrates on the more recently published systematic reviews: the Cochrane review
(2013/14),110,124 Shi et al. (2013)119 and an evidence-based analysis for the Ontario Health Technology
Assessment series (2012).118 The reviews not mentioned further here are by Sin et al. (2003),117
TABLE 17 Secondary outcomes in trials comparing different types of NIV
FEV1 (l or % predicted)
Study Comparison Main findings
Dreher et al. 201032 High intensity (pressure) vs. low
intensity (pressure)
Significant increase from baseline to 6 weeks in
high intensity group. No significant between-group
differences at 6 weeks for FEV1 (l)
Oscroft et al. 2010112 Volume assured (higher pressure) vs.
pressure preset (lower pressure)
Slightly higher values with volume assured NIV.
No significant between-group differences at
6 weeks for FEV1 (l) or FEV1 (% predicted)
FVC (l or % predicted)
Oscroft et al. 2010112 Volume assured (higher pressure) vs.
pressure preset (lower pressure)
No significant between-group differences at
8 weeks for FVC (l) or FVC (% predicted)
PaCO2
Dreher et al. 201032 High intensity (pressure) vs. low
intensity (pressure)
Statistically significant difference in reduction in
favour of high-intensity NIV (p= 0.001)
Oscroft et al. 2010112 Volume assured (higher pressure) vs.
pressure preset (lower pressure)
No significant between-group differences at
8 weeks
Murphy et al. 2012113 High intensity (high pressure+ high
back-up rate) vs. high pressure (high
pressure+ low back-up rate)
No significant between-group differences at
6 weeks
6MWD
Dreher et al. 201032 High intensity (pressure) vs. low
intensity (pressure)
No significant between-group differences at
6 weeks
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Kolodziej et al. (2007),115 McKim et al. (2011)116 and Chen et al. (2011).114 The recent guidelines120 are
also not considered further, as their findings are based on systematic reviews discussed here. However, all
the reviews had reasonably similar aims to the current review with, in most cases, a focus more on the
physiological outcomes and less on those outcomes that might more readily populate an economic model
to determine cost-effectiveness from a health-service provision perspective.
The Cochrane review110,124 was fairly robustly conducted and it had narrow inclusion criteria relative to the
current review in that NIV use was required to be used for a minimum of 5 hours per night (for at least
3 weeks). Seven RCTs were included; of note is that a further seven RCTs were included in the current
report and, although these may not have met the narrower inclusion criteria of the Cochrane review,
they were not listed in the ‘excluded studies’ section of the Cochrane review. Some studies in abstract form
were excluded from the Cochrane review, but this does not appear to have been an exclusion criterion.
One study was listed as awaiting assessment because of clarification requests made to the authors, even
although it had been published in 2007; this study is included in the current report (Xiang et al.92 in 2007).
Survival and exacerbations were not included as outcomes in the Cochrane review, although one of the
publications124 mentions these outcomes in the discussion and states that there is insufficient evidence to
draw any conclusions (based on three RCTs). The review, however, did obtain IPD and undertake IPD
analysis for several outcomes, including for HRQoL. For the HRQoL, analysis was undertaken with data from
two studies, both of which enrolled a relatively stable COPD population and used the SGRQ. The main
conclusions from Cochrane review were that nocturnal domiciliary NIV for at least 5 hours per night and for
at least 3 months in hypercapnic patients with COPD had no consistent clinically or statistically significant
effect on gas exchange, exercise tolerance, HRQoL, lung function, respiratory muscle strength or sleep
efficiency. The conclusion highlights the small sample size and the effect on drawing conclusions.
The Ontario Health Technology Assessment Series118 aimed to review both the clinical effectiveness and
cost-effectiveness evidence of NIV compared with no ventilation in stable COPD patients. There appears to
have been no restriction on the location or duration of use of NIV. The effectiveness review aimed to
include only systematic reviews, meta-analyses and RCTs, published in English. Studies beyond RCTs were
excluded. The review included eight RCTs, three of which were excluded from the current report, as the
setting for NIV administration was deemed not to be domiciliary and this difference might be related to
the breadth of the review question (see Decision problem). Primary effectiveness outcomes were similar
to this report and the review was of a fairly good standard. A conclusion of the review was that there were
no long-term beneficial effects of NIV on mortality, FEV1, O2 and CO2 levels, exercise tolerance and
hospitalisations, and that HRQoL data were not substantial enough to allow the formation of conclusions.
The cost-effectiveness section of the Ontario Health Technology Assessment Series118 is reported in the
systematic review of cost-effectiveness studies section of this report (see Chapter 6, Commentary on
excluded studies).
The study by Shi et al.119 in 2013 was a meta-analysis of RCTs of NIV in patients with severe stable COPD.
The follow-up period had to be 2 weeks or longer; however, there was no restriction on setting of NIV
use, and thus some studies included in this meta-analysis (n= 2) are excluded from the current report, as the
setting was not domiciliary NIV use. Low-quality studies (Jadad score of < 2) were also excluded from the
meta-analysis (n= 2); however, a list of excluded studies was not provided. The meta-analysis included eight
RCTs and three crossover RCTs. One of these was not included in any other review or identified through
searches of bibliographic databases for the current report. This RCT by Zhou et al.81 in 2008 was undertaken
and published in China and was included in the current report through citation checking of the Shi et al.
meta-analysis. Primary effectiveness outcomes in the meta-analysis were similar to this report and the review
was of a fairly good standard. The main conclusions were that, although NIV may improve gas exchange and
dyspnoea, it has no effect on mortality, pulmonary function or exercise tolerance in severe stable COPD and
that unbiased medium-term studies are required.
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In summary, although there are a number of existing systematic reviews on NIV in COPD in what could be
considered a non-emergency setting, there are some subtle differences in the review aims of the more
recent reviews and thus differences in their study selections. However, the findings from these reviews are
fairly uniform in highlighting the absence of consistent effects of NIV across outcomes, the limitations of
the data and thus the difficulties in drawing firm conclusions of effectiveness.
None of the included systematic reviews subdivided studies by the proximity of the population to an
exacerbation requiring hospitalisation, therefore the current report adds to the current knowledge base
in this regard, as well as in relation to a primary focus on outcomes related to determination of
cost-effectiveness.
Ongoing studies
Searches (undertaken September 2014) of clinical trials registers identified 416 potentially relevant records
of apparent ongoing studies (see Chapter 3, Searches, and Appendix 1 for search strategies). Screening of
these records and application of review selection criteria was undertaken. The key difficulty with the
selection process was the absence of information in the records, given that these were not protocols for
studies but only brief outlines of study aims with limited associated methodological information provided.
Therefore, the relevance of some records to this report could not be ascertained. Despite this, it was
possible to identify a number of records that met the selection criteria. However, some of these had trial
registry records that had not been updated for several years (since April 2011), had not commenced
(e.g. because of lack of funding) or were terminated because of recruitment issues. These studies are not
considered further here. Table 18 details the remaining studies meeting the inclusion criteria.
For the reasons mentioned, the selection process could not provide definitive sets of included and excluded
records in regard to ongoing studies, and as such no lists are given in this report. Therefore, this section
serves to indicate that there are a number of ongoing studies which may add further data in the future.
Of the identified ongoing studies, one was known of prior to the start of this project.
A UK-based open-label trial (NCT00990132), commonly known as the HOT-HMV trial, aims to test the
hypothesis that home mechanical ventilation and LTOT increases admission-free survival compared with
LTOT alone in COPD patients who remain persistently hypercapnic following an acute exacerbation
requiring NIV. Patients 2 to 4 weeks post acute hypercapnic exacerbation are recruited, randomised and
then followed up for up to 12 months, with admission-free survival being the primary outcome measure.
This study is thus of relevance to the post-hospital subgroup considered in this report. The target
recruitment number is 116 patients across eight UK centres. An abstract by Murphy et al.78 in 2011 from
this trial was identified and included in the review of effectiveness (see Chapter 4, Clinical effectiveness
results: non-invasive ventilation versus usual care). This abstract contained interim (3-month) data on issues
related to sleep and adherence. Further details on the latter can be found in Chapter 4, Adherence and
adverse events.
Contact with the principal investigator of the HOT-HMV trial in December 2014 identified that the study
was still recruiting patients (105 out of 116 recruited so far), with full results expected in spring 2016.
While wishing to be helpful to the current report, the principal investigator was concerned that premature
analysis on an incomplete and underpowered data set would be meaningless and potentially misleading
in comparison to the final data from the study. As such, no early data were supplied for this report.
Enquiries about ways in which baseline patient data might be shared to additionally inform assumptions
made in the economic modelling carried out in this report were also undertaken, but time scale prevented
full pursuit of this.
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TABLE 18 Table of recent ongoing studies
Trial codea Research question Design Statusa/Details
NCT00990132 To test the hypothesis
that home mechanical
ventilation and LTOT
increases admission-free
survival compared with
LTOT alone in COPD
patients who remain
persistently hypercapnic
following an acute
exacerbation requiring NIV
RCT, open label, nocturnal
NIV+ LTOT vs. LTOT.
Follow-up: 1 year
Eight UK university centres
Estimated enrolment: 116
Study start: October 2009
Estimated completion: December 2014
Record last updated: May 2012
Known as: HOT-HMV trial
Status: this study is enlisting participants
at present
NCT01481727 To evaluate the efficacy of
high intensity non-invasive
mechanical ventilation
(during 1 year) to reduce
the severity and frequency
of acute exacerbations of
COPD in patients with
frequent exacerbations and
in GOLD stage 4
RCT, double blind, BIPAP
vs. CPAP sham control.
Follow-up: 1 year
National Institute of Respiratory
Diseases, Mexico
Estimated enrolment: 25
Study start: December 2011
Estimated completion: December 2013
Record last updated: May 2012
Status: unknown recruitment status as
information has not recently been
verified
NCT01526642 To determine whether or
not home NIV can reduce
recurrent acute HRF in
COPD patients who
survived an episode of
acute HRF treated by NIV
RCT, open label, home NIV
vs. LTOT. Follow-up:
2 years
Six French hospitals
Estimated enrolment: 86
Study start: December 2011
Estimated completion: December 2013
Record last updated: February 2012
Status: terminated
ISRCTN15832381 To assess the application of
NIV during an exercise
programme following
acute acidotic exacerbation
of COPD in hospital and
follow-up use at home,
feasibility of using the
Trilogy Ventilator
RCT, open label,
exercise+ oxygen versus
exercise+NIV+ oxygen
vs. continued
supervised exercise
program+NIV+ oxygen,
if indicated, at home.
Follow-up: 3 months
Bristol, UK
Estimated enrolment: 45
Study start: February 2013
Estimated completion: February 2015
Record last updated: February 2013
Status: study is ongoing
NCT01513655 To investigate whether or
not home NIV, as an
exacerbation prophylactic
treatment, may reduce
mortality in COPD patients
after first acute NIV
treatment and secondarily
reduce both exacerbations
and hospitalisations and
improve the QoL
RCT, single blind (outcome
assessor), NIV+ usual care
vs. usual care. Follow-up:
1 year
Copenhagen, Denmark
Estimated enrolment: 150
Study start: July 2013
Estimated completion: August 2015
Record last updated: July 2013
Status: this study is enlisting participants
at present
a Status and trial code. If starting ‘NCT’, as recorded on http://clinicaltrials.gov (last accessed 24 November 2014);
if starting ‘ISRCTN’, as recorded on www.controlled-trials.com (last accessed 24 November 2014).
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Two further studies are appearing completed or near completion according to trial registry records. A small
RCT (n= 25) to evaluate the efficacy of high-intensity non-invasive mechanical ventilation (during 1 year) to
reduce the severity and frequency of acute exacerbations of COPD in patients with frequent exacerbations
and in GOLD stage 4, appears to be ongoing in Mexico (NCT01481727). This trial is described as comparing
BIPAP and CPAP sham control in a double-blind fashion. The duration since last exacerbation at enrolment is
not stated for this trial. The completion date was stated in May 2012 to be December 2013. Contact with
the investigators of this study (October 2014) identified that the study is still ongoing and recruitment was
due to finish in November 2014 because of issues related to the strict inclusion criteria; thus no data are
currently available. The other study near completion is an open-label RCT of home NIV versus LTOT to
determine whether or not home NIV can reduce recurrent acute HRF in COPD patients who survived an
episode of acute hypoxaemic respiratory failure treated by NIV. This French study has an estimated
enrolment of 86 patients and the stated estimated completion date was December 2013; however, the trials
register indicates that the study has been terminated. For this report contact was attempted with the
investigators in this study, but no response was received (October 2014).
Finally, recently commenced studies are due to be completed in 2015. One is listed as being conducted in
Bristol, UK (ISRCTN15832381), and aims to assess the application of NIV during an exercise programme
following acute acidotic exacerbation of COPD in hospital and with patients in one arm of the three-armed
study being followed up after 3 months’ use of home ventilation. The other study (NCT01513655) aims
to investigate whether or not home NIV, as an exacerbation prophylactic treatment, may firstly reduce
mortality in COPD patients after first acute NIV treatment and secondarily reduce both exacerbations and
hospitalisations and improve QoL. This is a single-blind (outcome assessors blinded) RCT comparing
domiciliary NIV added to usual care, with usual care and it appears that patients will be recruited while
hospitalised for an exacerbation and will be followed up for 1 year. The study is being conducted in
Denmark and the enrolment target is 150 patients.
Based on the information available for these studies, it appears that the HOT-HMV, Danish and, possibly,
Bristolian studies might provide further evidence in a population commencing domiciliary NIV
post-hospitalisation for an exacerbation. The Mexican study may provide evidence on a population of
more frequent exacerbators.
None of the ongoing trials documented appear to be comparing two or more types or modes of NIV in a
domiciliary setting.
Clinical effectiveness review discussion
Main findings
Eighteen RCTs and 10 controlled studies were identified that compared domiciliary NIV with usual care.
Despite this fairly high number of studies, sample sizes were generally small (between 13 and 201 patients)
and not all reported on the primary outcomes relevant to this report. The main findings of studies
comparing NIV to usual care, for the two relevant COPD populations, are described below.
Stable population
For the stable population there was evidence to suggest that there was no difference between NIV and
usual care in terms of survival, for a follow-up time of between 12 and 24 months. This was based on
seven RCTs and four controlled studies. Longer-term survival data were available from three uncontrolled
studies,87,88,93 although there was no information to confirm whether or not two87,88 of these were in a
stable population. No longer-term study found a significant difference between NIV and usual care,
although there were slightly fewer deaths with NIV at later time points (4 and 8 years). There appeared to
be a trend towards fewer hospital admissions/days in hospital with NIV (based on five RCTs and three
controlled studies with follow-up times up to 24 months) but there were no statistically significant
differences. Heterogeneity in use of outcome measures meant that not all results relating to hospital
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admissions could be pooled; studies not included in the meta-analyses found no statistically significant
differences overall. There were no significant differences in exacerbations based on three RCTs and one
controlled study. QoL reporting was very heterogeneous in terms of use of instruments, time points and
presentation of results. There appeared to be a trend favouring NIV, but a consistent benefit could not be
demonstrated, and not all studies used, or reported on, appropriate methods for adjusting for
baseline differences.
Post-hospital population
For the post-hospital population, evidence from three RCTs suggested that, on average, there was no
difference between NIV and usual care (follow-up between 12 and 24 months) in terms of survival. Evidence
from four non-randomised controlled studies found a statistically significant pooled result in favour of NIV in
terms of survival. One of the non-randomised controlled studies86 found additional statistically significant
benefits with NIV at 5 years, and, with a smaller effect size, at 10 years. This study had a different NIV
schedule to all other studies (NIV intermittently for 15 minutes every hour during the daytime). Three
RCTs75,90,92 reported disparate results regarding hospital admissions: one found a statistically significant result
in favour of NIV,92 one marginally favoured NIV90 and one marginally favoured usual care.75
Time to first hospital readmission due to any COPD exacerbation, reported in the one study,90 was not
significantly different for the NIV and usual-care arms, although admissions occurred sooner in the
usual-care arm. This study also found no significant difference for exacerbations without acute HRF.
Only one RCT (Struik et al. 201475) in a post-hospital population reported quality of life; there were no
statistically significant differences between groups at 12 months, based on four different
measurement scales.
Exploratory analyses
Subgroup analyses by level of hypercapnia were not possible given the small number of studies and the
inconsistent reporting of the relevant variables. Performing a subgroup analysis based on reported mean
baseline CO2 values would also have meant dichotomising trials based on an arbitrary threshold, and this
was not considered appropriate. However, in a separate analysis, CO2 levels at baseline and change in CO2
levels were plotted against mortality in order to determine if baseline CO2 can predict response to NIV
and whether or not the effect of NIV on CO2 correlates with the effect on mortality. These analyses,
undertaken across both stable and post-hospital populations, did not suggest a relationship between CO2
levels at baseline and mortality; nor did changes in CO2 appear to correlate with mortality. It was unclear
if there was a trend towards a correlation between CO2 levels at baseline and hospital admissions. While
there does appear to be a trend towards a correlation between changes in CO2 and hospital admissions,
the analysis is using aggregate data for change in CO2 and also for mean difference in hospital admissions,
therefore a causal association cannot be inferred even if there is potential biological plausibility. Further, this
was a post-hoc analysis, which is subject to a number of limitations (see Appendix 7).
Uncontrolled studies
Uncontrolled studies were explored where there was a lack of data from controlled studies, for example
for long-term survival and QoL in a post-hospital population. Survival data were broadly consistent with
those found in the NIV arms of controlled studies, although comparisons were difficult because of different
time points of reporting and potential population differences. No useful QoL data were found in the
uncontrolled studies for the post-hospital population. Overall there were no findings from uncontrolled
studies that either contradicted or added meaningfully to data from controlled studies.
Quality of included studies (randomised controlled trials and controlled)
Overall, the RCTs comparing NIV with usual care appeared to be of reasonably good quality, although
there was a lack of reporting of some details relevant to quality. Only three RCTs included a ‘sham NIV’
arm, and only one of these reported a primary outcome of interest (Cheung et al. 201090 –
hospitalisations/exacerbations). It is possible that studies with no ‘sham NIV’ may have been subject to
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performance bias, with patients in the NIV arms (inadvertently) receiving more medical attention; this in
turn may have led to more positive outcomes overall. However, the use of sham NIV may also enhance the
apparent benefit of NIV by resulting in side effects without benefit in the control arm. A lack of blinding
may also have affected QoL reporting by patients. Some studies suffered from fairly substantial loss to
follow-up (up to 59%), and it was not always clear if an ITT analysis had been undertaken. Particularly for
secondary outcomes (e.g. blood gases), it was more common for completers only to be included, possibly
as a consequence of people with severe COPD finding it difficult to attend follow-up appointments.
Non-randomised studies are likely to be more prone to bias, particularly in terms of patient selection.
While the prospective controlled studies did not appear to have major differences in terms of patient
characteristics, some of the retrospective studies did allocate patients to NIV and usual-care groups on the
basis of different criteria (dependent on blood gases), thus complicating the interpretation of results. Three
retrospective studies also reported more frequent follow-up visits in the NIV arm. Overall, there were fewer
details on blinding, adherence and how incomplete data were dealt with in the non-randomised
(particularly retrospective) studies. Four of the five retrospective studies reported only survival, in which
case loss to follow-up may be less of a problem in terms of accessing outcome data. There does, however,
appear to be consistency in terms of direction of effect between non-randomised and randomised studies
for the stable population (survival and hospitalisation results) despite potential differences in quality and
robustness of data. For the post-hospital population, the controlled studies appeared to show more of a
benefit from NIV than the RCTs for survival. There were no controlled studies in this population reporting
hospital admissions.
Effect of patient characteristics on effectiveness of non-invasive ventilation
There are a number of patient characteristics that could potentially influence the effectiveness of NIV,
including comorbidities, level of hypercapnia, and whether or not a patient is on LTOT or suffers frequent
exacerbations. Formal subgroup analysis for these parameters was not feasible given the small number of
studies, lack of reporting detail and other study heterogeneity. Based on the data in this report, it is
currently not possible to make a judgement on the type of patient who is most or least likely to benefit
from NIV. COPD is being recognised as an increasingly diverse disease, and individuals may benefit from
more tailored treatment approaches applied to NIV. Examples of tailored treatment in COPD include
roflumilast for patients with chronic bronchitis125 and lung volume reduction surgery for patients with both
predominantly upper-lobe emphysema and low baseline exercise capacity.126
Effect of different pressure settings on effectiveness of non-invasive ventilation
Non-invasive ventilation pressure settings may influence effectiveness, and this report identified three RCTs
directly comparing different settings. The main outcomes of interest of these small, short-term crossover
RCTs were lung function, blood gases and adherence. QoL was also measured, but no firm conclusions
could be drawn from the available data. One study32 comparing high pressure with low pressure reported
a statistically significant result in favour of NIV (reduction of PaCO2) with the higher-pressure setting.
Pressure may be important not only in terms of effectiveness, but also in terms of adherence, as higher pressure
may be experienced as less comfortable by the patient and thus lead to discontinuation. There were no major
differences between pressure settings regarding adherence in the three small head-to-head trials. For RCTs
comparing NIV versus usual care only, it was not possible to undertake formal subgroup analyses based on
pressure, given the small number of studies, the inconsistency in how pressure was reported and other
potential sources of heterogeneity. It is conceivable that discontinuation rates may differ between stable and
post-hospital populations, with, for example, post-hospital patients being more motivated to use NIV. It was,
however, not possible to make a judgement on this given the available data.
Adverse events
Adverse events were inconsistently reported but in line with those known to affect NIV patients and
generally not serious (e.g. mask discomfort, pressure experienced as too high, inability to sleep, etc.).
There was only one potentially more serious adverse event, a suspected barotrauma.92
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Secondary outcomes
There was a clear trend among stable populations towards a benefit from NIV for improving blood gases
(PaO2 and PaCO2) and, based on more limited data, in the case of the post-hospital population, for
reduction in PaCO2. There was no consistent trend for the other secondary outcomes (lung function
parameters, 6MWD). Only one study79,80 presented appropriately adjusted results; it would be of interest to
undertake an analysis across all trials using appropriately adjusted results in order to examine the potential
impact. For 6MWD, in particular, there appeared to be substantial baseline imbalances, which may be a
reason for the inconsistent results found for this outcome.
Stable versus post-hospital patients
In this report a distinction was made between stable and post-hospital populations in order to capture
baseline imbalances in risk of future exacerbations. It is recognised, however, that there are likely to be not
two distinct groups, but, rather, a continuum of patients with differing baseline risks (which change over time).
The population in the RCT by Zhou et al. (2008)81 was defined as stable, but the rate of hospital admissions in
the usual-care arm was higher than that of the other stable populations and similar to the usual-care arm rates
in one post-hospital study. Benefit from NIV (in terms of reduction of hospital admissions and a trend towards
survival) appeared to be greater in this study than in the other studies with stable populations. Given the lack
of information in most studies on history of exacerbations, the dichotomisation into stable and post-hospital
patients was a pragmatic one. However, it is also known that patients with a recent exacerbation are more
likely than patients who have been stable for a period of time to experience a further exacerbation. More
recent GOLD criteria (from 2011)127 take into account the risk of exacerbations, but this classification was not
used in the included studies.
Generalisability of findings
In terms of applicability, RCTs have a tendency to use more stringent inclusion criteria than non-randomised
studies. A broader, potentially less well population might therefore be expected to be included in the
non-randomised studies. Given the relative consistency in the results between RCTs and non-randomised studies
(at least for the stable population), there is nothing to suggest significant differences between the populations,
although there may be other sources of heterogeneity obscuring these. Most of the RCTs and the prospective
non-randomised studies specifically excluded patients with obstructive sleep apnoea, so results are not applicable
to patients with overlap syndrome. While primary obstructive sleep apnoea is treated with CPAP, COPD patients
with overlap syndrome may benefit from NIV, and could be considered for future trials.128
A majority of patients in the post-hospital studies had a form of ventilation in hospital before commencing
domiciliary NIV. This might indicate a more severe population than a general COPD population being
admitted to hospital, where one might expect around 15% to be treated with ventilation during their
stay.129 However, previously ventilated patients might be the type of patient most likely to be selected
for NIV.
A recent analysis130 of UK COPD patients followed after one or more hospital admissions requiring NIV
found mortality rates of between 45% and 57% at 1 year, between 62% and 68% at 3 years and
between 72% and 75% at 5 years. This was broadly consistent with the 1-year mortality rates in the
usual-care arm of one post-hospital study97 included in this report. There were some differences between
the UK data and the study populations in this report at later time points, but comparisons were hampered
because of reporting of mortality at different time points.
Strengths and limitations of the available data
A number of RCTs of reasonably good methodological quality were available, particularly for the stable
population. However, there were several limitations, particularly concerning the outcomes relevant to the
economic model. Hospital admissions data were not reported consistently across trials, so not all available
evidence contributed to the pooled estimate for the stable population; further, admissions data may be
skewed and the mean (SD) may not be the most appropriate metric to use, although it was frequently
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reported. QoL was inconsistently measured in studies of stable patients, and in only one study of post-hospital
patients. As a result, the impact of domiciliary NIV on QoL remains uncertain for both populations. A trend of
improved QoL needs to be confirmed in stable patients. While a reduction in hospital admissions will likely have
a temporary impact on QoL, the effect of NIV on daily living (when COPD is stable) remains uncertain. Further
research on which instruments best capture QoL in this patient group and whether scores are translatable
between different instruments is necessary. Qualitative research may help to inform which aspects of QoL
should be reflected in assessment tools. The timing of QoL measurements is important. Patients may experience
a decrease in QoL early on (while they are adapting to the equipment) but an increase at later stages, provided
the treatment is effective. A potential survivor effect also needs to be taken into account; QoL may eventually
decrease in the later stages of COPD, but this could be in patients who might not have survived without NIV.
For secondary outcomes, most studies did not present adjusted results, despite there being baseline
imbalances. Only one study79,80 used an appropriate method of adjusting. Baseline imbalance should be
accounted for using an analysis of covariance model.131 In the absence of this, analyses that use the
summary results to adjust for baseline imbalance will not account for the within-study correlations
between these repeated measures. More sophisticated analyses may be possible; for example, external
evidence could be used to provide an informative prior for the within-study change variance, but this was
outside the scope of the current report.
Other limitations in the available data included poor description of when and where NIV was initiated;
a lack of detail to allow for a complete judgement on study quality; a lack of reporting of time-to-event
data and HRs (even for survival data); inconsistent reporting of adverse events; and a lack of data explicitly
linking the number of exacerbations to subsequent hospitalisations and survival. This last point has
potential implications for double-counting data, as these outcomes are not independent of each other.
Strengths and limitations of this report
A comprehensive search strategy (including citation checking) meant that this report identified more
relevant studies than previous systematic reviews (even taking into account different search periods).
The fact that no language restrictions were applied meant that 6 out of 31 (19%) of the included RCTs
or controlled studies were non-English language, constituting a substantial proportion of the overall
evidence base.
This is the first systematic review to attempt to account for differing baseline risks of exacerbation/
hospitalisation by categorising populations into stable and post hospital. This is also the first systematic
review to both focus on patient-related outcomes (survival, hospitalisation, exacerbations and QoL) and
incorporate data from non-randomised studies in separate analyses. Further, by calculating summary
measures from raw data or converting data, the number of results that could be presented in forest plots
was maximised.
In contrast to some previous systematic reviews, secondary outcome data (lung function, blood gases and
6MWD) were not pooled because of a lack of reporting of results which were appropriately adjusted for
baseline. A failure to do this can result in misleading results (e.g. where the usual-care arm shows a higher
final result but the improvement has been greater in the NIV arm). Instead, results were presented in forest
plots with the method of calculating the effect estimate highlighted, so that findings could be put into
the context of the robustness of the methods.
Heterogeneity in the way some outcomes were reported meant that not all studies could be incorporated
into meta-analyses (e.g. for exacerbations and some hospitalisation data). Small numbers of studies in
meta-analyses (up to seven maximum) precluded the construction of funnel plots, and the small number,
together with a lack of reporting of some quality criteria, meant that sensitivity analyses around study
quality were also not feasible.
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Chapter 6 Cost-effectiveness review
This chapter describes the methods and results of a systematic review of the literature on thecost-effectiveness of domiciliary NIV in patients with end-stage COPD.
Methods
The methods of this systematic review were broadly similar to those presented in Chapter 3 and thus only
key details and differences are given here.
Search strategy
Searches for economic studies were run on MEDLINE, EMBASE via Ovid and NHS Economic Evaluation
Database using, where appropriate, relevant terms for economic studies along with terms for clinical
populations. Examples of these strategies can be found in Appendix 1. These searches were supplemented
with any further economic evaluations and cost studies identified during screening of the search yield in
the clinical effectiveness review.
Study selection
All records were screened by two reviewers independently, and copies of potentially relevant articles were
obtained for scrutiny against the full selection criteria, with any disagreements resolved by discussion. The
inclusion criteria were the same as those for the clinical effectiveness review except that the study designs
were full economic evaluations, partial economic evaluations and cost-effectiveness analyses alongside
trials and economic modelling studies.
Data extraction and quality assessment strategy
Data on the following, where available, were extracted from included studies by one reviewer and checked
by another:
l study characteristics, such as study question, form of economic analysis, population, interventions,
comparators, perspective, time horizon and form of modelling used
l clinical effectiveness and cost parameters, such as effectiveness data, health state valuations (utilities),
resource-use data, unit-cost data, price year, discounting and key assumptions
l results and sensitivity analyses.
Studies were to be quality-assessed using the Drummond checklist132 for economic evaluations and the
checklist by Philips133 for model-based analyses.
Results
A total of 342 records were identified from the searches and, following the removal of duplicates, there
were 247 unique records. Eight additional articles were identified from the systematic review of clinical
effectiveness, three of which were duplicates.
Thirty-one records were deemed relevant to this economic review and hard copies were obtained for
scrutiny against the inclusion criteria for the review. Two of these met the inclusion criteria.40,134 A list of
excluded studies can be found in Appendix 10. A flow diagram summarising the selection process can be
found in Figure 15.
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FIGURE 15 Flow diagram depicting article selection for cost-effectiveness review.
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Summary of included studies
Both included studies conducted a cost analysis alongside a clinical study of domiciliary NIV in COPD
patients.40,134 Each study met at least eight of the 10 Drummond and Jefferson quality-assessment criteria
(see Appendix 11).132 Neither study was sponsored by industry, although some potential conflicts of
interested were declared by Tuggey et al. (2003).40 The characteristics and main results of each study are
summarised in Table 19.
TABLE 19 Summary of published economic evaluations
Economic
analysis features Tuggey et al. (2003)40 Clini et al. (2009)134
Country UK Italy
Sponsor Research was funded by the Northern and
Yorkshire NHS Executive. Ventilator equipment
was provided on loan by ventilator companies.
One of the authors received an honoraria from a
ventilator company for lecturing
Research was funded by the Italian Association
of Pulmonologists
Choice of therapy Patients admitted frequently to hospital who
responded well to NIV and were offered or
requested home NIV
Home NIV added to LTOT
Comparators Care in the year prior to treatment with home NIV LTOT alone
Form of analysis Retrospective cost analysis from a hospital
perspective
Retrospective cost analysis of NIV alongside
randomised trial
Sample size 13 monitored before and after commencing
home NIV
35 on LTOT and home NIV; 42 on LTOT alone
Patient
characteristics
69% male, mean age 55 years, FEV1 0.58 l
(SD 0.24 l)
78% male, mean age 66 years ± 6 years,
FEV1 % predicted 30% ± 10%, BMI median
23 kg/m2± 4 kg/m2 (range 18–28 kg/m2)
Model used N/A N/A
Inclusion criteria History of recurrent severe exacerbations. Good
tolerance of NIV during acute exacerbation
Prescription for LTOT. Diagnosis of COPD
Time horizon 1 year 2 years
Type of costs
considered
Ward costs: capital, nursing and pharmacy,
intensive care, acute NIV, home NIV, staff training,
outpatient appointments
Hospital admission because of exacerbation,
drug therapy, LTOT supplementation,
domiciliary ventilators including accessories
Cost year and
currency
2003, GBP 2008, EUR
Base-case results Cost per patient on home NIV was £4909.
Cost per patient on usual care was £13,163
Cost per patient per day in NIV and LTOT was
€23.72 ± €16.18. Cost per patient per day in
LTOT alone is €21.42± €20.38
Conclusions The provision of home NIV in patients subject to
frequent exacerbations who tolerate acute NIV
well was associated with cost savings because of
reduced hospital admissions and reduced lengths
of stay
The addition of home NIV to COPD patients
on LTOT did not result in an increase in cost as
the cost of home NIV was equalised by the
savings from reduced hospital admissions
BMI, body mass index; N/A, not applicable.
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Tuggey et al. (2003)
Tuggey et al.’s (2003)40 cost analysis was based on a before-and-after study of 13 patients offered
domiciliary NIV in one UK hospital between 1995 and 2000. Patients were started on NIV if they had a
history of recurrent COPD-related hospital admissions (mean of five per year) and had demonstrated prior
tolerance of NIV during treatment of an acute exacerbation. As the clinical study enrolled a highly select
group of COPD patients, the results are not necessarily transferable to a wider COPD population.
Outcomes were collected from case notes and as a result are potentially biased because of the risk of
reporting errors. The study found a statistically significant reduction in admissions, which was the primary
measure of effect considered in the subsequent cost analysis. Costs were collected retrospectively and
the cost analysis was conducted from a hospital perspective, and thus did not include costs incurred by
patients, carers, primary care or the wider society. Costs included acute and conventional hospital
admissions, intensive care treatment, outpatient appointments and the cost of domiciliary NIV. The cost of
trialled patients on NIV in hospital was not considered as an additional cost, as this was considered part
of usual care.
A number of assumptions regarding the costs of acute and domiciliary NIV were drawn from Plant et al.
(2003),135 a published economic evaluation of NIV for managing acute exacerbation in COPD patients. In
this analysis the provision of domiciliary NIV was estimated to cost £1060 per patient per year in 2003 NHS
prices. This included £570 for ventilator equipment discounted over 5 years, £224 for mask and tubing
with an assumed lifespan of 8 months, £179 for a warm air humidifier with an assumed lifespan of 1 year,
£28 for annual servicing and £60 for access to a respiratory nurse specialist.
The results of this analysis found domiciliary NIV in COPD patients with recurrent exacerbation, implemented
at discharge, to be cost-saving, resulting in a net saving of £8254 (95% CI £4013 to £12,495) per patient
per year. A one-way sensitivity analysis was conducted by varying key assumptions from baseline between
the 5th and 95th centiles, and in all scenarios domiciliary NIV was cost-saving compared with usual
care alone.
In summary, this study suggests domiciliary NIV may be cost-effective in NIV patients with a history of
readmission to hospital. Caution should be taken in interpreting these results, as they are based on a very
small sample size and highly select group of patients.
Clini et al. (2009)
Clini et al. (2009)134 presented the results of an Italian cost analysis, conducted alongside a RCT of
domiciliary NIV, where 77 patients were followed up for 2 years. Patients with stable COPD, with a prior
prescription of LTOT, were enrolled on the trial and randomised to NIV or usual care alone.
This cost analysis applied the mean reduction in hospital admissions and length of stay derived from
the RCT. It should, however, be noted that, while the outcomes found in the RCT were in favour of NIV, the
results applied were not statistically significant. The resources considered in the analysis included hospital
admissions, drug therapy, LTOT and domiciliary NIV equipment and training. Neither the other primary-care
resources and costs incurred by patients and their families nor the additional hospital and set-up costs to
familiarise patients with NIV were included.
The study estimated the cost of domiciliary NIV to be €160 per month or €1920 per year based on 2008
prices. This estimate was based on a contract with a regional health-care provider and included the
provision of equipment, a Respironics BiPAP® ST-30 (Murrysville, PA, USA) device and warm air humidifier,
as well as tubing and masks replaced every 6 months. The results suggest that the addition of domiciliary
NIV to LTOT results in a similar cost per patient per day of €23.73± €16.18, compared with
€21.42± €20.38 in the group with LTOT alone, from which the authors concluded that domiciliary NIV
was likely to be cost-neutral, as the additional costs were offset by savings from reduced hospital
admissions and shorter hospital stays.
COST-EFFECTIVENESS REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
In summary, this study suggests that domiciliary NIV may be cost-neutral in stable COPD patients.
However, as this study was conducted in Italy, the costs and outcomes are not directly transferable to UK
patients. The results should also be considered cautiously because of uncertainty around the effect.
Commentary on excluded studies
Two studies excluded from this review warrant comment.
Criner et al. (1995)136 conducted a retrospective cost analysis of providing NIV to patients admitted to a
ventilator rehabilitation unit for moderately severe respiratory failure in the USA. There was some ambiguity
as to whether or not this met the inclusion criterion, as it was unclear if patients were discharged with NIV
for home use. On balance, the decision was made to exclude the study, as it appeared to primarily assess
the effect of NIV delivered in an acute setting. This study demonstrated the interdependence between acute
and domiciliary NIV services when considering costs and outcomes.
Chandra et al. (2012)137 published a Markov model developed as part of a series of papers to evaluate the
effectiveness and cost-effectiveness of interventions in COPD populations sponsored by the Medical
Advisory Secretariat, Canada. NIV in stable COPD patients was included in this series and the authors
documented their intent to conduct a clinical review and economic evaluation.137 However, after conducting
the clinical review, they concluded that there was no evidence that domiciliary NIV was effective in COPD
patients and thus did not conduct an economic analysis.
Conclusions
This systematic review identified two studies that met the inclusion criterion. Tuggey et al. (2003)40
conducted a cost analysis alongside a before-and-after study and found that domiciliary NIV, provided in a
highly select COPD population prone to severe exacerbation, may be cost-effective in this subpopulation.
However, there was a lot of uncertainty around their results because of the nature of the study design and
the small population size. Similarly, the cost analysis by Clini et al. (2009)134 suggested that the additional
cost of NIV may be offset by cost savings resulting from a reduction in hospital admissions in ambulatory
COPD patients. These results were also not generalisable to the UK population, as the costs were
estimated from an Italian hospital perspective, and the results should be considered cautiously because of
the uncertainty regarding clinical effectiveness estimates applied.
While both studies provided useful estimates on the cost of providing domiciliary NIV to inform an
economic model, neither addressed lifetime cost-effectiveness of NIV in a UK population. This suggests
there is a need for a de novo study of the cost-effectiveness of domiciliary NIV in end-stage COPD patients.
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Chapter 7 Economic evaluation
This section provides a description of the economic model developed and used to evaluate thecost-effectiveness (cost–utility) of domiciliary NIV in patients with end-stage COPD, when compared
with usual care alone. The two COPD populations considered in the systematic review of clinical
effectiveness (see Chapter 4) were also considered in this economic evaluation:
l patients started on domiciliary NIV when stable in the community, referred to as the ‘stable’ population
l patients started on domiciliary NIV following an admission to hospital for exacerbation, referred to as
the ‘post-hospital’ population.
The underlying assumption in differentiating between these two populations was that COPD patients with
a recent history of hospital admission were more likely to have a higher baseline risk of COPD events and a
shorter life expectancy.
Using appropriate evidence where possible from the systematic review of clinical effectiveness, a
speculative model was built to estimate the cost-effectiveness of domiciliary NIV if it were to result in a
reduction in the risk of hospital admissions. Hospital admission was chosen as the primary outcome for
modelling, as severe exacerbations resulting in hospital admission were expected to be the main cause of
COPD-related morbidity and mortality. Using this outcome would capture the potential costs and utility
associated with any change in the risk of readmission. There was little evidence of an improvement in QoL
for the stable population and none for the post-hospital population; therefore, an assumption was made
that the only improvement in QoL would be based on avoided hospital admission. A potential additional
change in utility in either direction was considered in a sensitivity analysis.
The model was run using hospital admissions data from RCTs in the two populations. The base-case risk
reduction for hospital admission for the stable population was based on the rate ratio derived from the
pooled results of the five RCTs76,80,81,99,101 suitable for meta-analysis (see Chapter 4, Hospitalisations).
For the post-hospital population, three RCTs75,90,92 provided evidence on hospitalisations (see Chapter 4,
Hospitalisations). As the size and direction of the effects reported were very different, three base cases
were considered by applying three different rate ratios derived from the RCT data.
The long-term effect of NIV on hospitalisations is unclear, as there is no evidence beyond 24 months for
either population. However, for the purposes of the model base cases, it was assumed that the effect on
hospitalisation lasted for up to 10 years, and the costs were assumed to last for the cohort lifetime. The
uncertainty around this assumption was considered in sensitivity analyses in which different assumptions
were applied for the duration of the effect.
Methods
Model description
A Markov decision model was built in TreeAgePro (TreeAge Software, Inc., 2013) to compare the
cost-effectiveness of domiciliary NIV with usual care from a UK perspective.
The model was developed subsequent to a review of published Markov decision models138–147 in stable
and post-admission COPD populations, and considers stable and post-admission populations separately.
The model incorporated both the short-term increased risk of readmission and subsequent mortality after a
hospital admission, and the long-term natural history of the disease, taking into account exacerbations,
increasing COPD severity and mortality (Figure 16). Health states are linked to GOLD severity (using the
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pre-2011 definition of GOLD because of a lack of available data for the current classification). It
incorporates evidence on the increased risk of mortality and readmission in those recently discharged after
admission for COPD exacerbation. Tunnel states were added to incorporate the increased risk of mortality
and readmission in those recently discharged after admission for COPD exacerbation.129
The model considers stable or post-discharge health states (at months 1, 2 and 3); that is, patients can
be a stable condition or in month 1, 2 or 3 of recovery after a recent exacerbation. Patients can move
between stable and post-discharge health states, and there is a risk of death while in any health state.
The two populations, stable and post-hospital, differ in where they enter the model and in the probability
of moving between the different health states.
The model had a time cycle of 1 month and a lifetime time horizon (30 years) was used. All costs and
outcomes were considered from a UK NHS perspective for a price year of 2012.
The model had three transition health states and one stable health state, with each state subdivided into
two disease severity levels (see Figure 16). The three transition health states captured patients’ elevated risk
of readmission or death in each of the 3 months subsequent to a hospital admission and were referred
to as the ‘post-discharge’ health states. A post-discharge period of 3 months was chosen as there are
consistent data to indicate elevated risk of readmission and death during this period (2011 audit129). The
‘stable’ health state represented patients’ ongoing risks of events (e.g. exacerbation, hospital admission,
death) beyond this period. The subdivision of these states represented GOLD stages 3 and 4. At any point
patients could transition to a worse disease severity or die. As COPD is a progressive disease, patients
could not transition to an improved health state (e.g. from GOLD stage 4 to 3).
The two COPD severity levels considered were defined according to the traditional GOLD classification
stages 1–4. GOLD stage 3 (severe COPD) was defined as having a predicted FEV1 ≥ 30% but < 50% and
GOLD stage 4 (very severe COPD) a predicted FEV1 ≤ 30%. Health states for GOLD stage 1 (mild COPD)
and GOLD stage 2 (moderate) were excluded, as it was assumed that the majority of patients with
end-stage COPD were at GOLD stage 3 or 4. After any cycle, patients in GOLD stage 3 could move to
a GOLD stage 4 health state as their disease progressed, but GOLD stage 4 patients could not move
back to GOLD stage 3.
GOLD stage 4
Post discharge
Month 2
GOLD stage 3
Post discharge
Month 2
GOLD stage 3
Post discharge
Month 1
GOLD stage 4
Post discharge
Month 1
GOLD stage 3
Post discharge
Month 3
GOLD stage 4
Post discharge
Month 3
GOLD stage 3
Stable
GOLD stage 4
Stable
Death
Post-hospital COPD
cohort
start here
Stable
COPD cohort
start here
FIGURE 16 Model health states.
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The stable health states for the stable population reflected outcomes (e.g. exacerbation, readmission, death)
reported in large cohorts of COPD patients who were stable for at least 12 weeks, and the post-discharge
health states reflected short-term outcomes immediately after admission for severe exacerbation.
The stable health states for the post-hospital population were adapted slightly and populated using
different sources to reflect outcomes reported in cohorts of COPD patients followed up after admission to
hospital. The post-discharge health states for the post-hospital population were identical to those applied
in the stable population (further details on parameterisation of the model are given in Estimation of
model parameters).
Model entry
The stable cohort entered the model in one of the two stable health states (GOLD 3 or 4) and the
post-hospital population entered the model in one of the two first month post-admission health states.
Transitions within the stable health states
In the stable health state, patients could die from a non-COPD-related cause, live exacerbation-free or
experience an exacerbation. The exacerbation could be moderate (managed at home) or severe (requiring
admission) or be fatal. Those who survived a severe exacerbation were discharged and moved to a first
month post-discharge health state. Those who lived without experiencing an exacerbation or experienced
a moderate exacerbation re-entered a stable health state. An example of the pathway within a stable
health state is illustrated with reference to GOLD stage 3 for the stable population in Figure 17.
This pathway was almost identical for GOLD stage 4 in the stable population, but patients were not able
to move to a GOLD stage 3 health state.
The pathways for the GOLD stage 3 and 4 stable health for the post-hospital population were similar but
populated using different sources. As the risk of a moderate exacerbation (managed at home) was not
reported for this population, the risk of exacerbation without admission was not considered for the
post-hospital population.
Transitions within the post-discharge health states
Patients who entered the post-discharge health state could die at home, continue their recovery or be
readmitted, where they could die during admission. If they survived the hospital admission, they re-entered
one of the first month post-admission health states. If recovery continued without being readmitted, they
moved to the second and then third post-admission health states where they faced similar pathways. The
additional costs and utility losses associated with a non-severe exacerbation during the recovery period
were considered negligible, as patients were already assumed to have incurred higher costs and utility loss.
FIGURE 17 Example of pathway within stable health state with reference to GOLD stage 3 for the
stable population.
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The pathways within the post-discharge health states were almost identical for months 1–3, but in month
3 patients could transition to a stable health state and differed only in disease severity, allowing GOLD
stage 3 patients to transition to a parallel GOLD stage 4 state. As noted above, the post-discharge health
states were identical for the stable and post-hospital populations. An example of the pathway within a
post-discharge health state is illustrated with reference to the first month post discharge for GOLD stage 3
in the stable population in Figure 18.
Population demographics
The stable COPD population was assumed to have similar demographics to those patients enrolled in
the studies included in the clinical effectiveness systematic review. The 2011 COPD hospital admissions
audit was considered to be a more appropriate source of UK demographics data for the post-hospital
population, as the studies included in the systematic review were small and non-UK based. It should be
noted that a relatively small proportion of patients included in the audit received in-hospital ventilation
(before commencing domiciliary NIV), while the studies included in the systematic review had larger
proportions of patients receiving this treatment, indicating a potentially more severe population compared
with the one audited.
The base-case age, sex, smoking status and disease severity applied in both cohorts are detailed in
Table 20.
FIGURE 18 Example of pathway within a post-discharge health state with reference to GOLD stage 3 for the
stable population.
TABLE 20 Base-case population characteristics
Population Stablea Post-hospitalb
Age (median) 65 72
Sex (% male) 70.0 47.4
Smoking status (% current smokers) 10.0 39.4
GOLD stage (%)
3 50 50
4 50 50
a Controlled studies: estimation from studies included in this report.
b European Audit 2012.129
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Estimation of model parameters
This section outlines in detail the assumptions applied and sources used to populate the base-case
parameters for usual care and domiciliary NIV in both populations. For those readers wishing to just read a
summary of the assumptions and data sources applied in the model, these are provided in Chapter 7,
Assessment of cost-effectiveness.
Exacerbation and hospitalisation risks for the stable chronic obstructive
pulmonary disease population
The probabilities of exacerbation and hospital admission for the stable population in the stable health
states were obtained from the TORCH129,148 and Eclipse2,129 studies respectively and are reported in
Tables 21 and 22. These studies were chosen as they reported outcomes in large cohorts of COPD patients
followed up for at least 3 years. Therefore, the mean exacerbation and hospitalisation risks were expected
to reflect COPD-related mortality in stable GOLD stage 3 and 4 patients.
As exacerbation rates from the TORCH trial148 were reported by type of treatment, assumptions were
required for the proportion of patients on each type of treatment in each GOLD stage health state. These
proportions were obtained from unpublished data collected from a cohort of UK COPD patients recruited
as part of the Birmingham Lung Improvement (BLISS) studies149 in the West Midlands. Exacerbation rates
were then weighted by the proportion of patients on each treatment, in each GOLD stage severity group.
As the TORCH148 study did not report the proportion admitted to hospital for an exacerbation, this was
obtained from the Eclipse Study.2
TABLE 21 Treatment and exacerbation rates in the stable population
Treatment and exacerbation rates
Treatment type
Othera ICS LABA ICS/LABA
GOLD stage 3
Proportion on treatment (%) (BLISS149) 26.27 0.85 5.08 67.80
Annual exacerbation rate (TORCH148) 1.24 0.99 1.08 0.91
GOLD stage 4
Proportion on treatment (%) (BLISS149) 16.28 4.65 2.33 76.74
Annual exacerbation rate (TORCH148) 1.79 1.53 1.40 1.54
ICS, inhaled corticosteroids; LABA, long-acting β2-agonists.
a Patients may have been on other treatments, such as long-acting muscarinic antagonists and short-acting
muscarinic antagonists.
TABLE 22 Exacerbation and hospitalisation rates applied in stable health states for the stable population
Severity stage
Overall weighted
exacerbation rate148
Proportion of exacerbations hospitalised2
% Beta distribution
GOLD stage 3 1.00 25 α= 225, β= 675
GOLD stage 4 1.57 54 α= 158, β= 135
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Hospitalisation and mortality risks in the post-discharge health states
(for both post-hospital and stable populations)
The majority of the transition probabilities for post-discharge health states were obtained from the
European Audit129 and are reported in Table 23. This study was chosen as it included recent UK audit data
of patients admitted to hospital. Risks of readmission and mortality were assumed (1) not to differ by
GOLD stage and (2) to be evenly distributed over the 3-month period. These risks were applied to the
post-discharge health states for both the stable and post-hospital populations. While it may be the case
that GOLD stage 4 patients are at high risk of readmission compared with less severe patients,150 no prior
publications have been able to differentiate GOLD stage 3 and GOLD stage 4, hence the assumption
employed in the model.151
Mortality risks for the stable population
Age- and sex-specific all-cause mortality among stable COPD rates were obtained from Office for National
Statistics life-tables and adjusted to avoid double counting of COPD-related mortality (see Appendix 12).
These were applied only to the stable health states for the stable population, as all-cause mortality was
expected to be higher in the post-hospital population.
Chronic obstructive pulmonary disease-related mortality was captured through the risk of death during
admission, applying the risk of death during admission and in the 90 days following an admission reported
in the COPD European audit129 (see Table 23).
Hospitalisation and mortality risks for the post-hospital population
Beyond 3 months post discharge, there was greater uncertainty regarding baseline risks for admission rates
and mortality in the post-hospital population. The health status may be underestimated by using airflow
limitation as a definition of disease severity. Furthermore, long-term survival was expected to be lower than
that reported in large cohort studies (TORCH, Eclipse) because of the recruitment criteria for inclusion in
clinical trials. To investigate this, survival rates were extracted from five clinical studies of domiciliary NIV in
cohorts discharged from hospital and five studies that followed up cohorts of COPD patients admitted for
exacerbation, which are reported in Appendix 13 and Appendix 14. Annual mortality rates in the year
following admission were very variable, ranging from 10% to 50%.
TABLE 23 Mortality and hospitalisation risks applied in post-admission states
Definition Probability Beta distribution
COPD-related death during admissiona
Men 0.050 α= 118, β= 2243
Women 0.051 α= 133, β= 2490
90-day COPD-related death post admission
Men 0.062 α= 203, β= 1998
Women 0.067 α= 124, β= 2320
90-day COPD-related readmissiona
Men 0.052 α= 932, β= 1269
Women 0.051 α= 954, β= 1490
All-cause COPD mortality post admission
All 0.023 α= 201, β= 4785
Source: European Audit, 2012.129
a Mortality and readmission rates were adjusted to only include those where the primary cause was COPD or
respiratory failure.
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In the base-case analysis, the risks of annual all-cause mortality and COPD-related admission were obtained
from Garcia-Aymerich et al. (2003)152 and are reported in Table 24. All annual rates were converted to monthly
probabilities. This study also reported COPD admission rates as well as all-cause and COPD-related mortality.
Chronic obstructive pulmonary disease-related mortality was captured through the risk of a COPD-related
death either during admission or in the 3-month post-discharge period, as reported in the COPD audit.129
Applying these risks and the all-cause mortality risk reported in Garcia-Aymerich et al. (2003),152 and
assuming they remained constant for the cohort’s lifetime, the model projected cumulative mortality similar
to that reported in long-term (5-year) studies.86,130 The mortality rates reported in post-hospital studies and
cohorts of COPD patients discharged from hospital are reported in Appendix 13 and the baseline survival
curves for the stable and post-hospital populations are illustrated in Appendix 15.
As there was a lot of uncertainty around baseline survival in this group, and the model was expected to be
sensitive to this uncertainty, two one-way sensitivity analyses were applied using lower and higher baseline
mortality. The first applied the admission and mortality rates reported in Bucknall et al. (2012)153 to show
outcomes in cohorts admitted to hospital but had lower readmission and mortality rates than those
reported in Garcia-Aymerich.152
The second sensitivity analysis considered cohorts with shorter survival. Two of the non-randomised
studies96,97 of domiciliary NIV in post-hospital populations reported that over 40% in the usual-care arm
had died during the first year and one other non-randomised study86 reported that 55% had died by the
second year. To reflect costs and outcomes in similar populations with shorter survival, the risks of all-cause
mortality, death during admission and death 90 days post-admission were increased by a factor of 2. This
increased the proportion expected to die in the first year in the usual-care arm from 27% to 47%.
The base-case and usual-care arm survival curves for the stable and post-hospital populations, and the
alternative survival curves based on lower and higher mortality (in sensitivity analyses) for the post-hospital
population are illustrated in Appendix 15.
Disease progression applicable to stable and post-hospital population
The probabilities of progressing to a more severe GOLD stage, applied to all living health states for both
the stable and post-hospital populations, were taken from a published model141 (see Appendix 16). This
model was selected as it represented disease progression in a UK population and reported the annual risk
of disease progression by age, sex and smoking status, which were converted to monthly probabilities.
TABLE 24 Hospitalisation rate and risk of non-COPD-related mortality applied in the stable health state for the
post-hospital population
Definition
Rate Sample sizeBase case (Garcia-Aymerich et al. 2003)152
COPD admissions per year 1.60 340
Non-COPD-related mortality 0.071 340
Sensitivity analysis 1 (Bucknall et al. 2011)153
COPD admissions per year 0.47 464
Non-COPD-related mortality 0.194 464
Sensitivity analysis 2 (higher rates)
All mortality risks increased by a factor of 2 N/A N/A
N/A, not applicable.
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Estimate for effectiveness of domiciliary non-invasive ventilation
The modelled estimate of the effectiveness of NIV was based on an assumed reduced risk of hospitalisation
which was expected to result in cost savings and short-term utility improvements. Owing to limited QoL
data, any effect of NIV on utility was not modelled in the base case but explored in sensitivity analyses.
Hospital admission data from the systematic review of clinical effectiveness were available mainly as (pooled)
mean differences. In order to be able to use these data in the economic model, all means (SD) were converted
to rate ratios (CI) by converting the data into the estimated numbers of events and total time at risk assuming
complete follow-up. The rate ratio and its SE were then calculated using Poisson regression. Any reduction in
hospital admission in the model was assumed to result in improved mortality; however, it should be noted
that there was no evidence of reduced mortality with NIV in the studies included in the effectiveness review
for the stable population (RCTs and controlled studies) or the post-hospital population (RCTs only); evidence
from non-randomised controlled studies in the post-hospital population suggested a survival benefit with NIV.
As such, the estimates of hospitalisations applied in the model contain uncertainty that gives rise to both
reduced and increased hospitalisation (and thus mortality) from the use of NIV.
The base-case risk reduction for hospital admission for the stable population was based on the rate ratio
derived from the pooled effect estimate of five RCTs76,80,81,99,101 suitable for meta-analysis (see Chapter 4,
Hospitalisations). Four further RCTs74,85,89,94 in this population did not report the number of admissions per
patient specifically and thus could not be included in this pooled analysis. These studies reported the
proportion of patients affected by hospital admissions and hospitalisation rates and found no difference
between NIV and usual-care patients. Such data added to the meta-analysis would be likely to have
brought the pooled rate ratio for readmission in the stable population closer to the line of no effect.
For the post-hospital population, three RCTs75,90,92 reported hospital admissions data (see Chapter 4,
Hospitalisations). As the size and direction of the effects reported were very different, it was not appropriate
to pool these results. One small study92 found a statistically significant difference in favour of NIV and the two
remaining studies found no significant differences; however, one marginally favoured NIV90 and the other,
the largest study, marginally favoured usual care.75 As there was no clear choice for a single base case, three
base cases were considered, using three different rate ratios derived from the RCT data.
The rate ratios for the base cases are reported in Table 25. As there was a high level of uncertainty around
rate ratios for admission, an estimate that strongly favoured NIV and an estimate that marginally favoured
usual care were applied in the sensitivity analysis for the stable population. For the post-hospital
population, no further rate ratios were applied in a sensitivity analysis, as three rate ratios were applied in
the base case. The assumptions applied are reported in Table 26.
TABLE 25 Base-case rate ratios for admission applied to domiciliary NIV
Definition
Rate ratio (95% CI) SourceStable population
Marginally favours NIVa 0.751 (0.583 to 0.968) Pooled result of 5 RCTs76,80,81,99,101
Post-hospital population
Marginally favours usual carea 1.36 (1.061 to 1.756) Struik et al. 201475
Marginally favours NIV 0.5981 (0.2208 to 1.273) Cheung et al. 201090
Most favourable for NIV 0.3717 (0.235 to 0.3645) Xiang et al. 200792
a Note that as the CIs are now on a different scale, and different statistical methods and assumptions were used for their
calculation, this has resulted in two of the rate ratios being statistically significant where the corresponding weighted
mean differences for hospital admissions were not.
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Discontinuation rates
It was expected that a proportion of patients starting on domiciliary NIV would discontinue treatment after
an initial trial period, either because they suffered adverse events or because the discomfort outweighed
the benefit, or for other reasons. The non-adherence and discontinuation rates reported across both stable
and post-hospital populations varied from 5% to 43% (see Chapter 4, Adherence and adverse events).
This variability may have been partly explained by study design, but factors such as the recruitment criteria,
initial patient training and motivations of the patient were also expected to have contributed. In the base
case it was assumed that 15% of patients would discontinue using NIV after an initial trial period of
3 months, with a distribution varying this between 10% and 20%. This assumption was tested in a
one-way sensitivity analysis by varying values from 5% to 45% for both populations. Patients who
discontinued using domiciliary NIV were expected to incur the cost but not the benefits of NIV in the first
3 months and incur neither the costs nor benefits associated with NIV beyond 3 months.
Estimation of quality-adjusted life-years
Utility values were required for all health states and exacerbation events, and were combined with
information on survival in order to calculate quality-adjusted life-years (QALYs). The model health states
were based on COPD severity defined by GOLD stages 3 and 4. Utility values for these health states were
calculated from unpublished data collected from the BLISS cohort.149 Utility scores for GOLD stages 3 and 4
were derived from the EQ-5D-5L, a revised version of the EQ-5D™ questionnaire. The EQ-5D-5L was
completed by 336 participants enrolled in the BLISS study with a confirmed diagnosis of COPD at GOLD
stages 3 or 4. This data source was chosen as it reflected a UK COPD population in a real-life setting. Data
from this cohort were deemed suitable for stable health states in the model, as participants were not
recovering from an exacerbation at the time of questionnaire completion, and therefore the utility scores were
expected to reflect QoL in the stable condition. EQ-5D-5L responses were converted to utility scores using the
interim crosswalk value set for a UK population reported by EuroQol154 (Table 27).
Data on utility loss suffered immediately after a moderate or severe exacerbation were extracted from
previously published models, although estimates varied greatly and the evidence underpinning these was
poor.138–140,143,147 It was assumed that there was a loss of utility for 1 month for moderate exacerbations
and a utility loss for 3 months with an improvement after 1 month for severe exacerbations as a result of
full recovery taking a longer period of time.13,155
The utility loss estimate of 15% for moderate exacerbation and 50% in the first month for severe
exacerbation was obtained from Rutten-van Molken et al.,139 reducing to 25% in the second and third
months for a severe exacerbation.31 An alternative assumption, obtained from Hertel et al.140 was applied
TABLE 26 Alternative rate ratios for admission applied in the sensitivity analysis for stable population
Definition
Rate ratio (95% CI) SourceStable population
High-value rate ratios for admission 0.6219 (0.384 to 0.9375) Zhou et al. 201081
Low-value rate ratios for admission 1.794 (0.88 to 3.23) Kaminski et al. 1999101
TABLE 27 Utility scores for stable GOLD health states
Sample size and utility score GOLD stage 3 GOLD stage 4
Sample size (n) 299 37
Mean utility score (SE) 0.6765 (0.01521) 0.6014 (0.0421)
Source: BLISS cohort study (unpublished data).149
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in a one-way sensitivity analysis. This assumed a loss of utility for 1 month: mean utility loss of 0.12 for a
moderate exacerbation and a utility loss of 0.54 for a severe exacerbation for 1 month. Utility scores taking
into account exacerbations that were applied in the model are shown in Table 28.
Resource use and costs
The resource use considered within the model was broadly concerned with primary and secondary health-care
professional contacts and pharmacotherapy for usual care and the additional costs associated with
domiciliary NIV. Health-care contacts for each GOLD severity state were estimated with reference to NICE
guidelines4 and expert opinion. Use of pharmacotherapy was estimated from data provided by the BLISS
cohort.149 Unit costs were primarily obtained from NHS reference costs156 and Unit Costs of Health and
Social Care.157 Where appropriate, unit costs were inflated to 2012 prices using NHS health index inflation
rates. Annual costs were divided by 12 to derive a monthly cost. Moderate and severe exacerbations were
treated as additional one-off costs and assumed to be the same irrespective of the underlying GOLD stage.
Routine health-care visits
The National Institute for Health and Care Excellence28 recommends that stable patients with COPD be
followed up at least once a year and those with very severe COPD at least twice a year, with rapid access
to hospital assessment where necessary. Based on these guidelines it was assumed that patients at GOLD
stages 3 and 4 would attend, respectively, two and two and a half assessments per year in secondary care.
The costs of follow-up and spirometry in secondary care were obtained from NHS reference costs.156 Costs for
follow-up in primary care were based on the cost of a home visit by a community nurse published in the
Personal Social Services Research Unit (PSSRU)157 and the cost of spirometry was extracted from a costing
document publish by NHS Commissioning Support for London.158 Additional health-care costs included were
the provision of annual flu vaccinations, home oxygen therapy and the cost of the process of prescribing.
As the mean age of both populations was over 65 years, it was assumed that 75%159 of patients in each
severity group received the vaccination at the current estimated cost of £6.21.160 This assumption was based
on vaccination rates of 50% and between 80% and 93% reported in Spanish and UK studies.161,162
The average number of days and cost of home oxygen therapy received in each severity group was derived
from expert opinion reported in Hertel et al. (2012).140
Smoking-cessation advice and pulmonary rehabilitation are also recommended by NICE as usual care for
COPD patients.4 However, these costs were assumed to be the same for both strategies, thus cancelling
each other out, and were omitted from the model.
The annual costs of health-care visits in GOLD stages 3 and 4 were estimated to be £358 and £486
respectively. A summary of the assumptions and reference costs applied to derive these estimates is
provided in Table 29.
TABLE 28 Utility scores incorporating loss of QoL with exacerbations
Severity of exacerbation and utility loss GOLD stage 3 GOLD stage 4
Moderate exacerbation 0.5750 (1 month) 0.5112 (1 month)
Severe exacerbation 0.3383 (first month);
0.5074 (months 2 and 3)
0.2556 (first month);
0.4511 (months 2 and 3)
Sensitivity analysis
U – 0.12 for 1 month 0.5565 (1 month) 0.4814 (1 month)
U – 0.54 for 1 month 0.1365 (1 month) 0.0614 (1 month)
Source: base-case assumptions extracted from Rutten-van Molken et al.139 applied to means scores obtained from BLISS.
Assumptions for sensitivity analysis extracted from Hertel et al.140
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Routine pharmacotherapy
NICE guidance is not prescriptive for each GOLD stage, and suggests that the number and type of treatments
prescribed should be determined by patient symptoms and response. Therefore, the model used data from
the previously described BLISS cohort149 for the proportion of patients on each line of therapy by GOLD stage.4
As 100% of patients were reported to be on an inhaled short-acting β2-agonist (SABA), assumptions on the
number of delivery devices in each severity stage were made by the clinical experts on this project. Drug
reference costs reported by NICE (2011)163 (as in Table 30) were compared with current unit costs listed on the
NHS Drug Tariff database164 in 2014. Most of the drug prices were consistent with those listed in the NICE
2011163 report, although some were higher and some were lower. As there did not appear to be a consistent
drug inflation rate during this period (2011–14) it was not appropriate to inflate the 2011 prices or deflate the
2014 prices to estimate the costs in 2012; thus, the prices listed in the NHS Drug Tariff database164 were
applied. Annual and monthly costs were calculated by applying the same unit cost to the annual cost reported
by NICE. Where there was more than one drug in each treatment class, an overall average cost was applied.
Monthly costs by GOLD stage are shown in Table 31.
Cost of exacerbations
Moderate exacerbations were assumed to be predominantly managed in primary care through GP appointments,
with a proportion of patients attending A&E without admission. As no data were found on the split between GP
and A&E visits, assumptions were derived from expert opinion reported in Hertel et al.,140 which assumed that
two-thirds would see a GP and one-third would attend A&E. Prescribed additional medication for a moderate
exacerbation was assumed to be a course of prednisolone (six 5-mg tablets per day for 5 days) and antibiotics
if exacerbations were associated with a history of purulent sputum.4 The total cost of treating a moderate
exacerbation was estimated to be £114, and a breakdown of how this cost was calculated is presented
in Table 32.
The majority of severe exacerbations were assumed to be managed in hospital, but 20% were assumed to
be managed through hospital-at-home or early discharge schemes. The 2011 NICE163 costing study
estimated the average cost of a COPD hospital admission to be £1978. These costs were not inflated,
as the current NHS tariff prices applied appeared similar to those listed in 2012. No data were available on
the tariffs for hospital-at-home or early discharge, although a UK-based cost analysis estimated the costs
incurred in a similar scheme to be £1653 in 2009 prices,165 inflated to £1769 for 2012. Following
discussion with clinical experts, it was assumed that 20% of those that suffered an exacerbation requiring
admission accessed services other than in-patient.
TABLE 29 Annual routine health-care utilisation and costs by GOLD stage
Health care GOLD stage 3 GOLD stage 4
Unit
cost (£) Source
Secondary care follow-up 2 visit 2.5 visits 111 NHS reference costs 2010-11,
inflated to 2012156
Secondary care spirometry 1 test 1 test 52 NHS reference prices 2010–11,
inflated to 2012 prices156
Primary care spirometry 1 test 1 test 18 NHS Commissioning for London
costing report for a community-led
COPD pathway158
Flu vaccination 75% take up 75% take up 6.21 Department of Health 2011160
Oxygen therapy 1.22 days 6.08 days 15 Hertel et al. 2012140
Prescription costs per consultation £42.70 (assuming one per annum) PSSRU 2012157
Annual cost (£) 357.66 486.01 – –
Monthly cost (£) 29.80 40.50 – –
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TABLE 30 Unit costs of pharmacotherapy. Reproduced with permission from Jordan RE, Majothi S, Heneghan NR,
Blissett DB, Riley RD, Sitch AJ et al. Supported self-management for patients with moderate to severe chronic
obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Health Technol Assess
2015;19(36)26
Class Drug formulation & dose
Price per pack
(NICE 2011163)
Price per pack
(NHS 2012164)
Annual cost
estimated
by NICE
Annual cost
adjusted to
drug tariff (£)
Monthly
cost (£)
SABA Salbutamol 100 µg metered
inhalation (generic)
3.52 3.31 25.70 24.17 2.01
Terbutaline 500 µg metered
inhalation (Bricanyl®, AstraZeneca)
6.92 6.92 101.03 101.03 8.42
SABA average cost 5.22
ICS Beclometasone 250 µg metered
inhalation (generic)
18.74 12.31 34.20 22.45 1.87
SAMA Ipratropium 20 µg metered
inhalation (Atrovent®, Boehringer
Ingelheim)
5.05 5.05 27.65 27.65 2.30
LABA Salmeterol 25 µg metered
inhalation (Serevent)
29.26 29.26 356.00 356.00 29.67
LAMA Tiotropium 18 µg inhalation
capsule (Spiriva)
32.49 33.50 395.30 407.58 33.97
LABA
and ICS
Budesonide 200 µg+ formoterol
6 µg metered inhalation
(Symbicort® turbohaler,
Astrazeneca)
38.00 11.84+ 24.80 462.33 445.78 37.15
Budesonide 400 µg+ formoterol
12 µg metered inhalation
(Symbicort turbohaler)
38.00 13.86+ 30.06 462.33 534.36 44.53
Fluticasone propionate
500 µg+ salmeterol 50 µg metered
inhalation (Seretide® accuhaler,
Allen & Hanburys Ltd)
40.92 40.92 497.86 497.92 41.49
LABA+ ICS average cost 41.06
ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic agonist; SAMA, short-acting
muscarinic antagonist.
Sources: NICE 2011163 and NHS Drug Tariff database.164
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National Institute for Health and Care Excellence guidance4 also recommends that patients should be
followed up after discharge, and therefore this cost was included in the average cost of a severe
exacerbation and was assumed to include one follow-up visit, 30% being seen by a community nurse,
30% attending a GP appointment and 40% attending an outpatient appointment. The total cost of
managing a severe exacerbation was estimated to be £2053 (Table 33).
As the cost of admission in the populations considered in this analysis may be higher if acute ventilation
was necessary, particularly in the post-hospital patients, higher costs for severe exacerbation were
considered in the sensitivity analysis.
TABLE 31 Proportion on type of pharmacotherapy and monthly cost by severity stage
GOLD stage and costs
Assumed no. of SABAs
used per month
Proportion on type of pharmacotherapy
SABA ICS LABA Combo LAMA SAMA
GOLD stage 3 (n= 216)149 2 1.00 0.01 0.05 0.68 0.62 0.04
GOLD stage 4 (n= 37)149 2.5 1.00 0.05 0.02 0.77 0.65 0.05
Monthly cost GOLD stage 3 (£) 59.36
Monthly cost GOLD stage 4 (£) 65.91
LABA, long-acting β2-agonists; LAMA, long-acting muscarinic agonist; SAMA, short-acting muscarinic antagonist.
Source of proportions on each treatment obtained from BLISS cohort data,149 n= sample size.
TABLE 32 Cost of moderate exacerbation
Resource use/cost % requiring resource Unit cost (£) Source of cost estimate
GP visit (12 minutes) 66.7 44.40 PSSRU157
A&E visit without admission 33.3 112.00 PSSRU157
Prednisolone 5mg tablets
(six times a day for 5 days)
100 0.11 NHS drug tariff database164
Amoxicillin 500mg capsules
(three times a day for 5 days)
100 0.09 NHS drug tariff database164
Prescription costs per consultation 100 42.70 PSSRU157
Estimated cost of moderate exacerbation £114.28
TABLE 33 Cost of severe exacerbation
Resource use/cost
Proportion requiring
resource (%) Unit cost (£) Source
Average cost of COPD hospital stay 80 1978 NICE 2011163
Average cost of hospital-at-home
programme
20 1769 Bakerley et al. 2009.165
Inflated to 2012 prices
Community nurse follow-up 30 57 PSSRU157
GP follow-up (12-minute visit) 30 44 PSSRU157
Outpatient appointment follow-up 40 139 NHS tariff prices156
Estimated cost of severe exacerbation (£) – 2053 –
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Cost of non-invasive ventilation
The cost of providing NIV was assumed to be the same irrespective of whether patients were started on
NIV post-hospital or when stable. In the base case, information from a domestic NIV service provided by an
established regional specialist centre in England was used to estimate resource use. Costs were estimated
using published Healthcare Resource Group (HRG) tariffs, costs reported in NIV costing studies166 and
clinical opinion within the project team. One-way sensitivity analysis was used to consider alternative
estimates reported in other NIV studies.
The resources considered included the cost of NIV equipment, set-up and monitoring activities in the first
3 months, and ongoing activities to monitor patients and service the NIV equipment. The NIV device was
treated as a one-off cost and applied in the model as a monthly cost, depreciated over 5 years at a rate of
3.5%. The NIV device and humidifier were estimated to cost £3600, varying between £3000 and £4000 as
reported in the NICE 2010 costing study of NIV in motor neuron disease.166
The initial set-up appointment was treated as an outpatient appointment where respiratory tests were
conducted and patients were started on domiciliary NIV. This was conducted in an NIV clinic led by a
respiratory team and expected to last up to 4 hours. The cost of this service was assumed to be covered by
the tariff ‘DZ37 A: NIV Support Assessment 19yrs & over’.167 After 8–12 weeks, patients on domiciliary NIV
attended a follow-up clinic, where their usage was monitored, their blood gases were checked and their
NIV pressure settings or masks were adjusted if required. The cost of this service was assumed to be
covered by the HRG tariff for a consultant-led outpatient appointment and the HRG tariff for conducting
blood gas tests. The set-up and follow-up costs were applied as monthly costs spread evenly over the first
3 months of starting NIV.
Follow-up care beyond 3 months included a bi-annual check of a patient’s usage of NIV and blood gases
and an annual NIV equipment check, in which consumables were replaced. As patients were already
expected to attend two respiratory appointments a year, the only additional cost for monitoring patients
was that of conducting a blood gas check. The cost for an annual NIV equipment check that included
device verification, consumable replacement and technical support within normal working hours was
estimated to be between £500 and £600 (based on knowledge of current service costs); thus, a point
estimate of £550 was applied.
The estimated costs of providing a domiciliary NIV service are reported in Table 34 and for NIV were £2373
in the first year and £1536 in subsequent years. This estimate was in between cost estimates reported in
the two studies identified in the clinical review. Tuggey et al. (2003)40 estimate domiciliary NIV to cost
£1060 per year in 2003 prices, which converts to £1344 in 2012 prices (assuming a 3% inflation rate), and
Clini et al. (2009)134 estimated NIV to cost €1920 in 2008 prices, which converts to £2727 (converting to
GBP at the mid-year conversion rate of 1.263168 and inflating to 2012 prices at a rate of 3%).
Assessment of cost-effectiveness
The incremental analysis was designed to generate the cost per additional QALY gained for the addition of
domiciliary NIV to usual care in two populations (stable and post-hospital), when compared with usual care
alone, in a cohort of COPD patients.
Where available, data were entered into the model as distributions in order to fully incorporate the
uncertainty around parameter values so that a probabilistic sensitivity analysis could be undertaken. Where
distributions were not available for cost estimates, a normal distribution was applied, assuming a 10%
variation either side of the point estimate. Beta distributions were applied to the proportion on different
treatments and the proportion accessing services in primary and secondary care. Beta distributions were
also applied to annual exacerbation rates and the proportion resulting in hospital admissions, as well as
the reduced risk of hospitalisation expected in the domiciliary NIV arm. Normal distributions were applied
to utilities and utility losses, as well as the utility improvement associated with NIV in the stable population.
The probabilistic sensitivity analysis was run with 1000 simulations, and cost-effectiveness planes and
cost-effectiveness acceptability curves (CEACs) were produced.
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Summary of key assumptions in the model
In summary, the key assumptions applied in the model were:
l The starting cohort for the stable population was assumed to be aged 65 years, 70% male, 10%
current smokers and 50% with GOLD stage 3 and the remainder with GOLD stage 4.
l The starting cohort for the post-hospital population was assumed to be aged 72 years, 47% male,
39% current smokers with 50% being in GOLD stage 3 and the remainder GOLD stage 4.
l Long-term exacerbation and hospitalisation risks for the stable population were taken from large
cohort studies of 3 years or more.2,148 (See Chapter 7, Exacerbation and hospitalisation risks for the
stable chronic obstructive pulmonary disease population.)
l Mortality and readmission risks during admission and immediately after discharge were taken from a
European audit129 and applied for 3 months post admission. (See Chapter 7, Hospitalisation and
mortality risks for the post-hospital population.)
l Long-term admission rates and all-cause mortality rates for the post-hospital population were taken
from a cohort study of patients admitted to hospital followed up for 1 year.152
l Utility values were obtained from the BLISS149 cohort and an estimate was applied for the utility loss
associated with exacerbation obtained from a published model.139 (See Chapter 7, Estimation of
quality-adjusted life years.)
l The cost of usual care was estimated with reference to pharmacotherapy use among the BLISS cohort,
best practice guidance, expert opinion and NHS reference prices. (See Chapter 7, Resource use
and costs.)
l The estimate for the risk reduction (rate ratio) for hospital admissions for the stable population was
derived from the pooled weighted mean difference based on five RCTs.76,80,81,99,101
TABLE 34 Cost of providing a domiciliary NIV service
Resource
Cost (£) (range used in
sensitivity analysis) Source of cost estimate
Equipment costs
NIV equipment for domiciliary use 3600 (3000–4000) NICE costing report166
NIV equipment for home use monthly cost
(depreciated over 5 years)
66.66 –
Set-up costs
NIV set-up and assessment in month 1 354 HRG 2012167
NIV follow-up in month 3: 1 × consultant-led
outpatient appointment+ 1 × blood gas test
189+ 95 HRG 2012167 (OPCS code for blood
gases is E92.4)
Annual costs thereafter
2 × blood gas test conducted at routine follow-up 95 HRG 2012167 (OPCS code for blood
gases is E92.4)
1 × annual NIV assessment and consumable provision 550 (500–600) Estimate
Monthly costs
Monthly costs in the first 3 months 279 Includes equipment and set-up costs
Monthly costs beyond 3 months 128 Includes equipment and annual
monitor and service costs
OPCS, Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures.
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l The estimates for the risk reduction (rate ratio) for hospital admission for the post-hospital population
were derived from the mean differences reported in three RCTs75,90,92 and applied as three separate
base cases.
l No additional improvement in baseline utility was applied to either the stable or post-hospital
population.
l The cost of domiciliary NIV was estimated to be £279 per month in the first 3 months and £128 per
month thereafter, inclusive of NIV device and based on NHS tariff prices and expert opinion.
l The effect of domiciliary NIV was assumed to last for up to 10 years and be driven primarily by a
reduced risk of hospital admission and associated mortality.
l Fifteen per cent of patients were assumed to discontinue using domiciliary NIV after 3 months. These
patients were assumed to incur costs but no benefits in the first 3 months and neither costs nor
benefits beyond 3 months.
Sensitivity analysis
Additional model runs were undertaken to determine the impact of changing key parameters on the
model results for each population. Those parameters where the incremental cost-effectiveness ratio (ICER)
was demonstrated to be particularly sensitive to change were explored in more detail. The following
analyses were undertaken for the stable population:
l The effect of domiciliary NIV on hospital admissions (rate ratio) was varied, applying high [0.6219
(95% CI 0.384 to 0.937581] and low [1.794101 (95% CI 0.878 to 1.707)] estimates from the three RCTs
that reported this outcome. The rate ratio required for domiciliary NIV to be cost-effective at a
threshold of £30,000 per QALY gained was then identified through a one-way sensitivity analysis of
this parameter.
l The effect domiciliary NIV had on baseline utility (QoL) was varied, assuming that it resulted in a 0.025
change in either direction. The utility improvement required for domiciliary NIV to be cost-effective
at a threshold of £30,000 per QALY gained was identified through a one-way sensitivity analysis of
this parameter.
l The duration of effect was tested, assuming the effect lasted for 2 years, 5 years, 20 years and a
lifetime (30 years). The duration of effect required for domiciliary NIV to be cost-effective at a threshold
of £30,000 per QALY gained was identified through a one-way sensitivity analysis of this parameter.
l The time horizon was varied, changing from the base-case assumption of 30 years, to 6 months,
2 years, 5 years, 10 years and 20 years.
l The monthly cost of domiciliary NIV was tested, varying the cost of the equipment between £2000 and
£6000 and the lifespan between 4 years and 8 years.
l The cost of NIV was tested, varying the cost of annual servicing and consumable replacement from
£200 to £1000.
l The cost of severe exacerbation was varied between £2000 and £4000.
l An alternative set of utility scores obtained from Borg et al. (2004)138 were applied (higher utility scores
for each severity stage and decreased utility loss from moderate or severe exacerbation) (see Table 28).
l Subgroup analysis was conducted to test whether the decision rules changed if targeted at different
subpopulations. This was tested by assuming patients were (1) all GOLD stage 3, (2) all GOLD stage 4,
(3) a cohort with a higher baseline risk of admission and mortality, (4) aged 55 years, (5) aged 85 years,
(6) male (entire cohort) and (7) female (entire cohort).
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Base cases were run for the post-hospital population, each using rate ratios from one of three relevant
RCTs. No further rate ratios were applied in the sensitivity analysis. The same one-way sensitivity analyses
were conducted for each of the three base cases and for the post-admission cohort, albeit with the
following changes made:
l Age and sex were not considered in a sensitivity analysis for this population, as all-cause mortality was
obtained from a cohort recently admitted for COPD exacerbations which did not report outcomes by
age and sex. As only the risk of readmission and death immediately after discharge differentiated by
sex, this was unlikely to represent the difference in mortality rates by sex over the lifetime of the model
and may thus be misleading.
l A sensitivity analysis was run in this population, assuming that they had a lower baseline risk of
mortality and readmission. This was done by substituting the baseline risks reported in Garcia-Aymerich
et al. (2003)152 with those reported in Bucknall et al. (2012),153 as patients in the latter, while recently
admitted for exacerbation, were expected to be a slightly healthier population, as they were recruited
to be enrolled on a self-management trial.
l A sensitivity analysis was run, assuming a higher baseline risk of mortality and readmission by adjusting
the baseline mortality risks reported in Garcia-Aymerich et al. (2003)152 by a factor of 2.
Expected value of perfect information
Expected value of perfect information (EVPI) analysis quantifies the economic value of removing all
uncertainty in a decision model.169 EVPI analyses were conducted based on the methods described by
Claxton and Posnett (1996)170 and applied to estimate the value of perfect information per patient and per
population in stable and post-hospital COPD populations in the UK.
The sources used to estimate the size of the stable and post-hospital populations are reported in Table 35.
The UK COPD population was estimated by applying the prevalence rate of 1.7% reported in Haughney et al.
(2013)172 to the mid-year population projections171 for the UK in 2014. The stable COPD population was
estimated from this, assuming that 25.5% and 5.2% were in GOLD stages 3 and 4, respectively, as reported in
Haughney et al. (2013).172
The same study also reported the proportion of patients in each of the new GOLD classifications (A–D1)
admitted to hospital at least once. This was used to estimate the post-hospital population, assuming that
only GOLD stage C and D patients were likely to be in end-stage COPD.
As there is a lot of uncertainty regarding both the prevalence of COPD and the proportion of COPD patients
who could be defined as end-stage stable patients and end-stage post-hospital patients, the estimated
value of perfect information per population reported should be interpreted cautiously and considered
indicative of the value of perfect information in decisions that affect these populations.
TABLE 35 Population estimated applied in the EVPI analysis
Definition of population Prevalence
Population
estimate (000s) Source of estimate
UK – 64,487 ONS mid-2014 projection171
Diagnosed with COPD 1.7% of the UK population 1096 Haughney et al. 2013172
Stable end-stage COPD
(GOLD stage 3 and stage 4)
30.6% of COPD population 329 Haughney et al. 2013172
Post-hospital end-stage COPD 8.8% of COPD population 96 Haughney et al. 2013172
ONS, Office for National Statistics.
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Results
This section presents the results for the base-case, sensitivity and subgroup analysis for the stable
population, followed by the results for the base case post-hospital population and accompanying sensitivity
and subgroup analysis.
Results for the stable population
Base-case analysis
The base-case results for the stable population presented in Table 36 show that, compared with usual care
alone, the addition of domiciliary NIV was more costly and resulted in better outcomes. The difference in
cost was £12,769, with 0.4534 QALYs gained, resulting in an ICER of £28,162 per QALY gained.
Results from the probabilistic sensitivity analysis can be found in the cost-effectiveness plane in Figure 19,
which shows the distribution of 1000 resampled cost and effect difference pairs. In all samples, domiciliary
NIV was more costly than usual care, but there was uncertainty regarding its effect. The samples to the left
of the line of no effect represent where domiciliary NIV results in more admissions and higher mortality, in
which case usual care is more favourable. The majority of the samples are to the right of the line of no
effect where cost-effectiveness is determined by the decision-maker’s willingness-to-pay threshold for
a QALY gained. The CEAC in Figure 20 shows that domiciliary NIV has a 55% probability of being
cost-effective at a threshold of £30,000 per QALY gained.
TABLE 36 Base-case results for the stable population
Strategy
Mean
cost (£)
Cost
difference
(£)
Mean
QALYs
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY
(%)
Probability
cost-effective at
£30,000/QALY
(%)
Usual care 23,969 – 5.3360 – – – –
Domiciliary
NIV+ usual
care
36,737 12,769 5.7894 0.4534 28,162 13 55
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FIGURE 19 Cost-effectiveness plane for NIV vs. usual care in the base case for a stable population.
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Sensitivity analysis for the stable population
This section presents the results of the sensitivity analysis conducted on the base-case assumptions for the
stable COPD population.
Alternative rate ratios for hospital admissions
Owing to considerable uncertainty around the estimate for the primary outcome, the rate ratio for hospital
admission, this parameter was expected to be the biggest driver of the cost-effectiveness results. High and
low rate ratio estimates were applied, obtained from the RCTs showing the most positive and negative
effect on admissions, and the results are reported in Table 37. The most favourable rate ratio increased the
difference in cost and effect to £13,593 and 0.7285 QALYs, respectively, and the ICER was £18,660 per
QALY gained, increasing the probability of domiciliary NIV being cost-effective at a threshold of £30,000
per QALY gained to 82%.
Conversely, applying the rate ratio that marginally favoured usual care decreased the difference in costs to
£8735, and domiciliary NIV was less effective than usual care, resulting in QALY difference of –1.0507
QALYs. Under this assumption, usual care dominated NIV and the probability of this being cost-effective
reduced to 1% at a threshold of £30,000 per QALY gained.
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FIGURE 20 Cost-effectiveness acceptability curve for NIV vs. usual care in for the base case for a stable population.
TABLE 37 One-way sensitivity analysis in the stable population varying the rate ratio for effect
Rate ratio
Cost
difference
(£)
QALY
difference
(QALY)
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Base
Pooled estimate 12,769 0.4534 28,162 13 55
High estimate
Zhou et al. 2008,81
0.6219 (0.1425)
13,593 0.7285 18,660 57 82
Low estimate
Kaminski et al. 1999,101
1.794 (0.6031)
8735 –1.0507 Usual care
dominates
< 1 1
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The ICERs obtained from varying the rate ratios between the low and most favourable estimates are
illustrated in Figure 21. The points where the trend line is not on the graph represent ICERs above £60,000
or below –£60,000 per QALY gained and the negative values signify scenarios where usual care dominates
domiciliary NIV (usual care costs less and is more effective). For the ICER to be below a threshold of
£30,000 per QALY gained, the rate ratio for hospital admissions needs to be 0.76 or lower; that is, a
24% reduction in rate of admissions per patient per year with NIV.
Alternative improvements in utility
The assumption that domiciliary NIV has no effect on utility (outside of utility loss avoided through lower
risk of admission) was tested by varying an assumption that NIV would lead to a change in utility score of
0.025 (on a QoL scale of 0 to 1) in either direction. Although not directly mappable, this could be
considered comparable to a 2.5 point variation on the SGRQ (scale 0–100 points). The effect this utility
variation has on the ICER is illustrated in Figure 22. Assuming that domiciliary NIV improved QoL and
increased the utility score by 0.025, the ICER decreased to £20,462, close to the threshold of £20,000 per
QALY gained. Conversely, assuming that domiciliary NIV decreased patients’ QoL, reducing the utility score
by 0.025 increased the ICER to above £40,000/QALY.
Alternative duration of effect
The duration of the effect of domiciliary NIV in reducing the risk of hospital admission and improving utility
was varied from 10 years to 2, 5, 20 and 30 years, with 30 years representing the lifetime of the
population. Table 38 shows that assuming that the effect lasted for only 2 years results in an ICER of
£93,091 per QALY gained and assuming it lasted for 5 years results in an ICER of £43,510 per QALY
gained, with the probability of this being cost-effective at a threshold of £30,000 per QALY gained being
less than 0% and 12%, respectively.
Conversely, assuming that these effects lasted for 20 years or more reduced the ICER towards £20,000
per QALY gained, and the probability of domiciliary NIV being cost-effective at a threshold of £30,000 per
QALY gained was greater than 70%.
The effect of varying the duration of effect between 2 years and 30 years is illustrated in Figure 23. This
shows that the ICER decreases at longer durations of effect but, even assuming that the effects last for up
to 30 years, the ICER is marginally higher than £20,000 per QALY gained.
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FIGURE 21 One-way sensitivity analysis of the rate ratio for admissions in a stable population.
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FIGURE 22 One-way sensitivity analysis of QoL for the stable population.
TABLE 38 One-way sensitivity analysis in the stable population varying the duration of effect
Duration
of effect
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
Probability cost-effective
at £20,000/QALY (%)
Probability cost-effective
at £30,000/QALY (%)
2 years 11,865 0.1275 93,091 0 0
5 years 12,328 0.2833 43,510 10 12
Base case
(10 years)
12,769 0.4534 28,162 13 55
20 years 12,944 0.5817 22,252 37 73
30 years 12,888 0.5969 21,592 42 75
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FIGURE 23 One-way sensitivity analysis of the duration of the effects.
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Alternative model time horizon
Table 39 presents the results of the model when varying the time horizon of the model. At a short time
horizon of 6 months, the ICER was above £475,000 per QALY gained, and using a time frame of 2 years it
gave an ICER above £116,000 per QALY gained, both well above the threshold of £30,000 per QALY
gained. While these are unlikely to represent realistic time frames, there were very few studies that
evaluated domiciliary NIV in this population beyond 2 years; therefore, projecting costs and outcomes
beyond this point is associated with uncertainty.
There was very little difference between applying a time horizon of 20 years and one of 30 years, as the
base case assumed that domiciliary NIV was effective for 10 years, and beyond this the monthly costs
would continue to accrue with no further benefit other than continued survival. Thus, at all time horizons
the ICER is above £30,000 per QALY gained and the probability of being below £30,000 per QALY gained
is less than 55%.
Alternative continuation rates
Varying the assumption that 85% of those started on NIV would benefit from and continue using NIV
beyond 3 months between 55% and 95% (representing low and most favourable estimates from selected
studies) suggested that the model was not very sensitive to this variable, as illustrated in Figure 24. While a
high dropout rate was expected to increase the costs and lower QALYs gained in the short term, these
costs were minimal compared with the costs and benefits that accrued in the population that continued
with NIV beyond 3 months.
TABLE 39 One-way analysis in the stable population varying the time horizons
Time
horizons
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
Probability cost-effective
at £30,000/QALY (%)
Probability cost-effective
at £60,000/QALY (%)
6 months 928 0.0019 476,982 0 0
2 years 2346 0.0201 116,857 0 0
5 years 4897 0.0908 53,910 0 5
10 years 8273 0.2526 32,757 7 41
20 years 12,604 0.4466 28,222 12 55
Base case
(30 years)
12,769 0.4534 28,162 13 55
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FIGURE 24 One-way sensitivity analysis of alternative continuation rates beyond 3 months in the stable population.
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Alternative costs of the non-invasive ventilation device
In the base case, it was assumed that the device would cost £3600 and a monthly cost was derived
assuming that it would be used continuously for 5 years. Varying the cost of the NIV device demonstrated
that, if over £4000, the ICER is above the threshold of £30,000 per QALY gained, as illustrated in Figure 25
(keeping the lifespan constant).
Keeping the cost of the device constant at £3600, the ICER rises above £30,000 per QALY gained when
the device is assumed to be used for 4 years (rather than 5 years), as illustrated in Figure 26.
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FIGURE 25 One-way sensitivity analysis of alternative costs of device in a stable population.
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FIGURE 26 One-way sensitivity analysis of alternative lifespan of device in a stable population.
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Alternative costs of the service aspects of non-invasive ventilation provision
The other costs involved in the provision of a domiciliary NIV service were tested by varying the tariff for
a NIV assessment and set-up (base case £354) and the cost of annual maintenance (base case £550)
between £200 and £1000. Changing the tariff for NIV assessment and set-up had minimal impact on the
cost-effectiveness of NIV, as this was a one-off cost incurred in the first 3 months of use (Figure 27). The model
was more sensitive to changes in the annual service cost; however, even when applying a very low cost of £200
the ICER was above £20,000 per QALY gained (Figure 28).
Alternative assumption for cost of admission
The results of varying the cost of an admission from the base-case assumption of £2053 between values of
£1500 and £3000 are shown in Figure 29 and demonstrate that the model was not very sensitive to
changes in this cost.
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FIGURE 27 One-way sensitivity analysis of alternative NIV assessment costs in a stable population.
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FIGURE 28 One-way sensitivity analysis of annual maintenance costs in a stable population.
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Alternative utility assumptions applied to the stable population
The difference in costs and QALYs when using the utility assumptions applied in Borg et al. (2004)138 are
reported in Table 40. As these were similar to the values in the base case, it is unsurprising that this made
very little difference to the ICER and cost-effectiveness of domiciliary NIV.
Subgroup analysis for the stable population
Global Initiative for Chronic Obstructive Lung Disease severity stage
Table 41 presents the ICERs when assuming stable end-stage COPD patients were started on NIV at a specified
severity stage. Assuming all patients entering the model were in GOLD stage 3, the ICER increased to £33,490
per QALY gained and the probability of domiciliary NIV being cost-effective reduced to 38%. Conversely,
assuming that all stable patients were started on NIV in GOLD stage 4, the ICER decreased to £23,124 per
QALY gained and the probability of domiciliary NIV being cost-effective at a threshold of £30,000 per QALY
gained increased to 72%.
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FIGURE 29 One-way sensitivity analysis of cost of admission in a stable population.
TABLE 40 One-way sensitivity analysis in the stable population using alternative utility assumptions
Strategy
Mean
cost (£)
Cost
difference (£)
Mean
QALYs
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Usual care 23,969 – 5.3330 – – – –
Domiciliary
NIV+ usual
care
36,737 12,769 5.7888 0.4558 28,013 14 55
TABLE 41 Subgroup analysis: alternative GOLD stage cohorts in the stable population
Severity
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Base case (50 : 50 split
between GOLD
stage 3 and stage 4)
12,769 0.4534 28,162 13 55
GOLD stage 3 14,761 0.4407 33,490 2 38
GOLD stage 4 10,777 0.4661 23,124 32 72
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This result is most likely to be because of the higher baseline risk of exacerbation, admission and
COPD-related mortality applied to GOLD stage 4 health states than to GOLD stage 3. This suggests
that domiciliary NIV is more likely to be cost-effective in patients with higher risk of admission if NIV
is effective at reducing this risk of admission.
Age
The starting age of the stable population entering the model was varied and results are presented in
Table 42. There was very little difference by changing the start age from 65 to 55 years; the ICER was
slightly lower, but this made little difference to the probability of domiciliary NIV being cost-effective at
a threshold of £30,000 per QALY gained.
By increasing the start age to 85 years, the ICER increased to £42,785/QALY gained and the probability
of domiciliary NIV being cost-effective decreased to 8%. This is most likely because of the shorter
time horizon for the effects of domiciliary NIV to accumulate as the risk of all-cause mortality increased
significantly with age. It should, however, be noted that the risk of a COPD-related event (exacerbation,
admission or death) was not linked to age because of lack of age-specific data available. Therefore,
while this result may suggest that domiciliary NIV is less effective in an older stable population, this may
not be the case if the risk of having a COPD-related event also increases with age.
Sex
The results for separate male and female cohorts are shown in Table 43 and show very little difference
in the ICERs or probability of NIV being cost-effective when targeting solely men or women. This may
be because only a limited number of parameters differentiated between sex, namely mortality and
readmission rates post-discharge and all-cause mortality. Until more gender-specific data on COPD-related
events in a stable population become available, it is assumed the cost-effectiveness of NIV is not influenced
by sex.
TABLE 42 Subgroup analysis: alternative cohort start ages in a stable population
Start age
(years)
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
Probability cost-effective
at £20,000/QALY (%)
Probability cost-effective
at £30,000/QALY (%)
65 (base case) 12,769 0.4534 28,162 13 55
55 14,621 0.5367 27,242 14 58
85 5895 0.1379 42,758 < 1 8
TABLE 43 Subgroup analysis: male and female cohorts in a stable population
Sex
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
% cost-effective at
£20,000/QALY
% cost-effective at
£30,000/QALY
Base case 12,769 0.4534 28,162 13 55
Male 12,500 0.4450 28,089 12 56
Female 13,444 0.4747 28,323 12 57
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Higher baseline risk of admission risk
Substituting the baseline admission and mortality risk in the stable health states (obtained from the TORCH
and Eclipse trials and the Office for National Statistics) with baseline risks applied in stable health states
for the post-hospital population (obtained from Garcia-Aymerich et al. 2003152) reduced the ICER to below
the threshold of £20,000 per QALY gained and increased the probability of being cost-effective to 86% at
£30,000 per QALY gained and 65% at £20,000 per QALY gained (Table 44).
Expected value of perfect information for the stable population
The EVPI per patient for the stable population was estimated to be £204 at a threshold of £20,000 per
QALY gained and £1812 per patient at a threshold of £30,000 per QALY gained. When this is multiplied
by the estimated population size (329,000 stable end-stage COPD patients in the UK), it results in an
EVPI per population estimate of £67M and £596M respectively. Figure 30 shows the EVPI per population
at all willingness-to-pay thresholds as between £0 and £60,000 per QALYs gained. These estimates reflect
the value of research that removes all uncertainty in the decisions to adopt NIV at these willingness-to-pay
thresholds. The high value at all thresholds above £20,000 per QALY gained reflects the fact that removing
all uncertainty in the decision to offer domiciliary NIV to all end-stage COPD potentially affects a large
patient base.
At a threshold of £20,000 per QALY gained, usual care is the preferred option. The EVPI per population
increases above the threshold of £20,000 per QALY gained and reaches a peak at around a little over
£28,000/QALY gained, where the decision changes and domiciliary NIV becomes the preferred option.
This sharp increase is because, at thresholds close to the base-case ICER, perfect information becomes
more important, as it is likely to change the decision to offer domiciliary NIV.
TABLE 44 Subgroup analysis: cohort with higher baseline risk of admission in a stable population
Risks in stable
health states
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
% cost-effective at
£20,000/QALY
% cost-effective at
£30,000/QALY
Base case 12,769 0.4534 28,162 13 55
Higher
readmission
and mortality
risks
6222 0.3594 17,313 65 86
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FIGURE 30 Expected value of per information per population for the stable COPD population.
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Results for the post-hospital population
This section presents the results of the base-case, sensitivity and subgroup analyses for the
post-hospital population.
Base-case analysis
The three base-case results for the post-hospital population presented in Table 45 show that, compared
with usual care alone, the addition of domiciliary NIV was more costly and resulted in better outcomes
where the rate ratios favoured NIV and resulted in higher costs and worse outcomes with the rate ratio that
favoured usual care; therefore, domiciliary NIV was dominated. Where the evidence marginally favoured
NIV, the ICER was £10,107 per QALY gained and this reduced to £6281 per QALY gained where the rate
ratio strongly favoured NIV. Therefore, both of the rate ratios that favoured NIV produced ICERs that were
well under the willingness-to-pay threshold of £20,000 per QALY gained; however, if NIV is not more
effective than usual care, it would not be considered cost-effective irrespective of the willingness-to-pay
threshold value.
The results of the probabilistic sensitivity analysis, showing the distribution of 1000 resampled cost–effect
difference pairs for each base case, are shown on three cost-effectiveness planes in Figure 31.
In all three base cases, domiciliary NIV was more costly; however, the results differed widely across the
three rate ratios with respect to the effect. For the base case that used evidence that marginally favoured
usual care, the majority of the samples are on or to the left of the line of no effect, but there was some
uncertainty around this. Similarly, for the base case that used evidence that marginally favoured NIV,
in most samples domiciliary NIV was more effective, but there was a lot of uncertainty regarding
effectiveness. In the most favourable base case, NIV was more costly and more effective in all samples.
TABLE 45 Base-case results for the post-hospital population
Strategy
Mean
cost (£)
Cost
difference (£)
Mean
QALYs
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Usual care 17,048 – 2.1452 – – – –
Domiciliary NIV +usual care
Marginally
favoured
usual care
(Struik et al.75)
21,912 4864 1.8196 –0.3255 Dominated 0 0
Marginally
favoured NIV
(Cheung et al.90)
22,879 5830 2.722 0.5769 10,107 72 79
Most
favourable
(Xiang et al.92)
23,533 6485 3.177 1.0325 6281 100 100
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FIGURE 31 Cost-effectiveness plane of NIV vs. usual care in the three base-case post-hospital populations.
(a) Base case marginally favours control; (b) base case marginally favours NIV; and (c) base case most favourable
to NIV.
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The CEAC in Figure 32 show that, at a threshold of £20,000 per QALY gained, domiciliary NIV has a 0%,
72% and 100% probability of being cost-effective in the base case that marginally favoured usual care, the
base case that marginally favoured NIV and the base case that was most favourable to NIV, respectively.
This suggests that the considerable uncertainty around the effect of NIV on admissions follows through into
the cost-effectiveness analysis findings.
Sensitivity analysis
This section presents the results of the sensitivity analysis conducted on the base-case assumptions applied
to the post-hospital COPD population.
Alternative rate ratios for hospital admissions
Varying the rate ratio for admission in this population between 0.05 and 0.95, as illustrated in Figure 33,
shows that the ICER for NIV is very sensitive to this parameter. At rate ratios of 0.85 and above (i.e. a 15%
reduction in the rate of admissions per patient per year with NIV), the ICER is above £30,000 per QALY
gained, and at rate ratios of 0.75 and below, the ICERs are below £20,000 per QALY gained.
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FIGURE 32 Cost-effectiveness acceptability curve for NIV vs. usual care in the three base-case
post-hospital populations.
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FIGURE 33 One-way sensitivity analysis varying the rate ratio for admissions in a post-hospital population.
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Alternative improvements in utility
While there was no evidence to suggest that domiciliary NIV had an effect on utility, the assumption that
domiciliary NIV may have a positive or negative effect on QoL was tested by applying a change of 0.025 in
the utility score (on a scale of 0 to 1) in either direction to the three base cases. The effects on the ICERs
are illustrated in Figure 34. Assuming that NIV had a small positive or negative effect on the utility score
(by 0.025), this had little impact on cost-effectiveness. Usual care dominated NIV in all cases in which the
base case marginally favoured usual care. Conversely, where the base cases favoured domiciliary NIV, in all
cases the ICER remained below £20,000 per QALY gained.
Alternative durations for effect
Figure 35 presents the results, varying the duration of the effect relating to the three base cases from
10 years to between 1 and 30 years. In both of the base cases in which the effectiveness estimate
favoured NIV, the ICERs were below £20,000 if the effect of NIV lasted for 2 years or more. Conversely,
in the base case in which the evidence marginally favoured usual care, changing the duration of this effect,
unsurprisingly, did not change the likelihood of NIV being cost-effective and, in all cases, usual care
dominated NIV.
This suggests that it is important to verify the effects of NIV beyond 2 years, as this assumption is an important
determinant of the cost-effectiveness of this intervention in this population, but it is less important if NIV is
effective beyond 5 years in this population.
Alternative model time horizons
Table 46 presents the results when varying the time horizon of the model. Usual care dominated NIV for
all possible time horizons. With a time horizon of 6 months, the ICERs for marginally favouring NIV and
strongly favouring NIV were £59,775 per QALY gained and £18,805 per QALY gained, respectively. After
2 years, the ICERs decreased to £14,806 per QALY gained and £2023 per QALY gained, both with an
increasing probability of being cost-effective. At all time horizons beyond 5 years, the ICER was £10,107
per QALY gained or less for both the cases that favoured NIV and there was only a small change to the
probability of domiciliary NIV being cost-effective, varying between 75% and 80% at a threshold of
£30,000 per QALY gained in the case that marginally favoured NIV and staying at 100% in the most
favourable case.
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FIGURE 34 Alternative assumption for effect on utility in a post-hospital population.
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FIGURE 35 One-way analysis changing the duration of effect in a post-hospital population.
TABLE 46 One-way sensitivity analysis varying the time horizon in a post-hospital population
Direction of
effect
Time
horizon
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Marginally
favoured
usual care
6 months 1289 –0.0057 Dominated 0 0
2 years 3164 –0.0465 Dominated 0 0
5 years 4719 –0.1476 Dominated 0 0
10 years 5085 –0.2655 Dominated 0 0
20 years 4881 –0.3209 Dominated 0 0
30 years
(base case)
4865 –0.3255 Dominated 0 0
Marginally
favoured NIV
6 months 504 0.0084 59,775 17 31
2 years 995 0.0672 14,806 60 68
5 years 2301 0.2277 10,106 67 75
10 years 4119 0.4509 9135 69 77
20 years 5697 0.5673 10,043 72 78
30 years
(base case)
5830 0.5769 10,107 71 77
Most
favourable
6 months 249 0.0132 18,805 53 80
2 years 221 0.1092 2023 98 100
5 years 1285 0.3828 3357 100 100
10 years 3581 0.7918 4523 100 100
20 years 6259 1.0141 6171 100 100
30 years
(base case)
6485 1.0325 6281 100 100
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Similar to varying the duration of effect, the model was less sensitive to changes in the time-horizon
beyond 2 years compared with the stable population because of higher baseline all-cause and
COPD-related mortality risks.
Alternative continuation rates
The effect on the ICER of varying the proportion of those who benefit from domiciliary NIV and continue
using it from 55% to 95% in the three base cases is shown in Figure 36. As with the stable population,
the model was not very sensitive to this assumption as the short-term costs of trialled domiciliary NIV on
those who discontinue without benefiting was minimal compared with the costs and benefits that accrue
over the lifetime of the population that continues with NIV.
Alternative costs of the non-invasive ventilation device
In the base cases it was assumed that the NIV device would cost £3600 and the monthly cost was derived
on the assumption that it would be used continuously for 5 years. The results of varying the cost of the
NIV device are illustrated in Figure 37 and show that at all costs of the device between £2000 and £6000
the ICER was below the lower threshold of £30,000 per QALY gained for the base cases in which the
effectiveness estimate favoured NIV, and was dominated at all costs for the base case that favoured
usual care.
–20
–15
–10
–5
0
5
10
15
20
0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95
IC
ER
s 
(£
00
0/
Q
A
LY
)
% continue after 3 months
Base case marginally
favours usual care
Base case marginally
favours NIV
Base case most favourable
to NIV
FIGURE 36 One-way sensitivity analysis of alternative continuation rates beyond 3 months in a
post-hospital population.
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FIGURE 37 One-way sensitivity analysis of alternative costs of device in a post-hospital population.
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Similarly, the assumption for the lifespan of the device was varied between 4 and 8 years and, as
illustrated in Figure 38, in all cases the ICER was below £30,000 per QALY gained for the base cases in
which the effectiveness estimate favoured NIV, and was dominated at all lifespans for the case that
favoured usual care.
Alternative costs of the service aspects of non-invasive ventilation provision
The tariff for an NIV assessment and set-up varied between £200 and £1000. The results in Figure 39
show that the model was not sensitive to variation in this cost in any of the cases, as it was a one-off cost
and had a minimal impact on the cost difference over the cohort’s lifetime. The model was more sensitive
to changes to the annual service cost (Figure 40). However, as with the cost of the NIV device, the ICERs
were below £15,000 per QALY gained for the two base cases in which the effectiveness estimate favoured
NIV and were dominated in all cases where usual care was favoured.
Alternative utility assumptions applied in the post-hospital population
The difference in costs and QALYs when using the utility assumptions applied in Borg et al. (2004)138 are
reported in Table 47. Similarly to when these were applied to the stable population, this made very little
difference to the cost-effectiveness of domiciliary NIV in any of the three post-hospital population
base cases.
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FIGURE 38 One-way sensitivity analysis of alternative lifespan of device in a post-hospital population.
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FIGURE 39 One-way sensitivity analysis of alternative NIV assessment costs in a post-hospital population.
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Alternative baseline risks applied in the post-hospital population
Replacing the parameters for hospitalisation and mortality obtained from Garcia-Aymerich et al. (2003)152
with those obtained from Bucknall et al. (2011)153 increased the ICER to £23,211 per QALY gained in the
case in which the effectiveness estimate marginally favoured NIV and to £13,101 per QALY gained with
the most favourable effectiveness estimate (Table 48). It reduced the probability of NIV being cost-effective
at a threshold of £30,000 per QALY gained to 61% in the case that the effectiveness estimate marginally
favoured NIV, but had no effect on the probabilities of the other cases. This suggests that domiciliary NIV is
less cost-effective in patients with lower baseline risk of hospitalisation and/or mortality.
Adjusting all mortality risks (risk of death during exacerbation, risk of death post-exacerbation and
risk of all-cause mortality) by a factor of two decreased both the costs and outcomes compared with the
base case, reflecting shorter survival in both arms. This reduced the ICER to £9593 per QALY gained in
the case where the effectiveness estimate marginally favoured NIV and £5756 per QALY gained with the
most favourable effect estimate and had a minimal impact on the likelihood of domiciliary NIV being
cost-effective at £20,000 or £30,000 per QALY gained. For all analyses, usual care remained dominant
over NIV with the case that used an effect estimate that favoured usual care.
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FIGURE 40 One-way sensitivity analysis of annual maintenance costs in a post-hospital population.
TABLE 47 One-way sensitivity analysis in the post-hospital population using alternative utility assumptions
Strategy
Mean
cost (£)
Cost
difference (£)
Mean
QALYs
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Usual care 17,048 – 2.2715 – – – –
Domiciliary NIV +usual care
Marginally
favoured usual
care
21,912 4864 2.1614 –0.3294 Dominated 0 0
Marginally
favoured NIV
22,879 5830 2.7447 0.5833 9996 72 79
Most
favourable
23,533 6485 3.2014 1.04 6236 0 0
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TABLE 48 One-way sensitivity analysis of alternative baseline risks in a post-hospital population
Severity
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Applying baseline risks from Bucknall et al.153
Marginally favoured
usual care
5613 –0.1346 Dominated 0 0
Marginally favoured
NIV
4034 0.1738 23,211 34 61
Most favourable 3562 0.2719 13101 99 100
Doubling all mortality risks
Marginally favoured
usual care
2567 –0.1637 Dominated 0 0
Marginally favoured
NIV
3019 0.3147 9593 75 80
Most favourable 3379 0.587 5756 100 100
Subgroup analysis for the post-hospital population
Global Initiative for Chronic Obstructive Lung Disease severity stage
Table 49 presents the ICERs when assuming that only one GOLD-stage severity group entered the model.
The post-hospital model was not expected to be as sensitive to changes in the proportion of each GOLD
stage severity group, as the same probability of admission, COPD and all-cause mortality were applied to
GOLD stages 3 and 4. The only differences between these health states by severity were the costs of usual
care and utility values.
TABLE 49 Subgroup analysis: alternative GOLD stage cohorts in a post-hospital population
Direction
of effect Severity
Cost
difference (£)
QALY
difference
ICER
(£/QALY)
Probability
cost-effective at
£20,000/QALY (%)
Probability
cost-effective at
£30,000/QALY (%)
Marginally
favoured
usual care
Base case
(50 : 50 split
between GOLD
stages 3 and 4)
4865 –0.3255 Dominated 0 0
GOLD stage 3 4913 –0.334 Dominated 0 0
GOLD stage 4 4814 –0.3171 Dominated 0 0
Marginally
favoured
NIV
Base case
(50 : 50 split
between GOLD
stages 3 and 4)
5830 0.5769 10,107 71 77
GOLD stage 3 5785 0.6001 9641 73 78
GOLD stage 4 5876 0.5537 10,611 71 78
Marginally
favoured
NIV
Base case
(50 : 50 split
between GOLD
stages 3 and 4)
6485 1.0325 6281 100 100
GOLD stage 3 6394 1.0706 5972 100 100
GOLD stage 4 6576 0.9945 6613 100 100
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
Assuming that 100% of the population were in GOLD stage 3, the ICER decreased to £9641 per QALY in
the case in which effectiveness evidence marginally favoured NIV and to £5972 per QALY gained with the
most favourable effect estimate, and, assuming that 100% of the population were at GOLD stage 4, the
ICER increased to £10,611 per QALY gained, and to £6613 per QALY gained, respectively. There was
almost no change in the probability of either being cost-effective. Where the effectiveness estimate was
more favourable for usual care, this option still dominated NIV.
Expected value of perfect information analysis for the
post-hospital population
The EVPI per patient for the post-hospital population was estimated to be £1541 and £1694 at a
threshold of £20,000 and 30,000 per QALY gained, respectively, for the case in which effectiveness
evidence marginally favoured NIV. This reflects the high value of removing the uncertainty in this case,
in which there was considerable uncertainty around the likelihood of NIV being cost-effective at these
thresholds. Conversely, the value of EVPI for the case in which the effectiveness estimate that marginally
favoured usual care and in which the intervention was most favourable for NIV was zero in both cases,
as the probability of NIV being cost-effective was 0% and 100%, respectively.
Multiplying the EVPI per patient to the estimated population size (77,000 post-hospital patients in the UK)
generated an estimate for the EVPI per population of £119M and £130M, respectively, for the case that
marginally favoured NIV. The EVPIs per population at thresholds between £0 and £60,000 per QALY
gained are illustrated in Figure 41. This EVPI curve reaches a peak at thresholds close to the base-case
ICER, at which point the decision changes and domiciliary NIV becomes the preferred option. These
estimates reflect the value of conducting research that would remove all uncertainty from this decision and
are high because of the uncertainty around the effect and the potentially large population that would be
affected by the decision to adopt this technology (albeit a smaller population than all stable end-stage
COPD patients).
In the case where effectiveness evidence marginally favoured usual care, the EVPI decreases between
£0 and £6000 per QALY gained, then remains at zero until the £30,000 threshold. The EVPI increases
above this point, reflecting the small probability that NIV results in higher costs and better outcomes.
At most willingness-to-pay thresholds the EVPI for the case that most favours NIV is zero, reflecting the
higher probability of NIV being cost-effect at all thresholds considered. There is a small peak around
the point estimate, suggesting that, if the willingness-to-pay per QALY gained threshold were close to
£6000, there would be some value to further research of knowing with greater certainty that NIV
was cost-effective.
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FIGURE 41 Expected value of perfect information analysis for the three post-hospital populations.
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Discussion
This is the first economic model to consider the cost-effectiveness of domiciliary NIV in two end-stage
COPD populations, namely stable end-stage COPD patients started on domiciliary NIV in the community
and end-stage COPD patients started on domiciliary NIV when recovering from an exacerbation requiring
hospital admission. In both populations the model-based analyses should be viewed as speculative, owing
to uncertainties in the base-case effects applied. For the stable population, the effect on admissions was
uncertain; while four of five RCTs included in the meta-analysis found a reduction in hospital admissions,
only one of these findings was statistically significant and the overall pooled result was also not statistically
significant. Further, not all available evidence could be included in the meta-analysis. This finding of a
trend towards a reduction in hospital admissions was not reflected in the available (short-term) mortality
data, which found no evidence of a difference in effect between NIV and usual care. However, the
uncertainty around the impact on admissions is captured in the analysis, as the 95% CI around the point
estimate of risk reduction is used in the probabilistic sensitivity analysis.
There was also considerable uncertainty regarding the effect in a post-hospital population, as the only
three RCTs reporting this outcome had inconsistent findings.
Stable population
Applying the assumption that domiciliary NIV results in a reduction in hospital admissions, the base-case
results for the stable population suggest that domiciliary NIV may be a cost-effective intervention at a
threshold of £30,000 per QALY gained. However, probabilistic sensitivity analysis estimates that the
probability of being cost-effective at this threshold is only 55%, demonstrating the uncertainty around the
impact of domiciliary NIV on admission and utility in this population. If a £20,000/QALY gained threshold is
applied, the intervention is not cost-effective. The impact of a reduced risk of admission led to lower mortality
and morbidity; however, as these effects were expected to last for 10 years and the costs were assumed
to accumulate over the cohort’s lifetime, it is uncertain whether or not benefits outweigh the higher
lifetime costs of domiciliary NIV provision. The one-way sensitivity analyses undertaken were informative in
highlighting the key drivers of the model results. As expected, cost-effectiveness was affected by the estimate
of effect on admissions and utility improvement, the duration of effect and elements of the cost of domiciliary
NIV provision. Applying the high effectiveness estimate reduced the ICER to £18,660 per QALY gained, and
the probability of NIV being cost-effective at £30,000 per QALY gained increased to 82%. However, when
applying the effectiveness estimate (which marginally favoured usual care), the intervention was dominated by
usual care and this probability was reduced to less than 1%, highlighting the uncertainty around the effect.
Varying the rate ratio for hospital admissions found that for NIV to be cost-effective at this threshold, the rate
ratio would need to be 0.76 or lower (i.e. a 24% reduction in the rate of admissions per patient per year with
NIV). Similarly, assuming domiciliary NIV improved QoL and increased the utility score by 0.025, the ICER
decreased to £26,462, closer to the threshold of £20,000 per QALY gained.
It is unsurprising that the intervention becomes more cost-effective when extending the duration of effect
beyond 10 years, and is less effective at shorter durations. While it is reasonable to conclude that the
effects are likely to last beyond those reported in trials (1 or 2 years) the model becomes more speculative
when assuming that the effects extend beyond 10 years. Taking into account all the uncertainty around
the effect estimate for hospital admission and effect on utility, it is plausible that the intervention may be
cost-effective at £30,000 per QALY gained if the effects lasted for a patient’s lifetime. As the base-case
ICER was between the willingness-to-pay thresholds of £20,000 and £30,000 per QALY gained, the
model was sensitive to costs that accumulated over the long term, such as the monthly equipment costs
and annual maintenance costs. If these costs were lower than those applied in the base-case analysis,
the ICER comes closer to £20,000 per QALY gained; however, the overall uncertainty around the results
would remain.
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The population EVPI was £596M, which reflects the value of removing all uncertainty regarding the
decision to adopt domiciliary NIV at a willingness-to-pay threshold of £30,000 per QALY gained. This value
is high because of the large population potentially affected by this decision, and should be considered
indicative because of uncertainties regarding the prevalence of COPD and the proportion considered end
stage and stable.
Post-hospital population
Three base cases were explored in order to reflect the considerable uncertainty of the effect of NIV on
hospital admissions. For the case in which the effectiveness estimate marginally favoured usual care, NIV
was more costly and resulted in worse outcomes; therefore, usual care was dominant. While there was
some uncertainty around the effect, there was a zero likelihood of NIV being cost-effective, and this
conclusion was not sensitive to any of the other assumptions tested in sensitivity analysis.
Conversely, the opposite conclusion could be drawn from the case in which the effectiveness estimate was
most favourable to NIV. Here NIV was more costly but more effective and, as the ICER was below £10,000
per QALY gained, there was a 100% probability of NIV being cost-effective at a threshold of £20,000 per
QALY gained. The case in which the effectiveness estimate marginally favoured NIV also produced an
ICER close to £10,000 per QALY, but there was a lot more uncertainty around the probability of NIV being
cost-effective, driven primarily by the uncertainty around the effect.
The disparity in the findings from the three base cases highlights the need for more studies to evaluate
the effect in this population. Although two out of the three studies informing the base cases favoured
NIV and thus found NIV to be cost-effective, the sample size was very small in both cases (n= 40 and 47)
and there was also a large difference in size of effect. The study that marginally favoured usual care was
larger (n= 201), but the direction of effect was not consistent with that of the other two RCTs.
The results from the EVPIs conducted for each case, not surprisingly, also gave very mixed values for
perfect information to inform the decision to offer domiciliary NIV to this population. The value of perfect
information in the case in which the effectiveness estimate marginally favoured usual care (obtained from
a large study) and the case in which the effectiveness estimate favoured NIV (obtained from a small study)
was much smaller than the value of perfect information in the case in which the effectiveness estimate
marginally favoured NIV. This was associated with a lot of uncertainty. As a pooled rate ratio for hospital
admissions is likely to be closer to the middle estimate (i.e. marginally favouring NIV) than the other two
cases, this suggest that there is a strong argument in favour of conducting further research to remove
this uncertainty.
Sensitivity analyses
The sensitivity analysis conducted for both populations found that the relative cost-effectiveness of
domiciliary NIV was not particularly sensitive to the initial costs of set-up or to the proportion that
discontinued using domiciliary NIV in the first 3 months (assuming that only those who benefited
continued using it and incurred costs beyond this point). Conversely, the model was sensitive to changes
in the size of the effects (rate ratio for admission and change in utility score) and duration of these effects
in both populations.
In the base cases for both populations it was assumed that there was no improvement in QoL associated
with domiciliary NIV outside of the short-term decrements to QoL avoided from a reduced risk of
readmission. This was based on limited QoL data being reported in the studies identified. As this was a
conservative assumption, it may have underestimated the relative cost-effectiveness of domiciliary NIV and
points to the importance of gathering more robust evidence QoL.
The one-way sensitivity analysis varying the baseline mortality risks applied to the usual-care arm in
both populations found that the model was sensitive to this variable and that domiciliary NIV was more
cost-effective in patients at greater risk of admission and death. This is logical, demonstrating that if
domiciliary NIV is effective in reducing admissions and associated mortality, it will be more effective and
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cost-effective in patients most at risk of these events. This also highlights the importance of collecting
more robust data on patient characteristics that determine the risk of admission and mortality. It also
suggests that prioritising those most at risk of these events within NIV services could be considered.
Strengths and limitations
A key strength of this analysis is that it is the first economic model to consider the cost-effectiveness of
domiciliary NIV in both stable and post-hospital COPD patients and illustrates the key variables that impact on
the results. A further strength of this study was the model structure applied, which is a modified version
of previously published decision model where additional post-admission health states were added to
incorporate evidence on the higher risks in COPD patients immediately after discharge. This was particularly
useful when modelling two different COPD populations with different baseline risks of admission
and mortality.
Although there was a great deal of uncertainty around effectiveness data and assumptions applied to
this model, distributions were applied to reflect this uncertainty. A probabilistic sensitivity analysis was
undertaken, and this was supplemented with an extensive one-way sensitivity analysis of key parameters,
thus demonstrating which parameters were mostly likely to influence decisions to implement domiciliary NIV
in each patient population. Furthermore, value of information analysis was conducted to quantify the
value of conducting further research to eliminate this uncertainty.
However, caution should be applied when interpreting the results of the analyses for both populations
modelled. This is a speculative decision model and should only be considered as indicative of the potential
cost-effectiveness of domiciliary NIV if it is effective at reducing hospital admissions. For the stable
population, there was some evidence of a reduced risk of admissions in some studies reporting this
outcome, but there was no evidence of a reduced risk of mortality (up to 2 years). There was also a lot of
uncertainty for the post-hospital population, as studies reported very different effect estimates for hospital
admissions. A further limitation is the lack of long-term admissions data (up to 2 years). However, both
models have assumed an effect on admissions over the first 10 years.
In addition to the uncertainty around the effect of domiciliary NIV, there was also uncertainty around
parameters and assumptions for usual care in both populations. The model was populated using
some trial evidence but, as the studies identified in the clinical effectiveness systematic review reported
limited data, parameters were additionally obtained from large cohort studies. Furthermore, while
the model was able to reflect mortality and readmission risks in the first 3 months after discharge, it was
assumed that, after those 3 months, those who were not readmitted would move to a stable health state.
The baseline admission and mortality rates were assumed to be different for each population. In the
post-hospital group, these risks were obtained from a cohort study that followed up patients admitted for
an exacerbation.152 In the stable population, data were extracted from the TORCH148 and Eclipse2 studies,
representing average exacerbation and hospitalisations rates in stable COPD cohorts over a 3-year period,
and these data were applied over a 30-year time horizon. In reality, these rates may vary over time in
both populations.
While a relatively simple EVPI analysis was conducted, which reflected the value of perfect information
across all parameters, as opposed to a more complex analysis of perfect information associated with
specific parameters, the high values (>£100M) for both populations at £30,000 per QALY gained are
indicative of the value of conducting further research to remove all uncertainty from adoption decisions.
This suggests that it is worth spending money on research up a maximum of these high values in order to
further inform all the model parameters, and eliminate uncertainty. Conducting further expected value of
perfect parameter information analysis would help quantify the value of removing uncertainty around
particular parameters, but it is expected that continued evaluation of the effect of domiciliary NIV on
admissions, mortality and QoL should be a research priority for both populations. Furthermore, the values
for EVPI per population analyses reported assumed a COPD prevalence rate of 1.7%171 and that 30.8%
and 8.5% of COPD patients would meet the criteria of being end stage and stable, and end stage and
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post hospital, respectively.172 As there is a lot of uncertainty around both the true prevalence of COPD and
how end-stage patients should be defined, the values for the EVPI per population reported should be
interpreted cautiously and considered indicative of the value of perfect information to inform decisions
that affect these populations.
The model highlights a number of areas where further research is required. Crucially, further evidence is
needed on the effectiveness of domiciliary NIV in reducing admissions and improving QoL. There is a lot of
uncertainty around the effectiveness and cost-effectiveness of domiciliary NIV in a stable population, and
the intervention may be cost-effective at £30,000 per QALY gained when applying current evidence, but
with only a 55% probability of being cost-effective. If NIV is effective in reducing the risk of admissions in
a post-hospital population, then it is likely to be below the willingness-to-pay threshold of £20,000. This
must be tempered with the fact that the largest study undertaken so far in this population found no
benefit of NIV in terms of hospital admissions. More evidence is required on what patient characteristics
predict exacerbations, hospitalisation and mortality in COPD populations. It is clear that these events differ
by severity of COPD and by recent experience of a hospital admission, although more data are needed on
how these two variables interact over time. Finally, while utility values in COPD populations are relatively
consistent by GOLD severity, there is a dearth of data available on the impact of exacerbations on QoL.
Summary
l Currently, there are no published economic models on the cost-effectiveness of domiciliary NIV versus
usual care in end-stage COPD either starting on NIV when stable in the community or at discharge
when recovering from an exacerbation.
l This is the first economic model to attempt to estimate the cost-effectiveness of domiciliary NIV in these
patient groups.
l This speculative model indicates that domiciliary NIV may be cost-effective in the stable population
at a threshold of £30,000 per QALY gained, but there is considerable uncertainty around this result.
Changing parameter estimates around the duration of effect, cost of NIV and target group (e.g. stable
patients in GOLD stage 4 or those with a higher risk of repeat exacerbation and mortality) reduces
the ICER further to values closer to £20,000 per QALY gained. However, there is a lot of uncertainty
around these results.
l There is a lot of uncertainty around the cost-effectiveness of NIV in the post-hospital population.
Two cases based on effectiveness estimates from single RCTs with small sample sizes indicated that
domiciliary NIV might be cost-effective in a post-hospital population at a willingness-to-pay threshold
of £30,000 per QALY gained. This is consistent with the findings above, that if NIV is more effective in
reducing the risk of admission it is more likely to be cost-effective in patients with a higher risk of
admission and mortality. However, the opposite conclusion was drawn from a third base case, which
used data from a larger RCT that favoured usual care with regard to the effect on hospitalisations.
More evidence is thus required to investigate the reason for this disparity in outcome between studies
in this population.
l The model has a number of limitations, the most important relating to the large amount of uncertainty
around the effectiveness estimate driving the model results.
l The analysis highlights the importance of conducting further research on the effect and duration of
effect of domiciliary NIV, and on whether or not a population of COPD patients not likely to benefit
can be identified, to allow a more robust analysis of cost-effectiveness.
l It also highlights the importance of estimates of baseline risk of admission and COPD-related mortality
when assessing the cost-effectiveness of NIV.
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Chapter 8 Overarching discussion and future
research recommendations
Overarching discussion
Two COPD populations were considered in this report, stable and post-hospital, in order to account for
underlying risk of future exacerbations. Recent hospitalisation (due to exacerbation) was used as a proxy
for a higher risk of recurring exacerbation. This division could be seen as artificial, as it does not take into
account overall exacerbation history, but was the only possible approach given the information reported in
the included studies. In order to be able to gauge the totality of the evidence, clinical effectiveness results
for stable and post-hospital populations were presented, where possible, in one forest plot.
For the stable population, there was evidence available to suggest no difference between NIV and usual
care in terms of survival (up to 24 months); however, there was a lack of longer-term controlled data on
survival. There was a trend (not statistically significant) towards fewer hospital admissions with NIV where
studies had reported this outcome, and possibly for improved QoL, although this was not consistent.
Not all available evidence on admissions in a stable population could be incorporated into the meta-analysis
(and subsequent economic modelling), and it is possible that, based on all evidence, the effect may have
been more equivocal. There was less evidence available for the post-hospital population. A benefit from NIV
in terms of survival was demonstrated in non-RCTs but not confirmed by RCTs. Hospital admissions findings
were inconsistent across three RCTs in this population and there was a lack of QoL data.
In line with these results, the speculative economic model found that NIV may be cost-effective in a stable
population at a willingness-to-pay threshold of £30,000 per QALY gained. This is driven by the trend
towards fewer hospital admissions but is associated with large uncertainty. The disparity between effect
estimates for the post-hospital population is reflected in the cost-effectiveness estimates which range from
NIV being dominated by usual care, to ICERs for NIV of near or below £10,000 per QALY gained. This is
the first model-based economic evaluation in domiciliary NIV; however, it remains speculative because of
the uncertainty around a potential benefit from NIV for a stable population and because of limited and
inconsistent evidence for the post-hospital population. The main drivers of the model were clinical
effectiveness estimates, duration of benefit (which is currently unknown) and, to a lesser extent, NIV
costs. Speculative modelling indicated that a reduction of 24% and 15% (for stable and post-hospital
populations respectively) in rate of hospital admissions (per patient per year) would result in NIV being
cost-effective at a threshold of £30,000 per QALY gained. Similarly, a 2.5% utility improvement would also
hypothetically make NIV cost-effective in a stable population, while a similar change in the post-hospital
population does not much affect the current cost-effectiveness estimates. A 2.5% improvement in utility is,
however, difficult to translate into a clinically meaningful measure. Given the limited QoL evidence, no
changes in utility were included in the base case (other than those caused by avoided hospital admissions),
which is contrary to anecdotal patient reports of improvement in daily living with NIV. Assuming there was
an improvement in QoL (of daily living), which has not been adequately captured by studies so far, this
may increase cost-effectiveness of NIV.
One potential drawback of the model is that it had to consider the two populations separately, while in a
real-life setting there is likely to be much more of a continuum of risk. It is possible that the post-hospital
population considered represents only a small proportion of COPD patients at the more severe end of
the disease spectrum. There was limited information in the included studies on baseline risk in relation to
exacerbation history. The model did, however, account (for both populations) for the fact that baseline risk
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changes, both over time and dependent on exacerbations. Further uncertainty in the model stemmed
from the fact that estimates for clinical parameters for the NIV and usual-care arms were in some cases
obtained from different sources, and it is unclear how potential differences in populations may affect
model outputs.
The remit for this report specified ‘patients with stable end-stage COPD plus chronic HRF, who have
required assisted ventilation (whether invasive or non-invasive) during an exacerbation or who are
hypercapnic or acidotic on long term oxygen therapy (LTOT).’ Based on the existing clinical effectiveness
evidence, no conclusions could be drawn on whether or not a certain type of patient is more likely to
benefit from NIV (e.g. in terms of LTOT use or level of hypercapnia), or whether or not a certain type of
NIV is more favourable (e.g. higher pressure), and the economic model has not considered any such
differences. Most included populations were hypercapnic and in many studies a majority of patients were
on LTOT. Performing subgroup analysis based on reported mean baseline CO2 values would have meant
dichotomising trials based on an arbitrary threshold and this was not considered appropriate. Exploratory
analyses undertaken across both stable and post-hospital populations suggested a trend towards a
correlation between changes in CO2 and hospital admissions. Such a potential correlation was not
observed for mortality. However, the analysis is using aggregate data for change in CO2 and also for mean
difference in hospital admissions, and a causal association therefore cannot be inferred even if there is
potential biological plausibility. Further, this was a post-hoc analysis, which is subject to a number of
limitations (see Appendix 7). It does suggest that there needs to be further investigation into the
association between CO2 and clinical outcomes such as hospital admissions.
The evidence overall indicates that some patients may be more likely to benefit from NIV than others, but
it is difficult to relate this to underlying risk of future exacerbations. It therefore remains uncertain at which
level of risk it might be beneficial to commence domiciliary NIV, if indeed such a risk could be determined
accurately for an individual patient during the course of their disease. The current recommendations in the
UK suggest that domiciliary NIV is considered on health-economic grounds if a patient has had three
hospital admissions with acute HRF.40 There may, however, be other, as yet undetermined, patient
characteristics which could influence the effectiveness of NIV.
Uncertainty also remains regarding the length of time NIV may provide benefit for. There are at least two
RCTs looking at the effect of discontinuing NIV (see Chapter 5, Discontinuation studies), but it was beyond
the scope of this report to explore this question.
Research recommendations
Based on the current evidence, it is possible that there are some patients who may derive greater benefit
from NIV, but at present it is not possible to define those patients’ characteristics.
A number of currently ongoing studies may go some way to adding to the evidence base, but this may
depend to some extent on how the study populations are defined (see Chapter 4, Ongoing studies, for full
details). There is at least one ongoing trial (the UK HOT-HMV trial) which includes a population with a
higher underlying risk of recurrent events similar to the post-hospital populations in this report. This study
had almost finished recruitment, but no results were available to include in this report. Recruitment
appears to have been slower than expected in at least some ongoing studies, which may be explained by
narrow inclusion criteria.
No further ongoing trials in a stable population were identified, which is perhaps a reflection of the lack of
evidence of benefit in this population. Uncertainty remains regarding a potential effect on QoL and
long-term effects on survival.
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The results from this report will need to be re-examined in the light of any new results from the ongoing
trials, particularly in terms of reducing some of the uncertainty in the economic model. As such,
recommendations for additional RCTs would be premature.
Should there be a need for additional new RCTs, these could include a sham NIV arm in order to minimise
potential bias, as well a higher-pressure and lower-pressure NIV arm, to enable further exploration of the
relationship between pressure and effectiveness. However, some argue that sham NIV may lead to an
overestimate of the potential benefit of NIV, because of its engendered disbenefits in terms of QoL, in
which case a control arm based on usual care only may be more appropriate. A three-arm trial (NIV vs.
sham NIV vs. usual care) may be required. In view of the small sample sizes in published and ongoing
trials, as well as recruitment issues, broader inclusion criteria could be considered, together with planned
subgroup analyses.
Future studies should consider measuring and reporting outcomes in a way that could usefully inform an
economic model. So QoL should be measured in way that enables conversion into utilities, exacerbations
should be reported with an indication of severity and the relationship between exacerbations,
hospitalisations and mortality should be clearly reported. Where continuous data are reported, analysis of
covariance should be used for adjusting for baseline imbalances. Alternatively, the proportion of patients
achieving a level of clinically important improvement could also be reported.
An appropriately conducted IPD analysis of all study data may help to answer some of the outstanding
questions about the type of patient that might benefit most from NIV. A recent Cochrane review110,124 has
incorporated IPD analyses but based on a smaller group of studies and without considering hospitalisations
or survival. The Cochrane analysis was not aimed at identifying potential effect modifiers. Feasibility of an
IPD analysis would depend on the availability of information on potential effect modifiers for all patients
and differences in methodological quality between studies. Small patient numbers and potentially
insufficiently high event rates in the trials published so far may also preclude analysis of all effect modifiers
of potential interest (e.g. age, GOLD severity, level of hypercapnia, use of LTOT, history of exacerbations).
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Chapter 9 Conclusions
Overall, the evidence from RCTs could not demonstrate a benefit from NIV compared with usual carein either stable or post-hospital populations, although there was a trend towards fewer hospital
admissions and, to a lesser extent, improved QoL for the stable population. A benefit in terms of survival
for the post-hospital population was shown in non-randomised controlled studies only and the findings for
hospital admissions (from RCTs) were inconsistent. There was also too little evidence to draw any conclusions on
the potential benefits of higher-pressure NIV settings. A speculative economic model found that NIV may be
cost-effective in a stable population at a threshold of £30,000 per QALY gained, but this is associated with a
large amount of uncertainty. It is not possible to draw any overall conclusions regarding cost-effectiveness in a
post-hospital population, as the results based on three different base cases are too disparate and also based
on limited evidence. It is likely that the broad categorisation into stable and post-hospital patients has not been
able to capture more subtle differences between patients, who may derive more or less benefit from NIV.
Further evidence, potentially from currently ongoing trials but more likely from IPD analyses, is required to
determine whether or not there are any patient characteristics (such as baseline hypercapnia level) or equipment
settings that are predictive of a benefit of NIV and to establish optimum time points for starting (and potentially
discontinuing) NIV.
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Appendix 1 Search strategies
Clinical effectiveness searches
Cochrane Central Register of Controlled Trials Issue 9 of 12 2014
#1 copd
#2 “chronic obstructive pulmonary disease”
#3 “chronic obstructive lung disease”
#4 “chronic obstructive airway disease”
#5 “chronic respiratory disorder*”
#6 “smoking related lung disease*”
#7 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees
#8 emphysema
#9 MeSH descriptor: [Emphysema] explode all trees
#10 MeSH descriptor: [Bronchitis] explode all trees
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 non-invasive near/2 ventilation
#13 noninvasive near/2 ventilation
#14 MeSH descriptor: [Positive-Pressure Respiration] explode all trees
#15 MeSH descriptor: [Intermittent Positive-Pressure Ventilation] explode all trees
#16 cpap
#17 bipap
#18 “bi-level ventilation”
#19 “bilevel ventilation”
#20 niv
#21 nippv
#22 nppv
#23 “positive pressure ventilation”
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#24 “positive airway pressure”
#25 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 #11 and #25 from 1980 to 2014
MEDLINE (Ovid) 1946 to August Week 4 2014
1. chronic obstructive pulmonary disease.mp. or exp Pulmonary Disease, Chronic Obstructive/
2. copd.mp.
3. chronic obstructive lung disease.mp.
4. chronic obstructive airway disease.mp.
5. chronic respiratory disorder$.mp.
6. smoking-related lung disease$.mp.
7. Pulmonary Emphysema/
8. exp Bronchitis/
9. emphysema.mp.
10. or/1-9
11. exp positive-pressure respiration/ or intermittent positive-pressure ventilation/
12. cpap.mp.
13. bipap.mp.
14. bi-level ventilation.mp.
15. niv.mp.
16. nippv.mp.
17. positive pressure ventilation.mp.
18. positive airway pressure.mp.
19. ((noninvasive or non-invasive) adj2 ventilation).mp.
20. nppv.mp.
21. or/11-20
22. 10 and 21
23. limit 22 to yr=“1980–2014”
MEDLINE (Ovid) In-Process & Other Non-Indexed Citations
8 September 2014
1. copd.mp.
2. chronic obstructive lung disease.mp.
3. chronic obstructive airway disease.mp.
4. chronic respiratory disorder$.mp.
5. smoking-related lung disease$.mp.
6. emphysema.mp.
7. chronic obstructive pulmonary disease$.mp.
8. bronchitis.mp.
9. or/1-8
10. cpap.mp.
11. bipap.mp.
12. bi-level ventilation.mp.
13. niv.mp.
14. nippv.mp.
15. positive pressure ventilation.mp.
16. positive airway pressure.mp.
17. ((noninvasive or non-invasive) adj2 ventilation).mp.
18. nppv.mp.
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19. positive pressure respiration.mp.
20. or/10-19
21. 9 and 20
22. limit 21 to yr=“1980–2014”
EMBASE (Ovid) 1980 to 8 September 2014
1. chronic obstructive lung disease/
2. chronic obstructive pulmonary disease.mp.
3. copd.mp.
4. chronic obstructive lung disease.mp.
5. chronic obstructive airway disease.mp.
6. chronic respiratory disorder$.mp.
7. smoking-related lung disease$.mp.
8. lung emphysema/
9. emphysema.mp.
10. exp bronchitis/
11. or/1-10
12. noninvasive ventilation.mp. or exp noninvasive ventilation/
13. positive end expiratory pressure/
14. positive pressure respiration.mp.
15. positive pressure ventilation.mp.
16. cpap.mp.
17. bipap.mp.
18. bi-level ventilation.mp.
19. niv.mp.
20. nippv.mp.
21. positive airway pressure.mp.
22. nppv.mp.
23. ((noninvasive or non-invasive) adj2 ventilation).mp.
24. or/12-23
25. 11 and 24
26. limit 25 to yr=“1980- 2014”
Cumulative Index to Nursing and Allied Health Literature (EBSCOhost) 1981:
September 2014
S1 MH “pulmonary disease, Chronic Obstructive+”
S2 chronic obstructive pulmonary disease
S3 chronic obstructive lung disease
S4 copd
S5 chronic obstructive airway disease
S6 chronic respiratory disorder*
S7 smoking-related lung disease
S8 MH “Emphysema”
S9 MH “bronchitis+”
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S10 emphysema
S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10
S12 MH “positive pressure ventilation+”
S13 cpap
S14 bipap
S15 bi-level ventilation
S16 niv
S17 nippv
S18 nppv
S19 positive pressure ventilation
S20 positive airway pressure
S21 non-invasive ventilation
S22 “noninvasive N2 ventilation”
S23 S12 or S 13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22
S24 S11 and S23
S25 S11 and S23 limited by years 1980-2014
Science Citation Index (Web of Knowledge) 1900–8 September 2014
Conference Proceedings Citation Index (Web of Knowledge)
1900–8 September 2014
#1 Topic=(copd) OR Topic=(chronic obstructive pulmonary disease) OR Topic=(chronic obstructive lung
disease) OR Topic=(chronic obstructive airway disease) OR Topic=(chronic respiratory disorder*) OR
Topic=(smoking related lung disease) OR Topic=(emphysema) OR Topic=(bronchitis)
#2 Topic=(cpap or bipap or niv or nippv or nppv) OR Topic=(positive pressure respiration) OR Topic=
(positive pressure ventilation) OR Topic=(bi-level ventilation) OR Topic=(positive airway pressure) OR
Topic=(noninvasive ventilation) OR Topic=(non-invasive ventilation)
#3 #1 and #2
Limited to time span 1980–2014 (searched 8 September 2014).
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Clinical Trials Registers Searches for ongoing studies
Search strategies run 8 September 2014.
World Health Organization International Clinical Trials Registry Platform
Search terms
“NIV” AND “COPD”
“Home” AND “ventilation”
“Chronic” AND “Pulmonary”
“Non invasive ventilation” AND “outpatients”
All limited to status: “Recruiting”
ClinicalTrials.gov
Search terms
“Non-invasive ventilation” AND “home”
Limited to “Recruiting” OR “Active, non-recruiting”
Current Controlled Trials
Search terms
“Ventilation” AND “Home” AND “Pulmonary”
“COPD” AND “Home” AND “Ventilation”
Limited to “Recruiting” OR “Active, non-recruiting”
UK Clinical Research Network Portfolio
Search terms
“COPD”
Limited to “Open” OR “In set-up”
Economic models
MEDLINE (Ovid ) 1946 to August Week 4 2014
Search strategy
1. chronic obstructive pulmonary disease.mp. or exp Pulmonary Disease, Chronic Obstructive/
2. copd.mp.
3. chronic obstructive lung disease.mp.
4. chronic obstructive airway disease.mp.
5. chronic respiratory disorder$.mp.
6. smoking-related lung disease$.mp.
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7. Pulmonary Emphysema/
8. exp Bronchitis/
9. emphysema.mp.
10. or/1-9
11. decision support techniques/
12. markov.mp.
13. exp models economic/
14. decision analysis.mp.
15. cost benefit analysis/
16. or/11-15
17. 10 and 15
18. limit 18 to yr=“1980- 2014”
EMBASE (Ovid) 1980 to 9 September 2014
1. chronic obstructive lung disease/
2. chronic obstructive pulmonary disease.mp.
3. copd.mp.
4. chronic obstructive lung disease.mp.
5. chronic obstructive airway disease.mp.
6. chronic respiratory disorder$.mp.
7. smoking-related lung disease$.mp.
8. lung emphysema/
9. emphysema.mp.
10. exp bronchitis/
11. or/1-10
12. noninvasive ventilation.mp. or exp noninvasive ventilation/
13. (non-invasive adj2 ventilation).mp.
14. positive end expiratory pressure/
15. positive pressure respiration.mp.
16. positive pressure ventilation.mp.
17. npvv.mp.
18. cpap.mp.
19. bipap.mp.
20. bi-level ventilation.mp.
21. niv.mp.
22. nippv.mp.
23. positive pressure ventilation.mp.
24. or/12-23
25. 11 and 24
26. decision support.ti,ab.
27. decision analysis.ti,ab.
28. markov.ti,ab.
29. model$.ti,ab.
30. or/26-29
31. 25 and 30
32. limit 31 to yr=“1980–2014”
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
Economic evaluations
The Cochrane Library (Wiley) NHS Economic Evaluation Database 2014
Issue 3 of 4
#1 copd
#2 “chronic obstructive pulmonary disease”
#3 “chronic obstructive lung disease”
#4 “chronic obstructive airway disease”
#5 “chronic respiratory disorder*”
#6 “smoking related lung disease*”
#7 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees
#8 emphysema
#9 MeSH descriptor: [Emphysema] explode all trees
#10 MeSH descriptor: [Bronchitis] explode all trees
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 non-invasive near/2 ventilation
#13 noninvasive near/2 ventilation
#14 MeSH descriptor: [Positive-Pressure Respiration] explode all trees
#15 MeSH descriptor: [Intermittent Positive-Pressure Ventilation] explode all trees
#16 cpap
#17 bipap
#18 “bi-level ventilation”
#19 “bilevel ventilation”
#20 niv
#21 nippv
#22 nppv
#23 “positive pressure ventilation”
#24 “positive airway pressure”
#25 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 #11 and #25 from 1980 to 2014
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MEDLINE (Ovid) 1946 to August Week 4 2014
1. economics/
2. exp “costs and cost analysis”/
3. cost of illness/
4. exp health care costs/
5. economic value of life/
6. exp economics medical/
7. exp economics hospital/
8. economics pharmaceutical/
9. exp “fees and charges”/
10. (econom$ or cost or costs or costly or costing or price or pricing or pharmacoeconomic$).tw.
11. (expenditure$ not energy).tw.
12. (value adj1 money).tw.
13. budget$.tw.
14. or/1-13
15. chronic obstructive pulmonary disease.mp. or exp Pulmonary Disease, Chronic Obstructive/
16. copd.mp.
17. chronic obstructive lung disease.mp.
18. chronic obstructive airway disease.mp.
19. chronic respiratory disorder$.mp.
20. smoking-related lung disease$.mp.
21. Pulmonary Emphysema/
22. exp Bronchitis/
23. emphysema.mp.
24. or/15-23
25. exp positive-pressure respiration/ or intermittent positive-pressure ventilation/
26. cpap.mp.
27. bipap.mp.
28. bi-level ventilation.mp.
29. niv.mp.
30. nippv.mp.
31. positive pressure ventilation.mp.
32. positive airway pressure.mp.
33. ((noninvasive or non-invasive) adj2 ventilation).mp.
34. nppv.mp.
35. or/25-34
36. 14 and 35
37. 14 and 24 and 35
38. limit 37 to yr=“1980–2014”
EMBASE (Ovid) 1980 to 9 September 2014
1. chronic obstructive lung disease/
2. chronic obstructive pulmonary disease.mp.
3. copd.mp.
4. chronic obstructive lung disease.mp.
5. chronic obstructive airway disease.mp.
6. chronic respiratory disorder$.mp.
7. smoking-related lung disease$.mp.
8. lung emphysema/
9. emphysema.mp.
10. exp bronchitis/
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11. or/1-10
12. noninvasive ventilation.mp. or exp noninvasive ventilation/
13. (non-invasive adj2 ventilation).mp.
14. positive end expiratory pressure/
15. positive pressure respiration.mp.
16. positive pressure ventilation.mp.
17. npvv.mp.
18. cpap.mp.
19. bipap.mp.
20. bi-level ventilation.mp.
21. niv.mp.
22. nippv.mp.
23. positive pressure ventilation.mp.
24. or/12-23
25. 11 and 24
26. cost benefit analysis/
27. cost effectiveness analysis/
28. cost minimization analysis/
29. cost utility analysis/
30. economic evaluation/
31. (cost or costs or costed or costly or costing).tw.
32. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
33. (technology adj assessment$).tw.
34. or/26-33
35. 25 and 34
36. limit 35 to yr=“1980–2014”
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Appendix 3 Analysis methods
Meta-analyses primary outcomes
Calculation of relative risks
Most studies presented numbers of events but none reported the RR; these were therefore calculated from
the raw data. Where numbers of events were calculated from percentages (for survival data), an assumption
of an ITT analysis was made; that is, that proportions were based on total number of patients at the start of
the study (no loss to follow-up). When graphs were presented, percentages were estimated from these.
Calculation of hazard ratios
Where HRs were reported in the published papers, these were presented in forest plots. Where a HR was
reported showing the ratio of an increased risk from no NIV rather than a benefit from NIV, the HR and
upper and lower confidence limits were reversed by taking the reciprocal values. When data on numbers
of events and patients (aggregated interval-censored survival data) were reported, the log-HR was
calculated using complementary log-log (Clog-log) regression.173 This method assumes a constant event
rate in each arm and hence proportional hazards. As the proportional hazards assumption is made,
meta-analysis was only undertaken for studies with stable populations. One post-hospital population study
(Budweiser et al. 200796) presents HRs for multiple follow-up times and it is clear from these and the
presented Kaplan–Meier curve that the assumption of proportional hazards does not hold in this study.
In order to check the assumption of constant baseline rates, HRs calculated from Clog-log regression were
compared with reported HRs when these were presented. This was the case for one RCT (McEvoy et al.
2009,74 stable population). Both HRs were found to be very similar (0.8 calculated and 0.82 reported)
lending some credibility to this assumption in a stable population, albeit based on only one estimate.
Means and rates
Most hospital admissions data were presented as mean (SD) number of admissions per patient. When only
the proportion was presented, the rates and SD were calculated.174 An assumption of ITT analysis was
made where patient numbers were not given.
Secondary outcomes
In order to use as many data as possible, SDs were calculated from SEs or CIs. Where units had to be
converted (e.g. feet to metres, or mmHg to kPa), the correct mean and SD were found using a simple
linear transformation. For some studies,80,99 results were only available by estimating from graphs.
Most studies reported results for completers only, and most analyses were therefore not on an ITT basis.
In some studies it was uncertain whether baseline and/or follow-up values referred to completers only or
all patients.
Note that for the study by Clini et al. (2002)99 the lower CI limit presented for the adjusted mean
difference at 12 months (FEV % predicted) was thought to be inaccurate (–13.1) and was assumed to be
–3.1. Further, the results are presented as usual care minus control (so a negative score indicates benefit
from NIV); this has been inverted for the forest plot for consistency with the other studies. It is unclear
what the treatment effect estimates for PaCO2 at 12 and 24 months reported in the paper refer to, so
mean difference has been calculated from final scores.
The study by Kaminski et al. (1999)101 reports a SD of 1591 for 6MWD. This has been assumed to be
inaccurate and 159 used instead.
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Appendix 4 Excluded studies from the clinical
effectiveness review
This appendix includes reference lists of excluded studies from the clinical effectiveness review, studiesthat could not be obtained and studies where further information was sought but not obtained.
Excluded studies
This section details the articles excluded from the review of clinical effectiveness with the reason they were
not selected.
TABLE 54 Excluded studies
Article
Reason for
exclusion
Abramson MJ, Crockett AJ, Frith PA, McDonald CF. COPDX: an update of guidelines for the
management of chronic obstructive pulmonary disease with a review of recent evidence. [Review].
Med J Aust 2006;184:342–5
A
Adler D, Perrig S, Takahashi H, Espa F, Rodenstein D, Pepin JL, et al. Polysomnography in stable COPD
under non-invasive ventilation to reduce patient-ventilator asynchrony and morning breathlessness.
Sleep Breath 2012;16:1081–90
E
Agusti AG, Barbe F, Togores B. Noninvasive ventilation. N Engl J Med 1998;338:1388–9 A
Al JE, Fiorentino F, Reeves BC, Ind PW, Angelini GD, Kemp S, et al. Reply to the editor. J Thorac
Cardiovasc Surg 2013;146:1299–300
A
Alkhuja S. Effects of expiratory positive airway pressure on dynamic hyperinflation during exercise in
patients with COPD. Respir Care 2013;58:e34
A
Allan PF, Thomas KV, Ward MR, Harris AD, Naworol GA, Ward JA. Feasibility study of noninvasive
ventilation with helium-oxygen gas flow for chronic obstructive pulmonary disease during exercise.
Respir Care 2009;54:1175–82
E
Ambrosino N, Clini E. Noninvasive ventilation in COPD patients with chronic respiratory failure – pro.
Monaldi Arch Chest Dis 2000;55:54–7
A
Ambrosino N, Nava S, Bertone P, Fracchia C, Rampulla C. Physiologic evaluation of pressure support
ventilation by nasal mask in patients with stable COPD. Chest 1992;101:385–91
E
Ambrosino N, Nava S, Torbicki A, Riccardi G, Fracchia C, Opasich C, et al. Haemodynamic effects of
pressure support and PEEP ventilation by nasal route in patients with stable chronic obstructive
pulmonary disease. Thorax 1993;48:523–8
E
Ambrosino N, Vitacca M, Polese G, Pagani M, Foglio K, Rossi A. Short-term effects of nasal
proportional assist ventilation in patients with chronic hypercapnic respiratory insufficiency. Eur Respir J
1997;10:2829–34
E
Anon. Noninvasive positive pressure ventilation improves COPD patient outcomes. AHRQ Research
Activities 2012;(386):18–19
A
Anon. [NIPPV use increases, but mortality for some is also up]. AARC Times 2012;36:77 A
Anon. Noninvasive ventilation has been shown to be ineffective in stable COPD – rebuttal. Am J Respir
Crit Care Med 2000;161:691
A
Anon. Summaries for patients. Noninvasive positive-pressure ventilation for severe worsening of chronic
obstructive pulmonary disease. Ann Intern Med 2003;138:I27
A
Anton A, Guell R, Tarrega J, Sanchis J. Non-invasive ventilation. Thorax 2002;57:919 A
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TABLE 54 Excluded studies (continued )
Article
Reason for
exclusion
Anton A, Guell R. Home mechanical ventilation in COPD: do we know when and how to use it?
Chest 2000;118:1525–6
A
Aron C, Moutaux G. Non-invasive ventilation in acute or chronic respiratory failure: a comparison of
volumetric ventilation. Rev Mal Respir 1999;16:181–7
E
Aubier M, Muir JF, Robert D, Leger P, Langevin B, Benhamou D. [Chronic respiratory failure.
Non-invasive methods of long-term ventilation]. Rev Mal Respir 1993;10:385–400
A
Aufiero A, Citarella A, Cilotaj V, Cogliati A, Curto P, Damonte L, et al. Remeo Lago Maggiore: The first
Italian specialized nursing home for ventilated patients’ long term care. Italian Journal of Medicine
Conference: 19th Congresso Nazionale della Societa Scientifica FADOI, 10–13 May 2014, Bologna.
Conference Publication: pp. 6–8
E
Bai C. [Efficacy and safety of non-invasive ventilation in the management of chronic airway diseases].
Acta Anaesthesiol Ital 2008;59:6–17
A
Bai CX. [A comparative study of the effects of control ventilation and synchronized intermittent
mandatory ventilation on hemodynamic and blood gases in patients with chronic obstructive
pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 1992;15:220–1
E
Baliko Z. [Noninvasive mechanical ventilation in chronic obstructive lung diseases with acute or chronic
respiratory failure]. Lege Artis Med 2006;16:625–30
A
Barakat S, Michele G, Nesme P, Nicole V, Guy A. Effect of a noninvasive ventilatory support during
exercise of a program in pulmonary rehabilitation in patients with COPD. Int J Chron Obstruct Pulmon
Dis 2007;2:585–91
E
Barbano L, Bertella E, Vitacca M. Episodic medical home interventions in severe bedridden chronic
respiratory failure patients: a 4 year retrospective study. Monaldi Arch Chest Dis 2009;71:113–18
D
Benditt JO. Noninvasive ventilation at the end of life. Respir Care 2000;45:1376–84 A
Benhamou D, Muir JF, Raspaud C, Cuvelier A, Girault C, Portier F, et al. Long-term efficiency of home
nasal mask ventilation in patients with diffuse bronchiectasis and severe chronic respiratory failure –
a case–control study. Chest 1997;112:1259–66
C
Berzin A, Chopin C, Fourrier F. Study of efficacy of ventilation in intermittent positive pressure with a
mouth piece in patients with chronic obstructive lung disease. Lyon Med 1981;245:533–5
E
Bianchi L, Foglio K, Pagani M, Vitacca M, Rossi A, Ambrosino N. Effects of proportional assist
ventilation on exercise tolerance in COPD patients with chronic hypercapnia. Eur Respir J
1998;11:422–7
E
Birnbaumer DM. Noninvasive ventilatory support – saving a life without intubation. West J Med
1998;168:182–3
A
Boix JH, Tejeda M, Alvarez F, Ernesto E, Bertomeu F, Bano M. [Noninvasive ventilator support in
patients with chronic obstructive pulmonary disease. A comparison of 2 methods]. Rev Clin Esp
1995;195:678–83
E
Borel J-C, Burel B, Tamisier R, as-Domingos S, Baguet J-P, Levy P, et al. Comorbidities and mortality in
hypercapnic obese under domiciliary noninvasive ventilation. PLOS ONE 2013;8:e52006
C
Borghi SA, Mendes RG, Sampaio LMM, de-Souza HCD, Tania ST, Costa D. Noninvasive ventilation is
better than oxygen supplementation to improve performance during a physical training program in
COPD patients – a randomized study. [Abstract]. European Respiratory Society Annual Congress,
Barcelona, 18–22 September 2010; 3651
E
Borghi-Silva A, Di TL, Pantoni CB, Mendes RG, Salvini TF, Costa D. Non-invasive ventilation improves
peripheral oxygen saturation and reduces fatigability of quadriceps in patients with COPD. Respirology
2009;14:537–44
E
Borghi-Silva A, Mendes RG, Toledo AC, Malosa Sampaio LM, da Silva TP, Kunikushita LN, et al.
Adjuncts to physical training of patients with severe COPD: oxygen or noninvasive ventilation? Respir
Care 2010;55:885–94
E
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TABLE 54 Excluded studies (continued )
Article
Reason for
exclusion
Borghi-Silva A, Mendes RG, Toledo AC, Sampaio LMM, da Silva TP, Kunikoshita LN, et al. Different
adjuncts during physical training in severe chronic obstructive pulmonary disease patients: oxygen or
non-invasive ventilation? Am J Respir Crit Care Med 2010;181:A6502. American Thoracic Society
International Conference, ATS 2010, New Orleans, LA, 14–19 May 2010; various page numbers
E
Borghi-Silva A, Reis MS, Mendes RG, Pantoni CB, Simoes RP, Martins LE, et al. Noninvasive ventilation
acutely modifies heart rate variability in chronic obstructive pulmonary disease patients. Respir Med
2008;102:1117–23
E
Braghiroli A, Sacco C, Erbetta M, Ruga V, Donner CF. Overnight urinary uric acid: creatinine ratio
for detection of sleep hypoxemia. Validation study in chronic obstructive pulmonary disease and
obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure.
Am J Respir Crit Care Med 1993;148:173–8
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TABLE 54 Excluded studies (continued )
Article
Reason for
exclusion
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ventilation and external PEEP on diaphragmatic activity in patients with severe stable COPD. Chest
1993;103:143–50
E
Nava S, Ceriana P. Patient–ventilator interaction during noninvasive positive pressure ventilation. Respir
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TABLE 54 Excluded studies (continued )
Article
Reason for
exclusion
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TABLE 54 Excluded studies (continued )
Article
Reason for
exclusion
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TABLE 54 Excluded studies (continued )
Article
Reason for
exclusion
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TABLE 54 Excluded studies (continued )
Article
Reason for
exclusion
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A
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E
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E
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Jiu Yi Xue 2009;21:247
E
Reasons for exclusion: A, study design; B, publication type; C, population; D, intervention; E, setting; F, other
(e.g. economic evaluation or qualitative study).
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Unobtainable studies
This section details the 16 articles which could not be obtained to allow assessment against the selection
criteria for the review of clinical effectiveness.
TABLE 55 Unobtainable studies
Article
Anon. Non-invasive Positive Pressure Ventilation in Patients with Chronic Respiratory Failure. Switzerland: Lausanne; 2007
Borghi SA, Sampaio LMM, Toledo A, Pincelli MP, Costa D. [Acute effects of BiPAP application on physical exercise tolerance
among chronic obstructive pulmonary disease patients]. Revista Brasileira de Fisioterapia 2005;9:273–80
Briones Claudett KH. Influence of F(IO2) on Pa(CO2) during noninvasive ventilation in patients with COPD: what will be
constant over time? Respir Care 2014;59:e104–5
Chatburn RL. Simulation studies for device evaluation. Respir Care 2014;59:e61–6
Ishihara H. [Non-invasive ventilation for chronic respiratory failure]. Respiration and Circulation 2003;51:15–20
Jones LD, Park JG. Simulation studies for device evaluation. Hosp Med Clin 2014;3:e149–61
Lierl D, Chaney M. Nocturnal bilevel ventilation for the COPD patient. J Respir Care Pract 2000;13:59–60,62,64,(19 ref)
Liu J, Xiong SD. Effectiveness of BiPaP for pulmonary hemodynamics and output of sodium and potassium in urine in
chronic obstructive pulmonary disease. J Clin Internal Med 1999;15:73
Mihaltan F, Deleanu O, Ulmeanu R, Nemes R, Mihaltan F, Deleanu O, et al. Non-invasive positive pressure ventilation in
stable COPD: has it any role? [Review]. Pneumologia 2012;61:183–7
Muir J-F, Cuveller A. Long-term invasive ventilation in the home. Int J Respir Care 2006;2:48–53
Perruchoud A, Tschan M, Kopp C, Blum V, Herzog H. [Rehabilitation program with IPPB-home treatment in severe chronic
obstructive lung disease: hospitalizations and cost analysis]. Schweizerische Medizinische Wochenschrift 1980;110:229–31
Pires DL, V, Silva AB, Sampaio LMM, Jamami M, Oishi J, Costa D. Effects of the physical and respiratory muscular training in
patients suffering from severe chronic obstructive pulmonary disease submitted to BiPAP. Revista Brasileira de Fisioterapia
2003;7:69–76
Raffenberg M, Muller-Pawlowski H, Geerdes-Fenge H, Petri M, Schaberg T, Loddenkemper R, et al. [Indications, methods
and results of intermittent positive pressure ventilation at home]. Atemwegs- und Lungenkrankheiten 1997;23:138–41
Servera E, Crescencio V, Vergara P, Pasrez D, Gonzalez M, Diaz J, et al. Non-invasive ventilation in patients with
decompensated COPD: initial daily administration versus day and night. Archivos de Bronconeumología 1997;33:4
Servera E. Chronic obstructive lung disease: Non-invasive mechanical ventilation. Archivos de Bronconeumología
2003;39:S35–38
Singh S. Is non-invasive positive pressure ventilation the answer to chronic obstructive pulmonary disease? British Journal of
Intensive Care 2003;13:114–18
Teixeira C, Savi A, Tonietto TF, Teixeira C, Savi A, Tonietto TF. Influence of F(IO2) on Pa(CO2) during noninvasive ventilation
in patients with COPD: what will be constant over time?–Reply. Influence of F(IO2) on Pa(CO2) in COPD patients with
chronic CO2 retention–reply. Respir Care 2014;59:e106-e107
Tsuboi T. Evidence based medicine in long-term NPPV. Respiration and Circulation 2003;51:47–56
Tuggey JM, Elliott MW. Titration of non-invasive ventilation in COPD. Thorax 2002;57:S81
Vargas F, Weissheimer KV, da Cunha LS, Filippin LI. [Noninvasive mechanical ventilation improves exercise tolerance in
patients with severe-to-very severe chronic obstructive pulmonary disease]. Revista Inspirar Movimento Saude 2011;3:47–52
Zhang JH, Gong L, Li X, Xin DG. Effect of Shenmai injection and bi-level positive airway pressure ventilation for
daphragmatic activities in chronic obstructive pulmonary disease. Chin J Integr Med 1995;15:726–7
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Studies where additional information was sought in order to
aid selection decisions but not obtained
This section details the four articles for which the authors were contacted for additional information to aid
selection decisions for the review of clinical effectiveness and where responses were not received.
TABLE 56 Studies where additional information was sought in order to aid selection decisions but not obtained
Article
Feature on which further
information was required
Duan Y. Observation of non-invasive positive ventilation united inhalation treatment
therapeutic effect on chronic obstructive pulmonary disease with type II respiratory failure.
Respirology 2011;93–4. 16th Congress of the Asian Pacific Society of Respirology,
Shanghai, 3–6 November, China. Conference
Setting
Ishihara, H. NPPV for chronic respiratory failure. Jpn J Chest Dis 2003;62:333–43 Study design
Laier-Groeneveld G, Gietl C, Bauer JU. Normocapnia following noninvasive ventilation in
acute exacerbations and chronic state of obstructive pulmonary disease. J Physiol
Pharmacol 2007;58:S339–44
Setting
Schucher B, Laier-Groeneveld G, Huttemann U, Criee CP. [Effects of intermittent
self-ventilation on ventilatory drive and respiratory pump function]. Medizinische Klinik
1995;90:S13–16
Setting
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Appendix 5 Uncontrolled studies meeting
inclusion criteria for review of clinical effectiveness
This appendix details the characteristics of the 72 uncontrolled studies meeting the inclusion criteria forthe review of clinical effectiveness.
TABLE 57 Uncontrolled prospective studies (at least some results presented for COPD patients separately)
Study Follow-up
Number of
patients Outcomes
Blankenburg et al. 2008175 At least 4 weeks 40 Lung function, blood gases, 6MWD, SF-36
Borel et al. 2014176 Median 47.7
months
118 Composite of survival and hospitalisation and
event-free survival
Budweiser et al. 2007102 Mean 32 months 188 Survival, lung function, blood gases
Budweiser et al. 2007103 2 to 4 years 98/231 Survival, HRQoL (SRI), blood gases,
lung function
Budweiser et al. 2006177 Up to 12 months 141 BMI, blood gases, lung function
Carroll and Branthwaite
1988178
Median 4 months 4 Blood gases, sleep time, spirometric values,
exercise tolerance
Chatwin et al. 2010179 6 months Approximately 182
(15% of 1211)
Number of calling emergency helpline, number
of home visits, nature of technical issue
Criner et al. 1999180 6 months 20/40 with COPD Complications, discontinuation rates,
compliance, FEV1, FVC
Duiverman et al. 2010181
(abstract)
3 months 11 Respiratory muscle activity
Elliot et al. 1991182 6 months 8 Blood gases and respiratory parameters
Elliot et al. 1992183 1 year 12 Blood gases and respiratory parameters,
QoL, sleep efficiency
Jones et al. 1998106 Up to 2 years 11 Blood gases, hospital admissions, use of GP
resources, survival
Khatun et al. 2011184
(abstract)
12 months 52/200 with COPD Discontinuation rates and patterns
Kobayashi et al. 2005185 Unclear (at least
3 months)
8/80 with COPD Survival, QoL (unclear what measure)
Nickol et al. 2008186 3 months 19 Blood gases, respiratory parameters
Oscroft et al. 2010105 Up to 2 years 35 Blood gases, ventilatory parameters,
compliance, survival
Perrin et al. 1997187 6 months 14 Lung function, QoL
Schönhofer et al. 2006188 2 months 25 Blood gases, compliance, inspiratory muscle
strength
Schönhofer et al. 2003189 1 year 13/33 with COPD Pulmonary haemodynamics
Schönhofer et al. 1999190 1 year 13/33 with COPD Blood gases, pulmonary arterial pressure
Simonds and Elliott 1995191 Up to 5 years 33/180 with COPD Pulmonary function, survival, discontinuation,
SF-36 (cross-sectional survey in subset only)
Skobel et al. 2011108 3 months 27/37 Survival, hospital stay, acceptance of NIV,
SGRQ, HADS
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TABLE 57 Uncontrolled prospective studies (at least some results presented for COPD
patients separately) (continued )
Study Follow-up
Number of
patients Outcomes
Storre et al. 2014192
(RCT, but only uncontrolled
element relevant)
3 months 12 Sleep quality, overnight gas exchange,
tolerance, overnight pneumotachygraphic
measurements, HRQoL, exercise capacity,
lung function
Tsolaki et al. 2011107 Up to 2 years 35/91 with COPD SF-36, exacerbations, hospital days, survival
Windisch 2008193 1 year 27/85 Blood gases, SF-36, SRI, side effects
Windisch et al. 2002194 6 months 14 Blood gases, respiratory muscle function,
discontinuations
BMI, body mass index; HADS, Hospital Anxiety and Depression Scale.
TABLE 58 Uncontrolled studies – retrospective analyses or surveys (at least some results presented for COPD
patients separately)
Study Follow-up
Number of
patients Outcomes
Adams et al. 1998195 Unclear 40 Prevalence, usage pattern-no clinical outcomes
Budweiser et al. 2008196 Mean 25 months 197 6MWD, survival
Budweiser et al. 2005197 Up to 12 months 46 Blood gases, respiratory parameters,
compliance, survival
Bullemer et al. 1996198 Up to 1 year 11/115 Blood gases, survival
Charbonnier et al. 2014199 6-year period Unclear for COPD
and NIV
Pattern of NIV use and settings
Chu et al. 2004200 Covers up to
36 months of
NIV use
121/249 with
COPD (119 on
NIV)
(Dis)continuation rates, deaths
Cuvelier et al. 2005201 1 year 42/100 with COPD
but only
proportion with
home NIV (15?)
Hospitalisation, mortality
Dale and Brocklebank
2012202
1 year 20 Blood gases, hospitalisation rates
Dellweg et al. 2007203 3 months 305 Blood gases, respiratory and lung function
Ekkernkamp et al. 2014204 Median 22 months 27 Minute ventilation
Eller et al. 1989205 Mean 64 months 215 (results only
for 78)
Dyspnoea, cough, sputum production, QoL,
hospitalisation
Fernandez Alvarez et al.
2013206
Cross-sectional 7 Leakage and blood gases
Ülger et al. 2014207 Survey Unclear (for
NIV+COPD)
Usage and maintenance of devices
Garner et al. 2013208 Cross-sectional 218 (approximately) Prevalence of home mechanical ventilation
Gay et al. 1991209 Mean 14 months 4/26 with COPD Arterial blood gases, pulmonary function tests,
discontinuation, adverse events
González-Rodríguez et al.
2005210
12 months 23 Blood gases, hospital admissions
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TABLE 58 Uncontrolled studies – retrospective analyses or surveys (at least some results presented for COPD
patients separately) (continued )
Study Follow-up
Number of
patients Outcomes
Janssen et al. 2003211 Median 24 months
(up to 7 years)
58/211 with COPD Blood gases, days in hospital, discontinuation,
compliance, survival
Kollert et al. 2013104 Up to 12.5 years 309 Haemoglobin levels, survival
Laier-Groeneveld and Criee
1989212 and Criée et al.
1989213
Up to 6 months 4/15 with COPD Hospital days, medication, exercise capacity
Leger et al. 1994214 up to 3 years 50/276 with COPD Arterial blood gases, discontinuation, hospital
days
López-Campos et al.
2008215
12 months 15/115 Dyspnoea, hospitalisation, HRQoL
McLaughlin and Keatings
2011216 (abstract)
1 year 30 Admissions, bed-days, blood gases
Örnek et al. 2014217 Median 17 months 34 Survival, hospitalisations
Pasquina et al. 2012218 2.5 years 32/150 Data recorded by ventilator software, leaks,
compliance
Perrin et al. 2000219 Mean 35 months 24 Blood gases, survival
Schönhofer and Kohler
1997220
3 months 78 Blood gases, acceptance/compliance, subjective
improvement
Schucher et al. 1999221 mean 13 months 25 Blood gases, lung function, acceptance
Schucher et al. 1999222 1 year 54/111 Blood gases, lung function, discontinuation/
acceptance
Sivasothy et al. 1998223 Median
17.5 months
26 Blood gases, survival, compliance, SF-36
Sugino et al. 2008224 Mean 2.3 years 16 Blood gases, survival
Takada et al. 2009225 11 years 28 Survival, days in hospital, risk factors for
death/survival
Takada et al. 2008226 Unclear (1 and
5 year survival rates)
26/54 with COPD Hospitalisation, survival
Thibout et al. 2006227 Up to 5 years (?) 37 Blood gases, survival
Tollefsen et al. 2009228 Cross-sectional 272 Prevalence of COPD patients using home NIV
in different regions of Norway
Tsuboi et al. 2011229 2 years 54 Blood gases, hospitalisation rates
Tsuboi et al. 1996230 Unclear (up to
11 year survival
rates)
6/41 with COPD Survival, probability of continuation
Vitacca et al. 2000231 Home NIV for
31 months
23 Blood gases, respiratory parameters
Waugh et al. 2001232 Over previous
6 months
36 QoL (RQL)
Wiebel et al. 1999233 Over 9 years 29 Blood gases, lung function parameters, survival
Wiebel et al. 1997234 Over 8 years 10/108 with COPD Survival
Windisch et al. 2009109 Up to 5 years 73 Physiological parameters, exacerbation rates,
survival, hospitalisation
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TABLE 58 Uncontrolled studies – retrospective analyses or surveys (at least some results presented for COPD
patients separately) (continued )
Study Follow-up
Number of
patients Outcomes
Windisch et al. 2008235 Questionnaire
refers to preceding
week
162 SRI
Windisch et al. 200533 2 months 34 Blood gases, lung function
Windisch et al. 2003236 Cross-sectional 78/226 COPD Blood gases, SF-36
Windisch et al. 1997237 Questionnaire
looks at changes
retrospectively
but length of
follow-up unclear
20/72 COPD QoL questionnaire, HADS, AQLQ
AQLQ, Asthma Quality of Life Questionnaire; HADS, Hospital Anxiety and Depression Scale; RQL, Respiratory
Quality of Life Survey.
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Appendix 6 Details of non-invasive ventilation
used in studies included in clinical effectiveness
review
TABLE 59 Non-invasive ventilation used in RCTs
Author Mask Target IPAP (cmH2O) EPAP (cmH2O) NIV kit
Bhatt et al.
201383
Full face Pressure Titrated to final
pressure of 15
Titrated to final
pressure of 5
BiPAP® Synchrony
Ventilator (Respironics
Inc, Murrysville, PA,
USA)
Casanova
et al. 200085
Nasal Pressure At least 8 targeted,
mean achieved 12
(SD 2)
At least 4 targeted
(minimum of 4
achieved)
DP-90 (Bilevel
pressure ventilation
system) (Taema,
Antony Cedex,
France)
Cheung et al.
201090
No details Volume 10–20 (as tolerated
to target a tidal
volume of
7–10ml/kg)
5 at start BiPAP® Synchrony®
(Respironics Inc,
Murrysville, PA, USA)
Clini et al.
200299
Nasal Pressure Set at maximum
tolerated, average
14 (SD 3)
Set in range of 2–5,
average 2 (SD 1)
BiPAP® ST30® ‘
Auto-Trak’™
ventilator (Respironics
Inc, Murrysville, PA,
USA, distributed in
Italy by Markos-
Mefar, Air Liquide
Group)
De Backer
et al. 201191
Full face Blood
gases
‘Modes were adapted
until O2 saturation
was > 90% during
90% of the time and
PaCO2 was decreased
5% in 1 hour’91
‘Modes were adapted
until O2 saturation
was > 90% during
90% of the time and
PaCO2 was decreased
5% in 1 hour’91
BiPAP® Synchrony®
device (Respironics,
Inc, Murrsville, PA,
USA)
Duiverman
et al. 200879
Nasal (30%) or
full face (70%)
Blood
gases
Up to maximal
tolerated pressure
titrated towards an
optimal correction of
nocturnal arterial
blood gases [mean 20
(SD 4) in completers
and 18 (SD 1) in
dropouts]
EPAP titrated on
patient comfort.
Mean 6 (SD 2) in
completers and 5
(SD 1) in dropouts
BiPAP® spontaneous/
timed mode
(Respironics, Inc.,
Murrysville, PA, USA)
(no further details)
Duiverman
et al. 201180
One patient with
nasal mask,
remaining with
full-face mask
Blood
gases
23 (SD 4) at start of
study
6 (SD 2) at start of
study
BiPAP® Synchrony®
(Respironics, Inc.,
Murrysville, PA, USA)
Garrod et al.
200084
Nasal Pressure Median 16
(range 13–24)
Median 4 (range 4–6) BiPAP® ST30®
ventilator
(Respironics, Inc.,
Murrysville, PA, USA)
Gay et al.
1996100
Nasal Pressure 10 (target level) 2 (lowest possible) BiPAP® (Respironics,
Inc., Murrysville, PA,
USA)
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TABLE 59 Non-invasive ventilation used in RCTs (continued )
Author Mask Target IPAP (cmH2O) EPAP (cmH2O) NIV kit
Kaminski et al.
1999101
Nasal Blood
gases
Settings adjusted to
decrease PaCO2, to
increase SaO2> 90%
and to obtain
maximum comfort for
patients
Settings adjusted to
decrease PaCO2, to
increase SaO2> 90%
and to obtain
maximum comfort for
patients
Monnal D ventilator
(Air Liquide Medical
Systems, Antony,
France)
Köhnlein et al.
201476
Face or nasal
mask according
to judgement of
investigator
Blood
gases
Mean 21.6 (SD 4.7) Mean 4.8 (SD 1.6) Ventilators marketed
post 2004 (ResMed,
Martinsried,
Germany; Weinmann,
Hamburg, Germany;
or Tyco Healthcare
Neuburg, Germany)
McEvoy et al.
200974
Choice of nasal
or full-face mask
and
humidification
Pressure Gradually increased
to maximum
tolerated (target of
IPAP–EPAP difference
of 10 or greater)
Lowest possible level
(approximately 3)
VPAP™ S mode
(ResMed, Sydney,
Australia)
Meecham-
Jones et al.
199577
Nasal Pressure Median 18
(range 16–22)
Median 2 (none
exceeding 4)
BiPAP® in S mode
(Respironics, Inc.,
Murrysville, PA)
Murphy et al.
201178
No details Pressure Discharge setting
26 (SD 3)
Discharge setting
5 (SD 1)
No details
Sin et al.
200782
Choice of nasal
or full-face mask
Pressure Patients started on 8,
then titrated up until
the highest tolerated
level or 20 was
reached (whichever
came first)
Set at 4 VPAP II™ with heated
humidifier
(HumidAire, ResMed,
Martinsried,
Germany)
Struik et al.
201475
Full-face mask Pressure Mean 19.2 (SD 3.4) at
discharge
Mean 4.8 (SD 1.0) at
discharge
BiPaP® Synchrony,
(Respironics Inc.,
Murrysville, PA, USA)
Strumpf et al.
199135
Nasal mask Blood
gases
Sufficient to maintain
PETCO2 at least
5mmHg below the
spontaneous resting
level. Mean 15 (SD 1)
in completers
Set at 2 (lowest
possible)
BiPaP® ventilator
(Respironics, Inc.)
Xiang et al.
200792
Nasal Pressure 16–20 at start then
adjusted to patient
2–4 at start then
adjusted to patient
BiPAP® (Hoffrichter
GmbH, Schwerin,
Germany, or
US-based company –
unable to translate)
Zhou et al.
200881
Full-face mask Pressure Mean 12–16 Mean 2–4 BiPAP® (Respironics,
Inc., Murrysville, PA)
PETCO2, partial pressure of exhaled carbon dioxide; SaO2, saturation of oxygen in the arterial blood.
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TABLE 60 Non-invasive ventilation used in controlled non-randomised studies
Author Mask Target IPAP (cmH2O) EPAP (cmH2O) NIV kit
Budweiser
et al. 200796
Nasal, full face or
custom made
Blood
gases
Mean 21 (SD 4) Mean 4.5 (SD 1.4) Twin Air® (Airox Inc.,
Pau, France) (13/99),
Smart Air® (Airox Inc.,
Pau, France) (14/99)
or BiPAP® Synchrony
ST® devices
(Respironics Inc.,
Murrysville, PA)
(51/99) or other
Clini et al.
199893
Nasal Volume Minimal pressure to
achieve an expiratory
tidal volume >8 ml/kg
(range 10–16ml/kg)
Set in order not to
overcome the
supposed intrinsic
positive expiratory
pressure (range 2–4)
BiPAP® (Respironics,
Inc., Murrysville, PA,
USA)
Clini et al.
199694
Nasal Volume Minimal pressure to
achieve an expiratory
tidal volume >8 ml/kg
(range 10–16)
Range 0–2 BiPAP® (Respironics,
Inc., Murrysville, PA,
USA)
Heinemann
et al. 201197
Nasal, oronasal or
individual
Blood
gases
Mean 22.7
(SD 4.3) mbar
(= 23.15 cmH2O)
Mean 5 (SD 1.3)
mbar (= 5.1 cmH2O)
No details
Laier-
Groeneveld
and Criee
199588
Nasal or oronasal Blood
gases
To achieve adequate
pO2
No details No details
Lu et al. 201298 No details Blood
gases
Mean 18.0 (SD 2.0) Mean 5.0 (SD 1.0) BiPAP® Harmony
(Respironics, Inc.,
Murrysville, PA, USA)
Milane and
Jonquet
198586
No details No
details
No details No details Bird® Mark 1, Bird®
Mark 7, Portabird
(Bird Products
Corporation, Palm
Springs, CA, USA)
Pahnke et al.
199787
No details No
details
No details No details No details
Paone et al.
201489
Nasal or full-face
mask
Volume Maximum inspiration
pressure value
tolerated by patients,
able to ensure an
exhaled tidal volume
of 6ml/kg (measured
body weight)
Between 2 and
8 cmH2O
Neftis (Linde, Munich,
Germany) or
Synchrony (Philips
Respironics, Andover
MA, USA)
Tsolaki et al.
200895
Full face Pressure Adjusted according to
patient’s comfort and
synchrony with the
ventilator and a
marked reduction in
use of accessory
muscles
Adjusted according to
patient’s comfort and
synchrony with the
ventilator and a
marked reduction in
use of accessory
muscles
VPAP™ III ST
(ResMed, Sydney,
Australia)
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TABLE 61 Different types of NIV being compared in RCTs
Author Mask Target IPAP (cmH2O) EPAP (cmH2O) NIV kit
Murphy et al.
2012113
Nasal or oronasal Pressure Mean 29 (SD 2) Mean 5 (SD 3) NIPPY3, NIPPY3+
(B&D ElectroMedical,
Warwickshire, UK)
Dreher et al.
201032
Nasal or oronasal Blood
gases
Mean 14.6 (SD 0.8)
low intensity, mean
28.6 (SD 1.9) high
intensity (mbar)
Mean 4.0 (SD 0) low
intensity, mean 4.5
(SD 0.7) high intensity
(mbar)
VIVO 40 (Breas
Medical AB,
Molnlycke, Sweden)
or modified Smart
Air® (Airox, Pau
Cedex, France). Two
patients used passive
humidification
Oscroft et al.
2010112
Unclear if nasal
or full-face mask
Pressure Va-NIV set to enable
adjustment of
inspiratory pressure
up to 25, the
maximum possible
with this ventilator;
pp-NIV set at similar
pressure settings that
the subject had
previously used
Settings that the
patients had
previously used
Va-NIV: iVAPs
(ResMed, Bella Vista,
Australia); pp-NIV:
VPAP™ III STA
(ResMed, Bella Vista,
Australia)
iVAPs, intelligent Volume-Assured Pressure Support; pp, pressure preset; va, volume assured.
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Appendix 7 Exploratory analysis of carbon
dioxide data and clinical outcomes
There is a discussion around whether or not the extent of hypercapnia at baseline or the change inhypercapnia status is related to the effectiveness of NIV. Performing subgroup analysis based on
reported mean baseline CO2 values would have meant dichotomising trials based on an arbitrary threshold,
and this was not considered appropriate. Therefore, CO2 levels at baseline and change in CO2 levels were
plotted against mortality in a separate analysis in order to determine if baseline CO2 can predict response
to NIV, and whether or not the effect of NIV on CO2 correlates with the effect on clinical outcomes.
Figures 42–45 show scatterplots of trial summary treatment effects (with 95% CIs) versus mean baseline
CO2 and change in CO2 levels for stable and post-hospital populations. It should be noted that these are
exploratory analyses only and as such results should be considered speculative and interpreted very
cautiously. The analysis uses aggregate data for change in CO2 and also for clinical outcomes, and a causal
association therefore cannot be inferred even if there is potential biological plausibility. Further caveats relate
to the fact that not all trials contributed data to these analyses (particularly for the hospital admissions data)
and that CO2 change scores were mostly not adjusted for baseline differences.
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FIGURE 42 Mortality (RR) and baseline CO2.
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
211
M
ea
n
 d
if
fe
re
n
ce
 in
 a
d
m
is
si
o
n
s
–2 –1.5 –1 –0.5
–0.5
–1.0
–1.5
–2.0
–3.0
–2.5
Stable population
Post-hospital population
0.0
0.0
0.5
1.0
1.5
Change in CO2 levels
FIGURE 45 Hospital admissions and change in CO2.
Baseline CO2 levels
Stable population
Post-hospital population
2.0
1.5
1.0
0.5
0.0
–0.5
–1.0
–1.5
–2.0
–2.5
–3.0
–3.5
M
ea
n
 d
if
fe
re
n
ce
 in
 a
d
m
is
si
o
n
s
6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 8.2
FIGURE 43 Hospital admissions and baseline CO2.
R
el
at
iv
e 
ri
sk
 o
f 
m
o
rt
al
it
y
Stable population
Post-hospital population
Change in CO2 levels
0.0
1.0
0.0
0.5
–0.5–1.0–2.0 –1.5
1.5
2.0
2.5
3.0
3.5
4.0
4.5
FIGURE 44 Mortality (RR) and change in CO2.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
212
Appendix 8 Clinical effectiveness findings from
selected uncontrolled studies
TABLE 62 Mortality (uncontrolled prospective studies)
Study
Patient
numbers Population Length of follow-up Survival rate
Budweiser
et al. 2007102
n= 188 Stable. Only subjects with an
event-free observation time
≥ 12 months were included
Up to 5 years. Mean
32 months
1-year survival rate, 84.0%
(n= 158 of 188 patients;
95% CI 69.3% to 96.3%);
2-year survival rate, 65.3%
(n= 98 of 150 patients; 95%
CI 49.5% to 82.8%); and 5-year
survival rate, 26.4% (n=28 of
106 patients; 95% CI 16.5% to
42.2%)
Budweiser
et al. 2007103
n= 98 Participants had to be in a
stable clinical condition
without signs of current
exacerbation or respiratory
tract infection
2–4 years.
Mean observation
28.9 months
(SD 8.8) months.
Range 0.2–45.8
months
Overall mortality, 31.6%
(31/98). Survival rates at 1 year
85.7% (SE 3.5%), 2 years 72.4%
(SE 4.5%) and 3 years 65.3%
(SE 5.3%)
Jones
et al. 1998106
n= 11 Stable Up to 2 years Two patients died, one
(patient 4) after 820 days and
the other (patient 5) after
1522 days of NIPPV treatment,
both of acute respiratory
failure. Median survival is
920 days (range 686–1240 days).
Small sample size
Oscroft
et al. 2010105
n= 31 (post-
exacerbation),
n= 16 (stable)
Post-exacerbation. Patients
transferred to the unit from
other hospitals following
emergency admission and
treatment for a severe
exacerbation of COPD.
Also compared with 16 stable
patients on NIV
Up to 2 years Median survival in the
post-exacerbation patients
was 28.6 months (95% CI
10.9 to 46.8 months), which
was significantly poorer than
that of the stable patients
(28.6 vs. 52.4, p=0.03). Survival
in the post-exacerbation group
was 68% at 1 year and 55%
at 2 years. Those who were
intolerant of NIPPV (n=4)
had a survival of 0.5 years
(95% CI 0 to 1 years). An ITT
analysis of all post-exacerbation
patients offered NIPPV following
exacerbation (n=35) shows
a 1-year survival of 63% and
median survival of 21.1 months
(95% CI 5.7 to 36.6 months)
Tsolaki
et al. 2011107
n= 35 Stable. Patients with acute
respiratory failure (pH < 7.35
and symptoms such as
increasing cough, purulent
sputum, need for antibiotics)
or patients with an exacerbation
during 4 weeks preceding
recruitment were excluded
Up to 2 years The survival rate after 2 years
of follow-up was 88.6% in the
COPD group
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TABLE 63 Mortality (uncontrolled, data analysis)
Study Patient numbers Population
Length of
follow-up Survival rate
Kollert et al.
2013104
n= 309 (207
normocythaemic)
Appear to be stable (no
mention of hospitalisation)
Up to 12.5 years Survival rates for
normocythaemic patients
(n= 207) were 72% at
2 years, 50% at 4 years,
47% at 5 years and 18% at
10 years (approximate,
estimated from graph)
TABLE 64 Hospitalisations (uncontrolled prospective studies)
Study Patient numbers Population
Length of
follow-up Hospitalisations
Jones et al.
1998106
n= 11 Stable Up to 2 years The median number of
admissions to hospital before
NIPPV was 2 per year (range
0–5); the median difference in
admissions to hospital before
and after NIPPV was 1
(95% CI 0 to 2). The duration
of stay in hospital decreased
from a median of 16 days
(range 0–47 days) to 7 days
(range 0–15 days); p= 0.023;
median difference 1 (95% CI
2 to 25)
Skobel et al.
2011108
n= 27 Post-hospital. Recruited from
weaning clinics or ICUs
3 months 22% of patients had to be
readmitted to hospital while
on NIV. No details on
admission rates before NIV
Tsolaki et al.
2011107
n= 35 Stable. Patients with acute
respiratory failure (pH < 7.35
and symptoms such as
increasing cough, purulent
sputum, need for antibiotics)
or patients with an
exacerbation during 4 weeks
preceding recruitment were
excluded
Up to 2 years 357 days of hospitalisation
(5.35/patient/year) (210 in the
first year and 147 in the
second, 6.00± 13.86 vs.
4.31± 10.91/patient/year;
p= 0.574)
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Appendix 9 Secondary outcome data for clinical
effectiveness review
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Appendix 10 Excluded studies from the
cost-effectiveness review
This section contains a list of the excluded studies from the cost-effectiveness review.
TABLE 72 List of studies excluded from cost-effectiveness review
Article
Reason for
exclusion
From cost-effectiveness searches
Acton RD, Hotchkiss J, Dries DJ. Noninvasive ventilation. J Trauma 2002;53:593–601 A, E
Barbano L, Bertella E, Vitacca M. Episodic medical home interventions in severe bedridden chronic
respiratory failure patients: a 4 year retrospective study. Monaldi Arch Chest Dis 2009;71:113–18
A, D
Chandra K, Blackhouse G, McCurdy B, Bornstein M, Campbell K, Costa V, et al. Cost-effectiveness
of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model.
Ont Health Technol Assess Ser 2012;12:1–61
A
Collett AS, Rees PJ. Non-invasive ventilation at home in chronic obstructive pulmonary disease.
Int J Clin Pract 2007;61:1434–6
A
Connolly MJ. Non-invasive ventilation in elderly patients with acute exacerbations of COPD: Bringing
pressure to bear. Age Ageing 2006;35:1–2
A, E
Cooke CR. Economics of mechanical ventilation and respiratory failure. Crit Care Clin 2012;28:39–55 A
COPD Working Group. Noninvasive positive pressure ventilation for chronic respiratory failure patients
with stable chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health
Technol Assess Ser 2012;12:1–51
A
Criner GJ, Kreimer DT, Tomaselli M, Pierson W, Evans D. Financial implications of noninvasive positive
pressure ventilation (NPPV). Chest 1995;108:475–81
E
Criner GJ. Cost/benefit of noninvasive mechanical ventilation. Monaldi Arch Chest Dis 1998;53:358–9 A
Decramer M, Sibille Y, Bush A, Carlsen K-H, Rabe KF, Clancy L, et al. The European Union conference
on chronic respiratory disease: Purpose and conclusions. Eur Respir J 2011;37:738–42
A, D
Dellweg D, Schonhofer B, Haidl PM, Barchfeld T, Wenzel MD, Appelhans P, et al. Short-term effect of
controlled instead of assisted noninvasive ventilation in chronic respiratory failure due to chronic
obstructive pulmonary disease. Respir Care 2007;52:1734–40
A
Diez AR, Abbona H, Ferrero G, Figueroa Casas JC, De VM, Lisanti R, et al. Argentine consensus of
non-invasive ventilation. Medicina (B Aires) 2005;65:437–57
A
Dwarakanath A, O’Flynn H. Impact of domiciliary non-invasive ventilation (NIV) service in chronic
ventilatory disorder on hospitalisation and quality-of-life: a Grimsby experience. Thorax 2009;
Conference: British Thoracic Society, BTS Winter Meeting 2009, London: A76
A
Ferrer M, Sellares J, Torres A. The use of non-invasive ventilation by Italian physicians in the clinical
practice. Minerva Anestesiol 2011;77:941–2
A, E
Franek J. Home telehealth for patients with chronic obstructive pulmonary disease (COPD):
an evidence-based analysis. Ont Health Technol Assess Ser 2012;12:1–58
D
Janssens J-P, Kehrer P, Chevrolet J-C, Rochat T. Non-invasive home ventilation (NIHV): analysis of
32 cases with an average 41-month follow-up. Rev Mal Respir 1999;16:511–20
A
Janssens J-P, Derivaz S, Breitenstein E, De MB, Fitting J-W, Chevrolet J-C, et al. Changing patterns in
long-term noninvasive ventilation: A 7-year prospective study in the Geneva Lake Area. Chest
2003;123:67–79
A
continued
DOI: 10.3310/hta19810 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 81
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dretzke et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
233
TABLE 72 List of studies excluded from cost-effectiveness review (continued )
Article
Reason for
exclusion
Mehta B, Goyal R, Reznik R, Fayaaz J, Allred C, DiFabrizio L, et al. Hospital utilization of bilevel
non-invasive positive pressure ventilation could become more cost-effective. Am J Respir Crit
Care Med 2010; Conference: American Thoracic Society International Conference, ATS 2010
New Orleans, LA
E
Muir JF, Voisin C, Ludot A. Organization of home respiratory care: the experience in France with
ANTADIR. Monaldi Arch Chest Dis 1993;48:462–7
A
Palmer JM, Hughes PD. Retrospective evaluation of home initiation for long-term non-invasive
ventilatory support. Thorax 2009; Conference: British Thoracic Society, BTS Winter Meeting 2009,
London. Conference Publication:(var.pagings):A79
A
Pandey R, Chokhani R. Use of non invasive ventilation in patients with respiratory failure in Nepal.
Kathmandu Univ Med J 2011;9:256–9
A, E
Rossi A. European respiratory monograph: Preface. European Respiratory Monograph 2001;6:a-b A
Schilling JP, Kasik JE. Intermittent positive pressure breathing: a continuing controversy. Iowa Med
102;70:99–100
A
Sikich N. Community-based multidisciplinary care for patients with stable chronic obstructive
pulmonary disease (COPD): An evidence-based analysis. Ont Health Technol Assess Ser 2012;12:1–51
D
From clinical effectiveness review
Budweiser S, Heinemann F, Meyer K, Wild PJ, Pfeifer M. Weight gain in cachectic COPD patients
receiving noninvasive positive-pressure ventilation. Respir Care 2006;51:126–32
A, C, D
Chatwin M, Heather S, Hanak A, Polkey MI, Wilson B, Simonds AK. Analysis of emergency helpline
support for home ventilator dependent patients: Risk management and workload. Eur Respir Rev
2008;17:33–5
A
Chatwin M, Heather S, Hanak A, Polkey MI, Simonds AK. Analysis of home support and ventilator
malfunction in 1211 ventilator-dependent patients. Eur Respir J 2010;35:310–16
A, C
Lloyd-Owen SJ, Donaldson GC, Ambrosino N, Escarabill J, Farre R, Fauroux B, et al. Patterns of home
mechanical ventilation use in Europe: Results from the Eurovent survey. Eur Respir J 2005;25:1025–31
A
Tsolaki V, Pastaka C, Karetsi E, Zygoulis P, Koutsokera A, Gourgoulianis KI, et al. One-year in chronic
hypercapnic COPD: effect on quality-of-life. Respir Med 2008;102:904–11
A
Reasons for exclusion: A, study design; B, publication type; C, population; D, intervention; E, setting; F, other
(e.g. economic evaluation or qualitative study).
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Appendix 11 Quality assessment of included
studies in cost-effectiveness review
TABLE 73 Quality assessment of included studies in cost-effectiveness review
Quality criteria Tuggey et al. (2003)40 Clini et al. (2009)134
Was a well-defined question posed in answerable form? Yes Yes
Was a comprehensive description of the competing alternatives given? Yes Yes
Was the effectiveness of the programme or services established? Yes Yes
Were all the important and relevant costs and consequences for each
alternative identified?
No No
Were costs and consequence measured accurately in appropriate
physical units?
Yes Yes
Were cost and consequences valued credibly? Yes, although some
ambiguity
Yes
Were costs and consequences adjusted for differential timing? Yes Yes
Was an incremental analysis of costs and consequences of alternatives
performed?
No No
Was allowance made for uncertainty in the estimates of costs and
consequences?
Yes Yes
Did the presentation and discussion of study results include all issues
of concern to users?
Yes Yes
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Appendix 12 All-cause mortality rates applied in
the economic model
T able 74 lists the COPD-adjusted all-cause mortality rates applied in the economic model. These werederived from all-cause and COPD-related mortality rates by sex and age for a UK population and
were obtained from the Office for National Statistics.
TABLE 74 Chronic obstructive pulmonary disease-adjusted all-cause mortality rates, by age and sex
Age (years)
All-cause mortality Deaths caused by COPD COPD-adjusted mortality
Male (%) Female (%) Male (%) Female (%) Male (%) Female (%)
60 0.8342 0.5361 4.2052 5.1115 0.7828 0.5095
61 0.8871 0.5810 0.8325 0.5522
62 0.9507 0.6165 0.8921 0.5859
63 1.0509 0.6812 0.9862 0.6474
64 1.1558 0.7478 1.0846 0.7107
65 1.2725 0.8201 6.1850 7.2580 1.1941 0.7794
66 1.4205 0.9119 1.3330 0.8666
67 1.5369 0.9737 1.4422 0.9254
68 1.7243 1.0949 1.6181 1.0405
69 1.9125 1.2158 1.7947 1.1554
70 2.1149 1.3856 1.9846 1.3168
71 2.3225 1.4768 2.1794 1.4035
72 2.5652 1.6469 2.4072 1.5651
73 2.7907 1.8063 2.6188 1.7166
74 3.1141 2.0492 2.9223 1.9475
75 3.3999 2.2567 6.6549 6.4764 3.1905 2.1447
76 3.8443 2.5538 3.6075 2.4270
77 4.2217 2.8839 3.9616 2.7407
78 4.7005 3.2547 4.4109 3.0931
79 5.2482 3.6732 4.9249 3.4908
80 5.9440 4.1742 5.5778 3.9670
81 6.6343 4.6620 6.2256 4.4305
82 7.4283 5.3215 6.9707 5.0573
83 8.1907 6.0585 7.6861 5.7577
84 9.2142 6.7739 8.6466 6.4376
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TABLE 74 Chronic obstructive pulmonary disease-adjusted all-cause mortality rates, by age and sex (continued )
Age (years)
All-cause mortality Deaths caused by COPD COPD-adjusted mortality
Male (%) Female (%) Male (%) Female (%) Male (%) Female (%)
85 10.2895 7.5849 5.5753 3.4135 9.6556 7.2083
86 11.2992 8.5749 10.6031 8.1492
87 12.7193 9.5838 11.9358 9.1080
88 14.0875 10.7790 13.2197 10.2438
89 16.0713 12.1602 15.0813 11.5565
90 16.6367 13.5352 15.6118 12.8632
91 17.8196 14.6525 16.7219 13.9250
92 18.8878 16.0748 17.7243 15.2767
93 21.4681 18.0517 20.1456 17.1555
94 23.7662 20.2789 22.3021 19.2721
95 25.6292 22.3947 24.0504 21.2828
96 27.5704 24.0167 25.872 22.8243
97 29.4811 25.9706 27.6650 24.6811
98 31.5556 27.8215 29.6123 26.4402
99 32.7281 29.6932 30.7120 28.2190
100 34.4584 31.8222 32.3357 30.2422
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Appendix 13 Survival reported in clinical studies
of domiciliary non-invasive ventilation in cohorts
discharged from hospital
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Appendix 14 Studies reporting outcomes in
patients followed up post hospital
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Appendix 15 Usual-care survival curves
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FIGURE 46 Base-case survival curve for usual care in the stable population.
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FIGURE 47 Base-case survival curve for usual care in the post-hospital population.
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FIGURE 48 Survival curve for sensitivity analysis assuming lower risk of admission and all-cause mortality for usual
care in the post-hospital population. Risks obtained from Bucknall et al.153
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FIGURE 49 Survival curve for sensitivity analysis increasing the base-case mortality risk for usual care in the
post-hospital population. Risk of all-cause mortality, death during admission and death post admission increased by
a factor of 2.
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Appendix 16 Disease progression rates applied in
the economic model
T able 77 lists the annual disease progression rates applied in the economic model. These wereobtained from a published COPD Markov model by Atsou et al. 2011.141
TABLE 77 Annual disease progression risks by age and smoking status
Age (years)
GOLD stage 2 to
GOLD stage 3
GOLD stage 3 to
GOLD stage 4
GOLD stage 2 to
GOLD stage 3
GOLD stage 3 to
GOLD stage 4
Ex-smoker (%) Ex-smoker (%) Smoker (%) Smoker (%)
60 5.803 5.120 9.338 7.823
61 5.926 5.229 9.535 7.989
62 6.049 5.338 9.733 8.155
63 6.104 5.386 9.822 8.229
64 6.159 5.434 9.912 8.304
65 6.213 5.482 10.001 8.379
66 6.268 5.530 10.091 8.454
67 6.322 5.579 10.180 8.529
68 6.367 5.618 10.252 8.589
69 6.412 5.658 10.324 8.650
70 6.457 5.698 10.396 8.710
71 6.502 5.737 10.468 8.770
72 6.547 5.777 10.540 8.831
73 6.561 5.789 10.562 8.849
74 6.575 5.801 10.584 8.868
75 6.589 5.814 10.607 8.887
76 6.603 5.826 10.629 8.905
77 6.617 5.838 10.651 8.924
78 6.638 5.857 10.686 8.953
79 6.659 5.876 10.720 8.982
80 6.681 5.895 10.755 9.011
81 6.702 5.914 10.789 9.040
82 6.724 5.933 10.824 9.069
83 6.792 5.993 10.935 9.161
84 6.861 6.054 11.045 9.254
85 6.930 6.114 11.156 9.347
86 6.998 6.175 11.266 9.439
87 7.067 6.236 11.377 9.532
continued
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TABLE 77 Annual disease progression risks by age and smoking status (continued )
Age (years)
GOLD stage 2 to
GOLD stage 3
GOLD stage 3 to
GOLD stage 4
GOLD stage 2 to
GOLD stage 3
GOLD stage 3 to
GOLD stage 4
Ex-smoker (%) Ex-smoker (%) Smoker (%) Smoker (%)
88 7.136 6.296 11.487 9.624
89 7.204 6.357 11.598 9.717
90 7.273 6.417 11.708 9.810
91 7.342 6.478 11.819 9.902
92 7.410 6.538 11.929 9.995
93 7.479 6.599 12.040 10.088
94 7.547 6.659 12.150 10.180
95 7.616 6.720 12.261 10.273
96 7.685 6.781 12.372 10.365
97 7.753 6.841 12.482 10.458
98 7.822 6.902 12.593 10.551
99 3.610 7.891 12.703 10.643
100 3.610 7.891 12.703 10.643
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